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Preface 
 
 
This doctoral thesis entitled “Mechanistic paradigm of Leptin receptor activation revealed by its 
complexes with wild type and antagonist leptins” encompass research work done during four 
years of doctoral study. The primary objective has been the structural and mechanistic 
characterization of leptin mediated receptor activation and to unravel the mechanism of 
antagonism. The results and conclusions have been described here in following chapters. 
Chapter 2, entitled “Introduction to leptin/leptin receptor system”, gives detailed account of the 
available information pertaining to physiological and pathophysiological roles of leptin/leptin 
receptor system, the structural aspects of leptin and its cognate receptor and the proposed 
mechanisms of leptin mediated leptin receptor activation. In the end of this chapter, objectives 
of this doctoral research project have been briefly described. 
In chapter 3, entitled “Structural and mechanistic paradigm of leptin receptor activation revealed 
by complexes with wild type and antagonist leptins”, results obtained from the research work 
1 
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with full length extracellular part of receptor with wild type and antagonist leptins have been 
presented. The results encompass first-of-it-kind biochemical, biophysical and structural 
analysis of the leptin induced receptor extracellular part oligomerization while pointing towards 
an unconventional mechanistic model for leptin receptor signaling complex. This chapter has 
been adopted from the manuscript currently undergoing peer review for publication. 
Chapter 4, entitled “Redundant role of FNIII domains in leptin mediated leptin receptor 
oligomerization” comprises the biochemical and structural characterization of a truncated variant 
of leptin receptor extracellular part lacking the membrane proximal fibronectin type III (FNIII) 
domains. This chapter attributes to the experimental work leading to the discovery of the 
redundant role of the  membrane proximal FNIII domains in agonist induced receptor 
oligomerization. The biochemical, biophysical and structural aspects of the resultant complexes 
have been presented. This chapter has been adopted from the manuscript prepared for 
publication. 
In chapter 5, entitled “Crystallization of leptin receptor and its complexes” experimental 
procedures adopted for optimized expression of receptor and crystallization trial of the various 
receptor constructs alone and in complex with wild type and antagonist leptins have been 
described. 
Finally, in chapter 6, this thesis has been concluded by providing a summary of the results 
obtained during this research work. The impact and future prospects of these results have been 
cited.   
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2.1 BACKGROUND 
Leptin, a term derived from the Greek word “leptos” meaning “thin”, was originally 
discovered as a protein hormone regulating food intake and energy homeostasis. Later, highly 
divergent pleiotropic activities of leptin have been unraveled, raising the necessity to understand 
its multi-dimensional aspects in human physiology and pathology. Leptin involves in diverse 
physiological processes ranging from immune system to reproduction to bone metabolism to 
energy homeostasis. Recent developments in leptin research have unmasked the darker side of 
leptin (patho)physiology, revealing its role in breast cancer and several autoimmune diseases 
and demanding investigation for a deeper understanding of leptin physiology. This four helical 
bundle cytokine transduces its signal via the membrane bound leptin receptor. Ironically, a 
consensus is still lacking in our understanding of the mechanistic paradigm of leptin dependent 
receptor activation, even though the scientific community has spent more than two decades 
studying this system. This chapter summarizes the available information and our current 
understanding of the structural, functional and mechanistic aspects of leptin and its cognate 
receptor. 
2 
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2.2 FUNCTIONS OF LEPTIN 
The primary function of leptin is to regulate the food intake by satiating appetite and thereby 
controlling the energy metabolism. Unlike ghrelin which is a fast acting hormone, leptin is a long 
term regulator of energy homeostasis. The originally-conceived “anti-obesity” role of leptin has 
rapidly changed with the discoveries of its broader pleiotropic functions in diverse physiological 
processes. These functions of leptin have been summarized as follows.  
2.2.1  Anti-obesity Hormone 
 Leptin is primarily produced by stomach adipose tissue. It controls the appetite and increases 
the energy expenditure by signaling via its cognate receptors expressed in hypothalamic nuclei 
in brain.  
  
A) Regulation of Leptin production: Sympathetic nervous system, that maintains the 
homeostasis in mammals, regulates the production of leptin (Rayner, 2001). The circulating 
leptin concentrations in blood has been found to be proportional to the adipose tissue content 
(Ahren et al., 1997; Maffei et al., 1995). Beside the adipose tissue mass, food intake also 
controls the leptin production. In vitro studies have shown that insulin and glucocorticoids 
synergistically act on the adipose tissue to upregulate the leptin mRNA levels and frequency of 
leptin secretion in a long term fashion (Fried et al., 2000). Increased leptin levels in obesity has 
been partly attributed to the chronic hormonal condition of hyperinsulinemia and high cortisol 
turnover. On the contrary, fasting leads reduction in insulin and enhancement in catecholamine 
levels in blood, thus causing downregulation of leptin production by adipose tissue. 
 
B) Mechanism of appetite control by Leptin: Appetite is a more complicated 
phenomenon compared to what was conceived at the time of the discovery of leptin. It involves 
inputs from hypothalamus (parasympathetic nervous system), thyroid (hypothalamic-pituitary-
adrenal axis), opoid receptor system along with involvement of hormones like neuropeptide Y 
(NPY), agouti-related peptide and ghrelin (Figure 2.1). Leptin still plays a critical role in both 
immediate and long term regulation of appetite. The immediate effects are manifested by the 
interaction of circulating leptin with the cognate receptor ObRb in brain hypothalamus initiating a 
cascade that triggers the synthesis of anorexigenic pro-hormone proopiomelanocortin (PMOC) 
2 
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causing decline of appetite and increased energy expenditure (Butler and Cone, 2002; Butler et 
al., 2000; Chen et al., 2000; Huszar et al., 1997; Marsh et al., 1999; Ste Marie et al., 2000). 
Leptin action on hypothalamus also causes reduction in production of orexigenic NPY and 
agouti-related protein (AgRP), thus resulting in loss of appetite and a feeling of satiety.  
Figure 2.1. Hormones that control eating: Leptin and insulin (lower part of the figure) circulate 
in the blood at concentrations proportionate to body-fat mass. They decrease appetite by inhibiting 
neurons (centre) that produce the molecules NPY and AgRP, while stimulating melanocortin-
producing neurons in the arcuate-nucleus region of the hypothalamus, near the third ventricle of the 
brain. NPY and AgRP stimulate eating, and melanocortins inhibit eating, via other neurons (top). 
Activation of NPY/AgRP-expressing neurons inhibits melanocortin-producing neurons. The gastric 
hormone ghrelin stimulates appetite by activating the NPY/AgRP-expressing neurons. Batterham et 
al.1 have now shown that PYY3-36, released from the colon, inhibits these neurons and thereby 
decreases appetite for up to 12 hours. PYY3-36 works in part through the autoinhibitory NPY 
receptor Y2R. (Adopted from Schwartz and Morton, Nature, 2002) 
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2.2.2 Role in Immune system: Innate immunity 
The major roles of leptin in regulation of innate immunity includes activation of neutrophils, 
cytokine production by monocytes and macrophages, activation of antigen presenting cells 
(APCs) and cytotoxicity (Figure 2.2). A more detailed account of these roles are as follow. 
A) Role in inflammation:  The regulation of innate immunity by leptin is somewhat in 
twilight zone as not much direct evidence exist in literature. The circulating leptin level has been 
observed to be high during the inflammation by LPS, turpentine and cytokines (Faggioni et al., 
2001; Matarese, 2000). Although there are evidences that the inflammation-induced and tumor-
induced anorexia are not mediated by leptin (Lopez-Soriano et al., 1999), the linkage between 
leptin and  inflammation have been demonstrated to be mediated by leptin induced IL-1β 
production (Luheshi et al., 1999). 
 
B) Activation of monocytes and Macrophages: Leptin has been found to stimulate 
proliferation and activation of circulating monocytes in vitro, upregulating surface markers like 
HLA-DR, CD11b, CD11c and activation markers like CD69, CD38 and CD71 in human (Santos-
Alvarez et al., 1999). Leptin has also found to stimulate proliferation of monocytes and dose-
dependent secretion of proinflammatory cytokines like TNF-α, IL-6 in human in vitro (Kiguchi et 
al., 2009). In vitro, murine leptin stimulates the expression of CC chemokine ligand via the 
JAK2-STAT3 pathway. Dendritic cells have been shown to express leptin receptor ObRb on cell 
surface and in response to leptin, increased production of IL-8, IL-2, IL-6 and TNF-α and 
decreased production of MIP-1-α have been observed (Mattioli et al., 2005). Based on the 
observation that mast cells express both leptin and leptin receptor simultaneously, a paracrine 
mode of leptin stimulation in these cell lines have been proposed (Taildeman et al., 2009). 
 
C) Activation of neutrophils:  Neutrophils have been shown to express short forms of 
leptin receptor. Leptin signaling in these cells increases the CD11b expression, preventing 
apoptosis (Zarkesh-Esfahani et al., 2004). Similar to G-CSF, leptin has been shown as survival 
cytokine for the human polymorphonuclear neutrophils (PMN) (Bruno et al., 2005). Several 
studies have suggested the effect of leptin on the chemotaxis of neutrophils (Caldefie-Chezet et 
al., 2003; Faggioni et al., 2001; Ottonello et al., 2004). Leptin induces release of inflammatory 
cytokines by eosinophils and stimulate chemokinesis (Wong et al., 2007). 
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Figure 2.2. Effects of leptin on innate and adaptive immune responses: Leptin affects both innate 
and adaptive immunity. In innate immunity, it modulates the activity and function of neutrophils by 
increasing chemotaxis and the secretion of oxygen radicals through direct and indirect mechanisms. In 
mice, leptin seems to activate neutrophils directly. In humans, the action of leptin seems to be mediated by 
tumour necrosis factor (TNF) secreted by monocytes. Leptin increases phagocytosis by 
monocytes/macrophages and enhances the secretion of pro-inflammatory mediators of the acute-phase 
response and the expression of adhesion molecules. On natural killer (NK) cells, leptin increases cytotoxic 
ability and the secretion of perforin and IL-2. In adaptive immunity, leptin affects the generation, maturation 
and survival of thymic T cells by reducing their rate of apoptosis. On naive T-cell responses, leptin 
increases proliferation and IL-2 secretion through the activation of MAPK and PI3K pathways. On memory 
T cells, leptin promotes the switch towards TH1-cell immune responses by increasing IFN-γ and TNF 
secretion, the production of IgG2a by B cells and delayed-type hypersensitivity (DTH) responses8. This 
process is then sustained by an autocrine loop of leptin secretion by TH1 cells. Finally, leptin has anti-
apoptotic effects on mature T cells and on haematopoietic precursors. APC, antigen-presenting cell. 
(Adopted from La Cava & Matarese, 2004) 
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D) Activation of Natural Killer (NK) cells: These cells have been shown to expressing 
long and short LR forms constitutively. Leptin has been shown to upregulate IL-2 and perforin 
expression in NK cells, an observation that can be correlated with the  the impaired NK cell 
function in mouse models with homozygous inactivating mutation in leptin receptor gene (db/db)  
(Tian et al., 2002; Zhao et al., 2003). Leptin potentiates the NK cell maturation, differentiation, 
activation and cytotoxicity; thus directly affecting the innate immunity (Matarese et al., 2005). 
 
2.2.3. Role in Immune system: Adaptive immunity 
The various roles of leptin in adaptive immunity includes thymic homeostasis, proliferation of T 
cells and regulation of T cell response (Figure 2.2). Leptin deficient ob/ob mice show atrophy of 
lymphoid organs, have lower circulating T cells, higher monocytes and present decreased 
sensitivity of T-cells, thus suggesting a direct involvement of leptin in the development and 
regulation of adaptive immunity (Fantuzzi and Faggioni, 2000; Howard et al., 1999; Lord et al., 
1998). Leptin induced expression of thymic growth factor IL-7 by thymic epithelial cells suggests 
a crucial role of leptin in thymic homeostasis (Gruver et al., 2009). Acute hypoleptinemia leads 
to apoptosis of thymic cells, atrophy of spleen (Montez et al., 2005) in mice. T-lymphocytes 
express long form leptin receptor (LR) by which it receives the survival signal during thymic 
maturation (Howard et al., 1999). A direct effect of leptin on T-lymphocytes in the absence of 
monocytes whereby costimulation of these cells by leptin and PHA or concavaline A drives 
activation, proliferation and enhanced cytokine (IL2, IFN-γ) production (Martin-Romero et al., 
2000) via the long form LR (Sanchez-Margalet et al., 2002). The hyporesponsiveness of T cells 
in obese subjects with monogenic obesity links the role of leptin for the modulation of T cell 
function. 
 
2.2.4 Effect of Leptin on Hematopoiesis  
The evidence for the involvement of leptin in hematopoiesis comes from the observation that the 
long form LR has been found to be expressed in yolk sac, fetal liver, bone marrow, fetal marrow 
stromal cells and megakaryocytes. (Bennett et al., 1996; Cioffi et al., 1996; Gainsford et al., 
1996; Konopleva et al., 1999). Leptin has been shown to promote formation of granulocyte-
macrophage colonies from murine bone marrow cell and stimulates activity of stem cell factor 
(SCF) and erythropoietin (Umemoto et al., 1997). Also proliferation of BaF3 and multilineage 
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progenitor cells have been observed to be induced by leptin (Bennett et al., 1996). Though there 
are evidences against a direct role of leptin in hematopoiesis (Gainsford et al., 1996), a reduced  
 
 
Figure 2.3. Leptin-induced endothelial cell migration and angiogenesis: Binding of leptin to LR on 
endothelial cells leads to tyrosine (shown by red bands) phosphorylation by JAK and induces their 
migration through activation of the PI3K–AKT–eNOS and ERK1–ERK2 signaling pathways. Activation of 
AKT induces reorganization of the actin–myosin cytoskeleton and subsequent cell movement. ERK1 and 
ERK2 modulate cell motility through downstream phosphorylation and activation of MLCK. Leptin is also 
able, in breast cancer cells, to increase VEGFA gene transcription through effects on the HIF-1α and 
NF-κB binding sites in the VEGFA promoter, via activation of canonical (PI3K, ERK) and noncanonical 
(p38 MAPK, JNK, and PKC) signaling pathways. VEGF, in turn, induces endothelial cell migration via 
PI3Kgnaling pathways. Activation of AKT induces reolls. In addition, VEGF activates PLC-γ1 in endothelial 
cells, increasing levels of intracellular calcium ions, which are also responsible for eNOS activation and 
nitric oxide production. Abbreviations: AKT, protein kinase B; eNOS, endothelial nitric oxide synthase; 
ERK, extracellular regulated kinase; HIF-1α, hypoxia inducible factor 1α; JAK, Janus kinase; JNK, 
mitogen-activated protein kinase; LEP-R, leptin receptor; MAPK, mitogen-activated protein kinase; MLCK, 
myosin light chain kinase; NF-κB, nuclear factor κB; PI3K, phosphatidylinositol 3 kinase; PKC, protein 
kinase C; PLC-γ1, phospholipaseC-γ1; VEGF, vascular endothelial growth factor; VEGF-R, VEGF 
receptor. (Adopted from Andò & Catalano, Nature Reviews Endocrinology, 2012) 
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level of lymphopoetic progenitor cells, defective erythrocyte production in spleen in db/db mouse 
(Bennett et al., 1996), decreased number of circulating lymphocytes and elevated levels of 
monocytes in ob/ob mice (Faggioni et al., 2000) clearly postulates some essential role of leptin 
particularly in lymphocytic lineage. 
 
2.2.5 Role in Angiogenesis 
Expression of leptin receptor on endothelial cells and leptin induced STAT-3 and Erk 1 
activation set the premise to investigate the role of leptin in angiogenesis (Figure 2.3) 
(Bouloumie et al., 1998; Sierra-Honigmann et al., 1998). Later observations of in vivo 
neovascularization and formation of capillary like structures in human umbilical venous 
endothelial cell culture in vitro have provided sufficient evidence to associate leptin with 
angiogenesis (Bouloumie et al., 1998). Leptin via tyrosine kinase-dependent signaling cascade 
generates growth signals necessary for formation of new blood vessels. However, knockout 
mice for leptin or its receptor, do not manifest any defect in angiogenesis due to compensatory 
mechanisms involving other angiogenic factors. Recent studies have shown the role of leptin as 
a pro-angiogenic signal in breast cancer inducing vascularization via upregulation of vascular 
endothelial growth factor (VEGF) (Ando and Catalano, 2012; Gonzalez et al., 2006; Newman 
and Gonzalez-Perez, 2013; Zhou et al., 2011).  
 
2.2.6 Role in reproduction  
Due to localization of leptin receptor in hypothalamus, which is also known to regulate 
reproduction, leptin was initially hypothesized to be involved in onset of maturity and regulation 
of reproduction. In vitro studies suggested the leptin induced dose-dependent acceleration of 
gonadotropin releasing hormone (GnRH) pulsatility in the arcuate nucleus of the hypothalamus 
(Lebrethon et al., 2000). About 90 % of the gonadotropes in the pars tuberalis and 30% of the 
gonadotropes in pars distalis in the anterior pitutitary have shown to express LR, suggesting 
gonadotropin (LH and FSH) secretion might be regulated by leptin signaling. The observation of 
minute to minute oscillation of serum adreno-corticotrophic hormone (ACTH) and cortisol levels 
in men (Licinio et al., 1997), serum luteinizing hormone (LH) and estradiol levels in women 
(Licinio et al., 1998), being significantly related to the leptin pulsatile levels in serum, adds an 
extra dimension to the role of leptin in reproduction. Administration of leptin to non-human 
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primates and prepubertal mice has shown it to accelerate puberty (Rogol, 1998).  Human 
subjects with an inactivating mutation in leptin receptor gene, remained prepubertal and had 
hypogonadotrophic hypogonadism (Clement et al., 1998). This suggests an important role 
played by leptin in onset of puberty. Expression of functional LR in gonads suggest the 
peripheral role of leptin (Caprio et al., 1999; Karlsson et al., 1997) in reproduction. 
 
2.2.7 Role in embryo implantation and development 
Leptin serum level has been shown to be correlated with fetal body weight gain (Harigaya et al., 
1999). This cytokine has direct effect on the oocyte maturation and preimplantation embryo 
development, in vitro (Craig et al., 2005). Indirect assessment based on the expression of leptin 
and leptin receptor at the implantation sites has led to the proposed role of leptin in embryo 
implantation (Cervero et al., 2005). Leptin’s role in various fetal physiological processes 
including erythroid and myeloid development (Mikhail et al., 1997), bone metabolism (Ogueh et 
al., 2000) are well established.  
2.2.8 Role in bone metabolism 
Leptin has been shown to induce growth of chondrocytes of skeletal growth centers (Maor G. et 
al., 2002). LR has been shown to be expressed in primary adult osteoblasts and chondrocytes 
while leptin plays essential role in skeletal growth and development (Steppan et al., 2000). 
Recent work has suggested central leptin injection stimulates bone formation increasing bone 
mineral density in leptin deficient ob/ob mice (Bartell et al., 2011). 
2.2.9 Role in wound healing 
Leptin whose angiogenic role has already been described, has also been shown to enhance 
wound re-epithelialization and skin repair when applied exogenously (Frank et al., 2000; Goren 
et al., 2006; Murad et al., 2003; Ring et al., 2000). Leptin expression is induced in wound tissue 
and this endogenous leptin plays potential role in wound healing (Marikovsky et al., 2002).  
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2.3 STRUCTURE OF LEPTIN 
The mature leptin is a non-glycosylated 16 kDa protein of 146 amino acid length (Figure 2.4A). 
As the purified human leptin aggregates extensively, crystal (PDB ID: 1AX8) structure of a point 
mutant carrying tryptophan to glutamate (W100E) mutation at 100th position (Figure 2.4B), has 
been successfully solved at 2.4 Å resolution (Zhang et al., 1997a).  
 
2.3.1 Structure of Leptin-E100  
Except for a disordered region from T27 to G38 which the crystal structure lacks, Leptin-E100 
X-ray crystal structure shows it to be a four helical bundle cytokine with four anti-parallel helices 
(A, B, C and D) in up-up-down-down fashion, two long crossover links AB and CD, the short BC 
loop and a kinked 310 helix formed by five residues of Helix D (Q139 to S143). The four helical 
bundle structure is maintained by four conserved regions : D9-T16, M54-A59, D79-H88, Y119-
Q130, contributed by four helices to form a hydrophobic core. The CD loop has a distorted helix 
E formed by residues L107 to E115 and positioned near-perpendicular to the four helices. 
Leptin has only two cysteine residues: C96 (on CD-loop) and C146 (C-terminal residue) (Figure 
2.4A), which form a solvent exposed disulfide bridge essential for the tethering the C-terminal 
end of D-helix to the CD loop via a kinked extension formed by residues N139-S143. This 
disulfide induced kinked extension is essential for the structural stability and/or activity of this 
cytokine, as the mutation of these conserved cysteines render the cytokine inactive.  The short 
E-helix with 2 turns separated by a kink in the CD loop has many highly conserved hydrophobic 
residues (L104, L110, L114, V113) that interact closely with hydrophobic residues at the C-end 
of helix B and N-end of Helix D, thus forming a cap enclosing a lipophilic nucleus that holds the 
B and D helices in position. Two glycines located in the kink region of helix-E are partly 
conserved. The W100E mutation is localized on the CD loop between the C helix and the 
distorted helix E. This tryptophan is not conserved across species and thus may not have any 
structural or functional role in leptin. 
Despite low sequence similarity, when compared with the atomic structures of other related 
cytokines like G-CSF, LIF, CNTF and hGH, the inter-helical angles and the characteristics of the 
long crossover loops in Leptin-E100 was found to be similar. The root mean square deviations  
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Figure 2.4. Structure of Leptin-E100: A) Pairwise sequence alignment of human and murine leptin 
shows high sequence conservation between these two species with sequence identity of 84.9%. The 
unaligned residues are colored blue while similar residues in yellow. Two cysteines have been colored as 
deep salmon. The corresponding scondary structure of human Leptin as derived from its crystal structure 
has been depicted as alpha helix (pink) and loop regions (black). The W100E mutation has been shown 
as red in human leptin sequence.  B) center: X-ray crystallographic structure of human Leptin-E100 (PDB 
ID:1AX8), shown as cartoon, with rainbow color scheme. The N- and C-termini have been labeled. Four 
helices have been named as A, B, C and D. All three loops viz. A-B, B-C and C-D loops have been 
labeled. Left & Right: Two other orientations of human leptin-E100 colored in rainbow scheme. 
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 (RMSDs) for the crystal structures of its homologues are as follows: LIF:2.50Å (85 Cα atoms); 
G-CSF: 2.37 Å (101 Cα atoms); human GH: 1.95 Å (85 Cα atoms). The low electron density for 
the T27-G38 region suggests high flexibility which might get stabilized upon interaction with 
receptor; a phenomenon already seen in IL6 system, where the corresponding region 
undergoes coil to helix transformation upon receptor interaction. The homology among these 
cytokines are further pronounced by the existence of the similar exon-intron boundaries in their 
respective genes (Sprang and Fernando Bazan, 1993). 
Unlike Leptin-E100, the helical kinks utilized to maximize the surface contact with the receptor 
binding epitopes are quite pronounced and localized on A, B and D helix of G-CSF, LIF and 
human GH, respectively. In Leptin-E100, this kink is as small as involving L139, E140 on helix 
D. Another difference between leptin-E100 and other classical type 1 cytokines like G-CSF, LIF 
and human GH is the B helix, which is about two turns shorter in leptin-E100. While an extra 
helix in the AB-loop is characteristic of GCSF, LIF and hGH, leptin-E100 lacks such helix; rather 
a small distorted helix-E is found in the CD loop. The highly conserved aromatic residue (F or 
W) in helix D, found in other type 1 cytokines is missing in leptin; rather Y61 on helix B 
neighboring the hydrophobic E helix cap is highly conserved and may serve similar purpose. All 
these distinctive features provokes to classify leptin into a sub class separate from these 
classical type-1 cytokines. 
 
2.3.2 Computational analyses and mutagenesis: 
 
A) Structural homology based mutagenesis:  
 
Homology modeling of murine leptin followed by superposition onto the structures of well 
characterized close homologues like IL-6 and GCSF led to discovery of the putative binding 
sites on leptin. IL-6 whose structure has been solved in complex with its cognate receptor IL-6 
receptor α (IL-6Rα) and shared co-receptor gp130, has three binding sites: site I is used to 
interact with IL-6Rα; sites II and III are used to interact with two gp130 receptors; thus forming a 
hexameric assembly of two IL-6:two IL-6Rα:two gp130 (Boulanger et al., 2003). GCSF on the 
other hand uses only site II and III to interact with two cognate receptors; thus forming a 
tetrameric assembly (Layton and Hall, 2006). Based on the superposition of the homology 
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modeled murine leptin onto the solved structures of type 1 cytokines like human leptin (1ax8), 
human CNTF (1cnt), human IL-6 
 
 
Figure 2.5. Position of mutations that affect LR activation in the mouse leptin model: The 
secondary structure of mouse leptin is presented by ribbons. Residues that are involved in mutations that 
affect luciferase activity are presented as space-filling spheres. The spheres are colored according to the 
residual maximal luciferase activity of the mutant: yellow, 0–30% of wild type; cyan, 30–60% of wild type. 
Ser-120, Thr-121, Arg-20, and Gln-75 are presented as orange space filling spheres. (Adopted from 
Peelman et al., 2004) 
 
(1alu), bovine GCSF (1bgc), vIL-6 (1ilr), ovine placental lactogen (1f6f), murine LIF (1lki) and 
human oncostatin M (1evs) followed by prediction of binding sites on murine model based on 
solvent accessibility, 31 mutants have been designed by Peelman et al. (2004). Studying the 
effects of these mutations on the leptin binding to LR and leptin induced LR signaling, has 
provided immense insight into functional roles of these binding sites on leptin surface. The 
location of these mutations on the surface of leptin has been represented in figure 2.5 and 2.6. 
The L13N mutant did not express while among the rest of 30 mutants, those with drastically 
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reduced activation efficiency can be categorized depending on the site of location into following 
categories: 
Site III mutants: S29Q/V30Q/S31N, Q34S/R35S, E115S, S117Q, E122S, S120A/T121A 
Site II mutants: D9S/T12Q, K15S, T16N, R20N, Q75S, N82S/D85S, L86S, L86N, L86Q,  
Site I mutants: F41S, Q138S/Q139S/V142A 
 
(i) Binding Site I: Site I in homologue cytokines bind to a CRH domain on the receptor. IL-
6 site I interacts with the CRH of the shared receptor gp130; while a similar site on GCSF is 
absent in GCSF/GCSFR complex. Based on the mutational analysis performed by Peelman et 
al. (2006), the only site I mutant Q138S/D135S/V142A studied has marked effect on receptor 
activation, while point mutations Q134S and D135S showed only minimal effect on receptor 
activation. Although residues in this region are not conserved and the receptor activation 
potential is only affected by a triple mutation (Q138S/D135S/V142A), possible existence of 
binding site I on leptin has led to the modeling of a hexameric signaling assembly (described in 
section 2.6.2). 
 
(ii) Binding site II: This site mediates the high affinity but non-signaling binding to the CRH 
domain of cognate receptor in type 1 cytokines; so perturbation of this region leads to an 
inactive ligand incapable of binding to its receptor (Figure 2.6 and 2.11). The IL-6 site I interacts 
with the CRH domain of IL-6Rα in the hexameric form of its complex (Boulanger et al., 2003). In 
GCSF/GCSFR complex, site II has been shown to be major binding interaction (Layton et al., 
1999). Structural superposition suggested site II to be present on the surface of antiparallel 
helices A and C. Mutation analysis in the predicted site II on Leptin showed R20N and Q75S to 
affect both binding and receptor activation. Another mutant R20Q located in site II has also 
been shown to be incapable of binding leptin receptor (Verploegen et al., 1997). Mutation of 
polar residues (K15S, D9S/T12Q, N82S/D85S) has shown to hamper the affinity of leptin to 
CRH2 domain. A hydrophobic cleft formed by L13, L86, between helices A and C may also play 
significant role for leptin binding (Iserentant et al., 2005). L13 mutants (L13A, L13N and L13S) 
did not express possibly because L13 is buried and so have important structural role. L86 
mutants (L86S, L86Q, L86N) showed drastically reduced affinity for CRH2.  
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Figure 2.6. Mutations that inhibit the binding to CRH2 in the mouse leptin model: The 
secondary structure of mouse leptin is presented by ribbons. Residues that are involved in mutations that 
affect binding to CRH2 are presented as yellow spacefilling spheres. The Arg-20 and Gln-75 residues are 
presented as orange space-filling spheres. (Adopted from Peelman et al., 2004) 
 
 
 
(iii) Binding Site III: The ligand site III has been found to be essential for interaction with the 
Ig domain of a shared receptor as in IL-6 system (Boulanger et al., 2003) or that of a cognate 
receptor as in GCSF/GCSFR system (Tamada et al., 2006), enabling the ligand to induce 
necessary conformational change in the receptor which is inevitable for the signal transduction. 
So site III mutations will not affect the binding of the ligand, but activation of the receptor after 
binding (Figure 2.5). Based on Peelman et al.’s mutation analysis, site III was found to be 
located in leptin on the N-terminus of D helix, C-D loop and A-B loop. Among all site III mutants 
studied, S29Q/V30Q/S31N, Q34S/R35S, E115S, S117Q, S120A/T121A and E122S affect the 
receptor activation without altering their binding potential. The double mutant S120A/T121A 
behaves as an antagonist leptin. 
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B) Hydrophobic cluster analysis based mutagenesis:  
Hydrophobic cluster analysis (HCA), depicts a binary pattern filtering the hydrophobic clusters 
from the polar background in a protein secondary structure and thus enabling the easier 
visualization and extraction of hydrophobic motifs stabilizing the structural topology and 
functional requirement of the proteins. Thus, this method has proven successful in multitude of 
objectives ranging from distant-homologue search to essential amino acid recognition in 
proteins by comparison with homologues. HCA of leptin in light of well-characterized vIL-6 (PDB 
Id: 1I1R) binding epitopes has led to identification of a hydrophobic strand (V36TGLDFI42) in the 
A-B loop of leptin corresponding to the hydrophobic cluster “IFHLKL motif” in the A-B loop of 
vIL-6 (Niv-Spector et al., 2005) (Figure 2.7). The leptin-E100 crystal structure (PDB ID: 1AX8) 
lacks electron density corresponding to the A-B loop and so this region is supposedly 
unstructured in the unbound leptin. Based on the structure based sequence comparison of 
leptin A-B loop with the corresponding loop of vIL-6 structure (PDB ID: 1ILR) and IL-6 
(PDB:1P9M), no significant information could be obtained due to low sequence similarity. But 
using HCA strategy, Niv-Spector L. et al. identified a hydrophobic cluster comprising 
V36TGLDFI42 at the center of the A-B loop. The corresponding hydrophobic cluster in vIL-6 
forms a typical β-strand “IFHLKL” in vIL-6 at the center of A-B loop as observed in the crystal 
structure of vIL-6/gp130 complex (PDB: 1ILR). This vIL-6 β-strand engages in interaction with 
the β-sheet of the Ig-domain of gp130, drives the receptor activation and thus essential for the 
function of vIL-6. A similar role was hypothesized for the hydrophobic cluster in leptin A-B loop. 
Further mutagenic analysis corroborated the role of this β-strand to be essential for the Leptin-Ig 
domain interaction necessary of LR activation. 
Mutations in the A-B loop of human and ovine leptins (L39A/D40A, F41A/I42A and 
L39A/D40A/F41A/I42A) did not affect the binding to LR; but they lost the potential to elicit the 
STAT signaling. As these residues have been proposed to interact with the Ig-domain of LR in a 
fashion similar as observed in vIL-6/gp130 crystal structure, these residues should be included 
in the site III of leptin. 
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Figure 2.7. Comparison of the HCA plots of human leptin and vIL-6: The IL-6’s site III 
interacts with the gp130’s IGD. The region including the short β-strand of the A–B loop of vIL-6 interacts 
with a short extended region preceding the IGD strand βA. The corresponding expressions of these short 
β-strands on the two-dimensional representations of the sequences (HCA plots) are shown with grey (vIL-
6) and black (gp130) arrows. In the HCA plots, the sequence is shown on a duplicated α-helical net, in 
which the hydrophobic amino acids (V, I, L, F, M, Y and W) are circled. These form two-dimensional 
hydrophobic clusters, the positions of which have been shown to mainly match those of regular 
secondary structures. Despite low levels of sequence identity, comparison of the HCA plots indicates the 
presence of conserved hydrophobicity (shaded in grey) within clusters, indicative of similar secondary 
structures. Although the experimental structures of leptin are known (PDB ID:1AX8), a poor density was 
observed for the first part of the leptin A–B loop (no residues are visible from Ser25 to Gly38), indicating a 
high flexibility of the loop in the uncomplexed form of the cytokine. The cluster associated with the β-
strand of the vIL-6 A–B loop, which is involved in the interaction with gp130, is shown in black. The two 
disulfide bonds located at the beginning and at the end of this loop are indicated by black lines. The only 
hydrophobic cluster of the leptin A–B loop, which is highly typical of an extended structure, is also shown 
in black. (Adopted from Niv-Spector et al., 2005) 
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2.3.3  Leptin Antagonists: Perspective tool for delineation of 
mechanistic principles 
Site directed mutagenesis of human leptin has led to discovery of site III mutants with 
comparable binding potential but no/low activation potential, (Verploegen et al., 1997; Peelman 
et al., 2004; Niv-Spector et al., 2005). Such antagonist leptin can bind LR without eliciting a 
signaling and hence they can potentially be used for therapeutic purpose as in auto-immune 
diseases (La Cava and Matarese, 2004) or as a tool to study the mechanism of signal 
transduction (Feldman et al., 2005; Shim et al., 2002). Two antagonist leptins S120A/T121A and 
39AAAA42 mutants have been described in detail for their relevance in the current doctoral 
research.   
A) Leptin S120A/T121A mutant: This mutation drastically reduced the ability of leptin to 
activate the cognate receptor while binding with the leptin receptor remained unaffected 
(Peelman et al., 2004). The maximal luciferase activity that is directly related to the leptin 
induced signaling intensity was found to have reduced by nearly 14 times for this mutant 
compared to that for wild type leptin. The half maximal effective concentration (EC50) was found 
to have increased approximately 10,000 times and thus a higher concentration of mutant is 
necessary to achieve maximal signal strength. In the competitive binding assay, the half 
maximal inhibitory concentration (IC50) of S120A/T121A mutant for wt-Leptin/Leptin binding 
domain interaction  was found to be 1.5 nM, emerging as the strongest antagonist of all 31 
mutants analyzed by Peelman et al (2004). The site of mutation was found to be located 
corresponding to the site III of other homologues on the superposed model (Figure 2.8). In vivo 
studies in mouse showed S120A/T121A mutant to stimulate feeding, reduce energy expenditure 
and thereby increasing the total body mass, possibly competitively inhibiting the binding of 
native wt-leptin to leptin receptor. Beyond the fact that S120 and T121 is part of site III and 
participate either directly or indirectly in leptin-site III/LR-Ig-domain interaction, the exact in vivo 
mechanism of antagonism is largely unknown.  
 
B) Leptin L39A/D40A/F41A/I42A mutant: This stretch of amino acids L39-I42 proceeds 
the missing electron density region of T25-G38 residues in the crystal structure solved for leptin-
E100 and forms the part of the A-B loop (Figure 2.8). This and other related mutants have been 
characterized to have similar binding affinities as wild type leptin for the ligand binding domain 
of cognate receptor LR.  
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Though both of these mutants act as antagonist preventing receptor activation following binding 
to CRH2 domain of LR, there exists possibility whereby these two may differ in the mechanism 
of their antagonism. Nonetheless, the events that lead to an active signaling complex following 
the site II/CRH2 binding would be missing in the antagonist leptin system. So these mutants can 
be used as molecular tools to study the behavior of resulting complexes by disintegrating the 
ligand binding from receptor activation. Subsequent blockade in the formation of a signaling 
complex on membrane can provide important insights into the mechanism of leptin mediated LR 
activation.      
 
 
 
Figure 2.8. Sites of mutation in antagonist leptins: The 120ST121 present in binding site III, upon 
mutation to alanine behaves as an antagonist. The 39LDFI42 stretch discovered by hydrophobic cluster 
analysis upon substitution mutation to alanine also confers antagonism.  
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2.4 LEPTIN RECEPTOR 
The leptin receptor was originally identified by scanning for tissue types capable of binding 
alkaline phosphatase tagged leptin and radioactive 125I labeled leptin (Tartaglia et al., 1995). 
The expression of the receptor in the choroid plexus mouse brain led to understanding of the 
mechanism of central nervous system regulating energy homeostasis and energy intake via the 
leptin/leptin receptor system. Expression cloning followed by nucleotide sequencing suggested 
it to be a single membrane-spanning receptor containing motifs similar to gp130. In spite of a 
heavy volume of data available today mostly based on indirect methods like mutagenesis and 
fluorescence spectroscopy, a mechanism for the leptin dependent activation of LR compatible 
with all available data is still to need be deciphered, largely because of the higher degree of 
complexity that exists in this system. 
 
2.4.1 Structure of Leptin receptor ectodomain 
The full length leptin receptor is 1162 residue long with following three regions: extracellular part 
(LRecto), single pass helix trans-membrane domain (LRTM) and an intracellular part (LRIC) (Figure 
2.9A). Leptin receptor belongs to the type 1 receptor family characterized by having a four 
helical bundle ligand, disulfide cluster and WSXWS motif.  
LRecto (Figure 2.9A) has a membrane-distal N-terminal secretion signal sequence which 
undergoes cleavage during insertion of the receptor into the membrane. This signal sequence is 
followed by the n-terminal domain (NTD), approximately of 100 residues but no sequence 
similarity to any known proteins. The rest part can be divided into 4 functional regions: first 
cytokine receptor homology (CRH1) domain, immunoglobuline (Ig) like domain, a second 
cytokine receptor homology (CRH2) domain, followed by two membrane proximal fibronectin 
type III domains. This modular structure shows striking similarity with many receptors belonging 
to gp130 family of shared receptors in having an Ig-like domain (gp130, G-CSFR, IL-6Rα) and 
having multiple CRH domains (as in LIFR and OSMR). 
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Each of the CRH domains in LRecto has a WSXWS motif and conserved disulfide cluster, 
characteristic of the type 1 cytokine receptor family. In erythropoietin receptor, WSXWS motif 
Figure 2.9. Schematic structure of leptin receptor: (A) Leptin receptor can be divided into three 
parts: extracellular (LRecto), transmembrane (LRTM) and intracellular (LRIC). The extracellular part LRecto
has a n-terminal domain (NTD) (red) which do not show any homology to any other known protein folds. 
The rest part can further be divided into four functional regions: distal most 1st cytokine receptor 
homology, CRH1 (red), immunoglobulin like, Ig domain (violet), 2nd cytokine receptor homology, CRH2 
(orange) and two membrane proximal fibronectin type III domains, FNIII (green). The transmembrane 
region (LRTM) is formed by a single pass helix. The intracellular part (LRIC) has a box1 motif that harbors 
janus kinase (JAK) binding site. Following receptor activation, JAK gets activated by cross-
phosphorylation. Activated JAK phosphorylates three highly conserved tyrosine residues, which then acts 
as the platform for the binding of Signal Transducer and Activator of Transcription (STAT3) proteins. Such 
bound STAT molecules undergo JAK mediated phosphorylation. This follows with dissociation of STAT 3 
and regulation of gene expression in nucleus. (B-C) Primary sequence of murine (top, B) and human 
(bottom, C) leptin receptor annotated to show different domains, predicted domain borders, N-linked 
glycosylation sites, position of free cysteins and disulfide clusters. The color scheme for different domains 
are as follows: secretion signal, SS (black); n-terminal domain, NTD (salmon); 1st cytokine receptor 
homology domain, CRH1 (red); Ig domain (purple); 2nd cytokine receptor homology domain (orange) and 
fibronectin type III domains, FNIIIs (green).  
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has been shown to be crucial for efficient folding of CRH domain (Hilton et al., 1996; Yoshimura 
et al., 1992). Recently, this motif has been shown to act as a molecular switch stabilizing the 
dimeric prolactin receptor upon prolactin binding and thus playing essential role in formation of a 
sustainable signaling complex (Dagil et al., 2012). In IL21 system, another type 1 receptor 
system, WSXWS motif has been shown to be essential for the A-shaped architecture of the 
receptor-ligand complex by the formation of hydrogen bond between two C-mannosylated 
tryptophans (1st W of WSXWS) of this motif coming from two CRH domains in single IL21R 
(Hamming et al., 2012). Though there is not much information of such role of WSXWS motif in 
leptin receptor, the WSXWS motif of CRH2 domain has asparagine (N624) at X position which 
has been reported to be glycosylated (Haniu et al., 1998).  
The extracellular part of the human LRecto has at least 20 putative N-linked glycosylation sites as 
determined by the signature motif NXS/T motif (Figure 2.9B-C). Mass spectrometric analysis 
showed hLRecto has unusually high amount N-glycosylation, accounting for a total of 18 sites 
(i.e. 1 in every 46.61 residues in average) and equivalent to 36% of the total molecular mass of 
the protein (Haniu et al., 1998). Only two putative N-glycosylation sites which were not found to 
be glycosylated are N433 (in CRH2) and N670 (in distal FNIII). Distribution of these 
experimentally determined N-glycosylation sites across different domains are as follows: 9 sites 
in CRH1, 2 in Ig domain, 2 in CRH2, 4 in distal FNIII and 1 in proximal FNIII domain. The 
glyosylation of the asparagine residue which is part of the conserved WSXWS motif in CRH2 
may assist in folding or the stabilization of the LR structure (Haniu et al., 1998). 
 
i) 1st Cytokine Receptor Homology domain (CRH1): Like CRH domains of other type 1 
receptors, this region is formed of two structural domains. It has no known function as it does 
not interact with leptin nor required for LR activation in vitro. Although recent evidences show its 
involvement in obesity among certain ethnic groups (Quinton et al., 2001; Duarte et al., 2006) 
and increased susceptibility towards protozoan infection in children (Duggal et al., 2011) due to 
a naturally occurring single nucleotide polymorphism Q223R in this region. This suggests CRH1 
might have some physiological role to play which is yet to be discovered. Deletion of CRH1 
domain results in reduced signaling intensity (Zabeau et al., 2004).  
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ii) Ig-like domain (Ig): Ig domain is essential for the activation of LR mediated by leptin site III 
interaction followed by ligand binding to CRH2 (Zabeau et al., 2004). There are two N-
glycosylation sites on N347 and N397. Two disulfide bridges (C352-C412 and C413-C418) have 
been shown to stabilize the Ig domain in human LR (Haniu et al., 1998). 
 
iii) 2nd Cytokine Receptor Homology domain (CRH2): Based on domain truncation study, 
Fong TM et al. (1998) has shown the deletion of the CRH2 domain led to loss of LR’s binding 
ability to leptin; thus suggesting CRH2 is the high affinity leptin binding domain on LR. 
Structurally, CRH2 region has two sub-domains. CRH2 domain expressed in isolation in 
Escherichia coli has shown to bind leptin with a KD of 15.4nM and a 1:1 stoichiometry 
(Sandowski et al., 2002). Structural superposition with homologues and mutagenesis suggests 
site II of leptin interacts with this domain (Peelman et al., 2004). Human CRH2 domain has 2 
glycosylation sites, 4 free cysteines and 2 disulfide bridges as shown by Haniu M. et al. (1998). 
Though there is no crystal structure available for leptin receptor or its subdomains alone or in 
complex with its cognate ligand, recently solved crystal structure of CRH2 domain expressed in 
prokaryotic expression system in complex with a monoclonal antibody 9F8 Fab (PDB ID: 3V6O), 
provides the first structural details of this domain at atomic resolution (Carpenter et al., 2012) 
(Figure 2.10). Presence of two copies of CRH2/9F8 Fab complex in the asymmetric unit with the 
two CRH2 in proximity to each other in a cross-shaped erythropoietin receptor (EPO) like 
conformation and sharing an interface with buried surface area of 700Å may not suggest ruling 
out the possibility of low affinity interaction via this interface on cell surface. Though authors 
have stressed on the crystal packing interaction to be more likely for this kind of dimerization 
interface. Interestingly, the IFLLS cluster shown to involve in high affinity binding with leptin 
(Iserentant et al., 2005) is located in the CRH2-CRH2 interface in the 3V6O crystal structure. 
 
This crystal structure shows CRH2 to be composed of two subdomains, each adopting a 
fibronectin type III fold containing beta sheet sandwich (Figure 2.10D and 2.9E). Missing 
electron density includes loop regions in B-C loop, J-K loop, L-M loop and accounting for 39  
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Figure 2.10. Crystal structure of a CRH2 domain binding monoclonal antibody 958 Fab in 
isolation and in complex with human Leptin expressed in Escherichia coli:(A) Ribbon 
representation of the 9F8 Fab. The CDRs from the light chain (light gray) and heavy chain (dark gray) are 
colored blue and red, respectively. The glycosylation of Asn-22 of the light chain is shown as sticks and 
marked by an asterisk. (B) Surface representation of the CDR regions of 9F8 Fab. The deep cavity at the 
interface between the light and heavy chains is clearly visible; the glycosylation of Asn-22 of the light 
chain is marked by an asterisk. (C) Ribbon representation of the two copies of the LBD-9F8 Fab complex 
in the asymmetric unit. The two LBD molecules are colored blue and magenta, the 9F8 Fab molecules 
are colored yellow (heavy chain) and green (light chain). (D) A single copy of the LBD-9F8 Fab complex 
showing that 9F8 Fab binds to the N-terminal subdomain of LBD. (E) Secondary structural elements of 
LBD colored by rainbow: N terminus, blue; C terminus, red. Key loops, which are discussed in the text, 
are labeled; unmodeled loops are indicated by dashed lines and marked with an asterisk. (Adopted from 
Carpenter et al., 2012) 
 
residues. The cysteinylation of the exposed cysteine C604 is a byproduct of refolding of CRH2 
in the presence of excess cysteine and have been shown to act as an important crystal lattice 
contact. The WSXWS motif, characteristic of type 1 receptor family, forms a π-cation stack with 
R573, W583, R612 and K614.  
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Disulfide map of CRH2 domain: Mass spectrometric analysis of CRH2 region from human LR 
has suggested existence of two disulfide bridges (C473-C526 and C486-C498) (Haniu et al., 
1998) (Figure 2.9B-C). Structural superposition and sequence comparison of murine Leptin with 
other long chain cytokine receptor CRH domains has led the assumption that C434 (C436 in 
human) and C445 (C447 in human) would be disulfide linked (Iserentant et al., 2005). Recently, 
the solved structure of human CRH2 domain in complex with a neutralizing Fab fragment (PDB 
ID:3V6O) has proven existence of three disulfide bridges in human CRH2: C436-C447, C473-
C528, C488-C498 (Carpenter et al., 2012).  The 7th and 8th cysteines in murine CRH2, C602 
(C604 in human) and C611 (C613 in human), does not form any disulfide bridge. Crystal 
structure of human CRH2 shows C613 to be completely buried in the core while C604 is solvent 
exposed. Earlier studies by Zabeau L. et al. (2005) suggesting involvement of free cysteine in 
CRH2 domain in homotypic interaction responsible for leptin-independent covalent-dimerization 
of LR have been contradicted by Carpenter B. et al. (2012), based on evidences of existence of 
intra-receptor disulfide bridge between C604 of CRH2 and C-674 of FNIII based on CRH2 
crystal structure alignment with gp130 ectodomain crystal structure (PDB ID: 3L5H). Out of total 
4 disulfide bonds in CRH2 domain, 3 are present in the distal domain and only 1 in proximal 
connecting CRH2 with FNIII, suggesting proximal domain might have a greater conformational 
plasticity to accommodate any leptin induced structural reorganization.     
 
iv) Fibronectin type III domains (FNIII): The membrane proximal tandem FNIII domains do not 
take part in ligand binding, but are essential for LR activation (Fong et al., 1998; Zabeau et al., 
2005). Mass spectrometric analysis has revealed FNIII of human LR has 3 free cysteines (Haniu 
et al., 1998): C674, C687 and C753 (Figure 2.9B-C). The FNIII domain of murine LR has only 2 
free cysteines: C672 and C751. Substitution mutation C672S in murine FNIII drastically reduces 
the STAT3-dependent signaling; while C751S has very limited effect (Zabeau et al., 2005). The 
double mutant C672S/C751S is devoid of signaling capacity, suggesting a critical role played by 
FNIII cysteines in LR activation. Presence of these surface exposed cysteines has resulted in a 
very high propensity of inter-FNIII covalent clustering in vitro when this domain was expressed 
in isolation. On the premise of the ligand induced receptor-receptor disulfide bridge formation in 
IL-3 receptor system and the critical role of FNIII cysteines in LR, a ligand-induced inter-receptor 
FNIII-FNIII disulfide bridge formation model have been put forth (Zabeau et al., 2005). A 
truncated receptor with only FNIII on extracellular part is constitutively active (Zabeau et al., 
2005). Comparing the results of Zabeau et al. (2005) showing that LR without CRH1 domain is 
2
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active and work of Fong TM et al. (1998) showing inactivity of LR without CRH1 and FNIII 
domains, precisely suggest that FNIII domains may play a major role in orienting the 
intracellular domains from a non-signaling conformation into a signaling conformation upon 
binding of ligand. On the other hand, constitutively active FNIII receptor suggests, CRH1, Ig and 
CRH2 domains orient the intracellular domains in an inactive configuration; so either ligand 
binding or removal of CRH1, Ig and CRH2 domains makes the receptor active. Mass 
spectroscopic analysis has shown the two FNIII domains to have 5 N-glycosylation sites in 
human (Haniu et al., 1998) (Figure 2.9B-C).  
 
2.4.2  Mapping of Interface between Leptin and CRH2 
Alanine scanning mutation of interface residues  based on homology model of 
CRH2/Leptin has provided important insights into the binding interface (Iserentant et al., 2005). 
Six out of sixteen mutants studied: I501A, F502A, L503A, L504A, S505A and D615A showed 
lesser sensitivity to leptin, distinct reduction in LR signaling. I501A, F502A, L503A, L504A and 
S505A mutants reduced the LR signaling drastically and increased the EC50 to 33.5-55.0nM vs. 
6.44nm of wild type LR. This motif IFLLS is present on the E-F loop close to the hinge region on 
the distal CRH2 domain (Figure 2.11A-C). The D615A mutant is rather less sever with EC50 
value of 24.1nM. This residue is located on the loop connecting the last β-strand “N” to the distal 
FNIII domain on the proximal CRH2 domain close to the inter-domain hinge at a distance of 
16.6 Å and 16.8 Å from the L503 and L504 respectively. D615 may interact with the K5 in leptin 
via polar salt bridge. The effect on the Leptin binding have been assessed to be most severe for 
the I501A mutant with the in vivo measured KD increased by 66 times. This appreciable 
reduction in the binding affinity for these mutants clearly suggests the crucial role played by 
these residues in leptin binding.  
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Figure 2.11. Molecular models of binding site II in leptin: (A) Hydrophobic and aromatic 
residues from the C-D loop (471–472) and E-F loop (505–506) of LBD (light blue) aligned with the 
hydrophobic cavity between helices 1 and 3 of leptin (pink). All contacts shown are less than 4.2 Å . (B) 
Leptin binding domain residues implicated in leptin binding by mutagenesis studies are shown as sticks. 
Important loops are C-D loop (yellow), E-F loop (cyan), J-K loop (magenta), L-M loop (green). The SSLY 
motif (red) is located within the C-D loop. (Adopted from Carpenter et al., 2012) (B) Residues in binding 
site II that affect binding to CRH2 are colored yellow. Residues in binding site II that affect both binding to 
CRH2 and LR activation are colored orange. (Adopted from Carpenter et al., 2012) (C) Model of the 
mouse leptin/CRH2 complex. The molecular surface of leptin is colored according to the surface 
hydrophobicity (blue, hydrophilic; green, hydrophobic). The CRH2 model is presented as ribbons, the Cα 
atom and heavy side chain atoms of residues I501, F502, L503, L504S and D615 are displayed as white 
sticks. L504 of CRH2 fits into the hydrophobic cleft of leptin and interacts with L13 and L86 of leptin 
(Adopted from Iserentant et al., 2005)  
 
The role of the hydrophobic patch “IFLLS” have further been assessed with 
hydrophobicity-reversal mutations by mutating IFLL residues to serine (Iserentant et al., 2005). 
F502S and L503S did not differ much from their alanine counterparts in signaling. I501S and 
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L503S showed sever effect on signaling; while L504S lost its signaling capacity. Interestingly, 
L504S not only lost the signaling capacity, but also the leptin binding affinity was reduced by 
more than 10 times. Thus L504 may provide the most of the buried surface area (210Å) for the 
leptin/LR interaction. Homology based modeling suggests this hydrophobic patch would be 
interacting the hydrophobic cleft (L13, L86, L89, F92) formed in A-C helix in leptin. 
Computational modeling has suggested the involvement of E565, R615 beside D617 (E563, 
R613 and D615 in mouse) of CRH2 with Leptin via polar interactions.  
While Y441A mutation has only limited effect, double mutant of chicken CRH2 with Y441A 
(Y442 in human) and F501A (F500 in human) showed complete loss of binding to ovine leptin 
(Niv-Spector et al., 2005). The authors have suggested important role of F501 in binding. Based 
on the location of the F500 (corresponding ovine F501) at the junction of the β-strand D and DE-
loop in the crystal structure of human CRH2 (PDB ID:3V6O) (Figure 2.11A-B), F501A mutation 
in ovine CRH2 domain can have a profound effect on the position and/or secondary structure of 
the DE-loop harboring the conserved motif I503FLLS507, shown crucial for leptin binding 
(Isenterant et al., 2005). The importance of IFLLS motif has been shown in chicken by 
corresponding 504-VFLL-507 substitution mutation resulting loss of binding capacity. 
Mutagenesis of A533D/D534V in chicken leptin abolished its binding potential (Niv-Spector et 
al., 2005); although sequence alignment with human CRH2, does not show any conservation of 
these residues.    
 
2.4.3  Physiological role of N-linked glycans in LR 
N-linked glycosylation is a posttranslational modification of proteins characteristic of 
eukaryotes, archaea,  but very rarely found in bacteria. Evidences suggest N-linked glycans 
play important role both in structure and function of the protein. LR has been shown to be 
unusually heavily glycosylated with 18 glycosylation sites in human LRecto (Haniu et al., 1998) 
(Figure 2.9). Analysis of importance of n-linked glycans in class I cytokine receptor neighbors 
has demonstrated crucial roles played by these glycans in some receptor systems if not in all. In 
GM-CSF receptor β, substitution of N-glycosylation site within CRH domain and 2 in close 
proximity interferes in ligand binding (Niu et al., 2000). In the shared receptor gp130, N-linked 
glycosylation has been shown to be highly crucial for the structural stability; though it has no 
role to play in signaling (Waetzig et al., 2010). In case of LR, treatment of short form LR with N-
2 
Mechanistic Paradigm of Leptin Receptor Activation 
33 
 
glycosidase F has shown to reduce the leptin binding on cell surface by nearly 80% (Kamikubo 
et al., 2008). When LR was expressed in megakaryoblastic cell line MEG-01, similar results 
were obtained; treatment of receptor with N-glycosidase F led to decrease in leptin binding. On 
the contrary, removal of N-linked glycans from isolated CRH2 domain did not abolish the leptin 
binding potential (Kamikubo Y. et al., 2008). Other groups have also showed unglycosylated 
CRH2 domain expressed in bacterial host binds leptin with a nanomolar affinity (Carpenter et 
al., 2012; Sandowski et al., 2002). It has been suggested that n-linked glycosylation in LR has 
no direct role in leptin binding; but these glycans may stabilize the active conformation of the full 
length receptor on cell surface (Kamikubo Y. et al., 2008). 
 
2.4.4  Leptin Receptor Isoforms 
The leptin receptor, also called obesity receptor (ObR) receives an extra dimension of 
complexity by having at least 6 isotypes which differ from each other both at structural and 
functional levels yet to be understood completely (Figure 2.12). The 6 isotypes named ObRa, 
ObRb and so on upto ObRf, differ from each other in their intracellular part. All these isotypes 
except ObRe have identical extracellular parts and a single pass transmembrane helix. But they 
differ from each other in the length and the C-terminal sequence of the intracellular part. All 
these isotypes are membrane bound except ObRe, composed of the extracellular part of LR. All 
these isotypes are formed by alternate splicing; while ObRe has been reported to be formed by 
membrane shedding and proteolytic cleavage of membrane bound LR isotypes in human (Ge et 
al., 2002; Maamra et al., 2001). The longest receptor isotype is the ObRb, which is also the only 
isotype with well-studied signaling capability. All other isotypes are signaling-incapable; though 
they may play crucial roles in modulating leptin mediated signaling in vivo (Yang et al., 2004; 
Zhang and Scarpace, 2009).  
ObRb is the only isotype functionally capable to signal upon leptin binding and thus controlling 
appetite and energy homeostasis. It is also known as long form LR owing it to be longest with 
1162 residues in human. The intracellular part has a functional JAK binding box1 motif and a 
putative box2 motif. 
ObRa, ObRc and ObRd, all are short form Leptin receptor; but they vary in their C-termini. 
ObRa has 894 residues with the unique C-terminal sequence RTDTL. ObRc has 892 residues 
ending with VTV as the unique C-terminus. ObRd is the longest of all short form LR isotypes 
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with 901 residues and the c-terminal sequence specific to this isotype is DISHFHEVFIFR-901. 
The expression of ObRa has been found to be ubiquitous in murine heart, brain, spleen, lung, 
liver, pancreas, adipocyte, skeletal muscle, kidney and testes; while ObRc and ObRd 
expression was extremely low (Fei et al., 1997) in these tissue types. But high level of 
expression have been reported for ObRa and ObRc in choroid plexus and brain microvessels, 
possibly playing role in blood-brain barrier transport of leptin (Tartaglia et al., 1995). All these 
three isotypes lack box1 motif and thus signaling incompetent. 
Initially discovered as a defective mutant (Lee et al., 1996), ObRe is unique from all other 
isotypes in that it is not membrane-bound and is secreted directly into blood plasma in rodents. 
In human this isoform is formed by ectodomain shedding of other membrane bound isoforms  
(Ge et al., 2002). ObRe isotype represent the major binder of leptin in circulating in human 
blood (Lammert et al., 2001). After binding leptin, ObRe regulates the bioactivity of leptin and 
modulates its bioavailability. The generation of ObRe by the proteolytic cleavage of membrane 
bound isoforms in human is not a random phenomenon; rather regulated by a disintegrin and 
metalloproteinase 10 (ADAM10), with increased levels of shedding during induced lipotoxicity 
and apoptosis and reduced levels during high leptin concentration and ER stress(Schaab et al., 
2012). The upregulation of ObRe antagonizes the effect of leptin by reducing levels of unbound 
leptin. The downregulation of ObRe levels in blood results from the decreased membrane 
expression of LR. 
Ob-Rf was first discovered in rat brain cDNA library (Wang et al., 1996). It has 895 residues in 
total with the first 889 residues aligning well with human and mouse leptin receptor ObRb with 
77 and 92% identity, suggesting homology in this region. The six C-terminal residues (IMPGRN) 
from 890 to 895 are unique without any known homologue in human or mouse at the time of its 
discovery, produced by splicing of discrete 3’ exons. There is no literature describing the 
specific role of this isotype. This isotype does not have box2 motif and so can not signal in a 
leptin dependent way. 
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Figure 2.12. Leptin receptor isoforms: At least six different LR isoforms are found in human named 
ObRa to ObRf. ObRb is the longest one with fully functional intracellular parts and thus is the only 
functional isotype. All other isotypes, except ObRe, have intracellular parts with JAK binding box1 motif, 
but lacking STAT binding region. Each of these four (ObRa, ObRc, ObRd and ObRf) have unique C-
terminal stretch of amino acids. The only soluble isotype is ObRe which lacks trans-membrane and 
intracellular parts. All these isoforms are formed by alternative splicing while ObRe is formed by 
ectodomain shedding in human. 
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2.4.5  Leptin Receptor Signaling pathways 
The leptin receptor lacks intrinsic kinase activity and thus depends on the extrinsic kinases for 
phosphorylation of its intracellular part. The receptor juxtamembrane region has the box1 motif 
(6th to 17th amino acid of LRIC) characterized by two highly conserved proline residues, providing 
a binding site for Janus Kinase 2 (JAK2) (Kloek et al., 2002) (Figure 2.9 and 2.13). JAK2 is 
constitutively bound to inactive receptor and only activated upon ligand induced receptor 
oligomerization and conformational change. There is a second conserved motif box2 (49th to 
60th amino acid on LRIC), a putative JAK2 interacting region which may play role in attaining 
maximal signaling activity (Bahrenberg et al., 2002; Kloek et al., 2002). 
While JAK2-binding box1 motif is present in all LR isoforms, three  highly conserved tyrosine 
residues (Y985, Y1077, Y1138 in murine LR) (Eyckerman et al., 2000; Myers, 2004) present only on 
the intracellular part of long form LR (ObRb) play role in recruitment of Signal Transducer and 
Activator of Transcription type 3 (STAT3) molecules. Activated JAK2 phosphorylates these 
three tyrosines and phosphorylated tyrosines form the binding sites for STAT3 molecules. 
Activated JAK2 phosphorylates bound STAT3 and activates it. Such phosphorylated STAT3 
proteins dimerizes and translocates to nucleus for further modulation of gene regulation.  
Although JAK2/STAT3 mediated signal transduction is the well-studied pathway of signal 
transduction in LR system, several other pathways have been shown to be associated with it 
(Figure 2.13). Non-canonical JAK1 activation has been demonstrated (Carpenter et al., 1998).  
STAT1 and STAT5B have been shown to linked with Leptin induced LR activation (Baumann et 
al., 1996). The first tyrosine Y985 has been shown to be involved in the recruitment of SH2-
containing-Phosphatase 2 (Carpenter et al., 1998; Li and Friedman, 1999). Numerous 
evidences exist for the involvement of suppressor of cytokine signaling (SOCS) in Leptin 
signaling (Bjorbaek et al., 2000; Waelput et al., 2000). Leptin and insulin signal crosstalk via the 
phosphatidylinositol 3-kinase (PI3K) pathway (Margetic et al., 2002; Szanto and Kahn, 2000). 
 
 
 
 
2 
Mechanistic Paradigm of Leptin Receptor Activation 
37 
 
Figure 2.13. Signaling pathways 
activated by the leptin receptor: Only 
the long form of the leptin receptor (OBRb) 
can signal intracellularly, whereas the short 
forms of the leptin receptor do not. The total 
length of OBRb is 1162 amino acids; the 
extracellular domain consists of 816 amino 
acids and is a class I cytokine receptor that 
contains two cytokine-like binding motifs, Trp-
Ser-Xaa-Trp-Ser (WSXWS), and a fibronectin 
type III domain. After binding leptin, OBRb-
associated Janus-family tyrosine kinase 2 
(JAK2) becomes activated by auto- or cross-
phosphorylation and tyrosine phosphorylates 
the cytoplasmic domain of the receptor. Four 
of the phosphorylated tyrosine residues 
function as docking sites for  cytoplasmic 
adaptors such as signal transducer and 
activator of transcription (STAT) factors, 
particularly STAT3 (in some cases, also 
STAT1 and STAT5). The membrane distal 
tyrosine (position 1138) functions as a 
docking site for STAT3, which is a substrate 
of JAK2. After subsequent dimerization, 
STAT3 translocates to the nucleus and 
induces the expression of suppressor of 
cytokine signaling 3 (SOCS3) and other 
genes. SOCS3 takes part in a feedback loop that inhibits leptin signaling by binding to phosphorylated 
tyrosines. SRC homology 2 (SH2) domain-containing phosphatase 2 (SHP2) is recruited to Tyr985 and 
Tyr974, and activates extracellular signal-regulated kinase 1/2 (ERK1/2) and p38 mitogen-activated 
protein kinase (MAPK) pathways through the adaptor protein growth factor receptor-bound protein 2 
(GRB2), ultimately inducing the expression of FOS and JUN. After leptin binding, JAK2 can induce 
phosphorylation of the insulin receptor substrate 1/2 (IRS1/2) proteins that are responsible for the 
activation of phosphatidylinositol 3-kinase (PI3K). Phosphotyrosine phosphatase 1B (PTP1B), which is 
localized on the surface of the endoplasmic reticulum, is involved in negative regulation of OBRb 
signaling through the dephosphorylation of JAK2 after internalization of the OBRb complex. (Adopted 
from La cava and Matarese, 2004) 
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2.5 TYPE 1 RECEPTOR ACTIVATION MECHANISMS 
Although type 1 receptors show similarity in various aspects like sharing similar structural 
modules comprised of domains with Ig-like fold and FNIII folds, lack of intrinsic kinase activity 
and presence of the WSXWX motif etc., their mechanism of activation on cell membrane differs 
significantly (Figure 2.14). Based on the usage of a shared receptor, they can be classified into 
following two groups: 
A) Shared cytokine receptors: This group shares common receptors among each other and 
so the signaling complex is always a heteromeric complex.  
B) Non-shared cytokine receptors: These receptors do not share their receptors with each 
other. Thus ligand binding leads to homo-oligomerization.  
 
As the mechanistic aspects and oligomeric nature of the leptin receptor signaling complex is 
not known yet, detailed analysis of the mechanistic principles followed by other members of type 
1 receptors will provide important insights into the commonalities shared with other members, 
while simultaneously contrasting the distinctiveness of LR system from others in the class. So 
far, leptin receptor has shown not to be using any shared coreceptor for signal transduction 
(Nakashima et al., 1997); thus it can be categorized in the non-shared cytokine receptor group. 
On the other hand, the modular structure of LRecto comprising CRH, Ig-like and FNIII domains, 
shows striking similairity with members of shared cytokine receptors utilizing gp130 as co-
receptor (Figure 2.14).    
 
2.5.1 Shared Cytokine Receptors 
This group of receptors utilize both a cognate receptor as well as a shared receptor to form a 
heteromeric signaling complex. Depending on the usage of shared receptors, these cytokines 
and their receptors can be divided into following four families: 
A) γ-chain family 
B) β-chain family 
C) gp130 family 
D) Interleukin 12 (IL-12) family 
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Figure 2.14. Modular structure and classification of type 1 cytokine receptors: Grouping of 
hematopoietic cytokine receptors by shared receptor usage. The majority of the hematopoietic cytokine 
receptors incorporate one of three shared signaling receptors, either the common beta (βc) chain, the 
common gamma (γc) chain or gp130. The crystal structure of the growth hormone (red) complex (inset) 
was the first structure of a four helix bundle cytokine in complex with its receptor (green) (de Vos et al., 
1992) and established the paradigm of cytokine/receptor complex formation. (Adopted from Boulanger 
and Garcia, 2004) 
 
 
A) γ-chain Family 
 
Members of this family are monomeric cytokines having a heterodimeric cognate receptor 
and sharing a common gamma chain among them. So they signal via a quaternary signaling 
complex on cell surface (Figure 2.15). This family includes following cytokine systems: IL-2, IL-
4, IL-7, IL-9, IL-15, IL-21 and Thymic stromal lymphopoietin (TSLP). 
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(i) Interleukin 2/Interleukin 15 Cytokine System  
IL-2 imparts its effect via its cognate receptor IL-2R composed of 2 subunits IL-2Rα, IL-
2Rβ and a shared receptor IL2Rγc. This γc receptor is shared by other ILs like IL-4, IL-7, IL-9 
and IL-15 (He and Malek, 1998). IL-2 rather than binding a preformed heterotrimeric receptor 
(IL-2Rαβγc), follows a more efficient stepwise assembly mechanism whereby it interacts with the 
highly expressing IL-2Rα cognate receptor via a long range, relatively weak and nanomolar 
ionic interaction with high Kon and Koff rates (Forsten and Lauffenburger, 1994). This induces a 
minor conformational change on the IL-2 enabling IL-2/IL-2Rα complex to interact with relatively 
low expressing IL-2Rβ solely via IL-2:IL-2Rβ polar interactions resulting in the heterotrimeric 
complex (IL-2/IL-2Rα/IL-2Rβ). Eventually, this heterotrimeric complex interacts with the 
common γc receptor, with major contributions from the IL-2Rβ:IL-2Rγc degenerate binding sites 
and a minor contribution from IL-2:IL-2Rγc interactions, thus forming the active quaternary 
signaling complex with picomolar affinity. The formation of this signaling complex is followed by 
the phosphorylation of 3 tyrosine residues on cytoplasmic part of IL-2Rβ mediated by JAK1 and 
JAK3 associated with β and γc receptors (Nelson and Willerford, 1998).  
In case of IL-15, the mechanism of activation is very much similar to IL-2 system along 
with participation of the IL-2Rβ/γc complex in the formation of the active quaternary signaling 
complex. The major difference is the trans-presentation of IL-15 leading to a juxtacrine 
signaling, whereby IL-15 bound to IL-15Rα is presented to the IL-2Rβ/γc binary complex from 
another cell (Dubois et al., 2002; Sandau et al., 2004). The binding of IL-15 to IL-15Rα is a high 
affinity interaction with KD value of 30-100 pM (Anderson et al., 1995; Bernard et al., 2004; Giri 
et al., 1995; Mortier et al., 2006).  However, cis-presentation has also been found in IL-15 
system, where by both the cognate and the shared receptors exist on the same cell surface 
(Olsen et al., 2007). 
 
(ii) Interleukin 4/ Interleukin 13 Cytokine System 
IL-4 binds to its cognate receptor IL-4Rα with sub-nanomolar affinity (LaPorte et al., 
2008). The IL-4/IL-4Rα binary complex, depending on the cell type, can form two different types 
of signaling complexes: in hematopoietic cells, this complex interacts with the γc shared receptor 
with a dissociation constant (KD) of 559 nM while in non-hematopoietic cells, this binary complex 
interacts with IL-13Rα1 receptor with binding constant KD of 487nM (LaPorte et al., 2008). An 
experimental set up causing forced homodimerization of IL-4Rα chimeric receptor has resulted  
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Figure 2.15. Receptors for γc family cytokines and TSLP: Shown are the receptors for 
interleukin-2 (IL-2), IL-4, IL-7, IL-9, IL-15, IL-21 and thymic stromal lymphopoietin (TSLP). IL-2 and IL-15 
are the only two of these cytokines to have three receptor chains. The receptors for these two cytokines 
share the common cytokine receptor -chain ( c; also known as IL-2R ) and IL-2R , and the receptors 
for IL-7 and TSLP share IL-7R . Of the cytokines shown, only TSLP does not signal through a receptor 
containing c. There are three classes of IL-2 receptor that bind IL-2 with low affinity (IL-2R  alone), 
intermediate affinity (IL-2R  and c) and high affinity (IL-2R , IL-2R  and c); only the high-affinity IL-2 
receptor is shown. The receptor for each c family cytokine activates Janus kinase 1 (JAK1) and JAK3, 
whereas the receptor for TSLP has been reported to not activate any JAK. The main signal transducer 
and activator of transcription (STAT) proteins that are activated by these cytokine receptors are shown in 
bold. STAT5 refers to both STAT5A and STAT5B. DC, dendritic cell; NK cell, natural killer cell; NKT cell, 
natural killer T cell. (Adopted from Rochman et al., 2009). 
 
in the IL-4 induced receptor activation in the absence of the co-receptors. But in vivo, IL-4Rα 
always works via the ternary IL-4/IL-4Rα/γc or IL-4/IL-4α/ IL-13α1 complex, suggesting 
inevitable requirement of the co-receptors in signaling. Interestingly, IL13 receptor has another 
isoform called IL-13Rα2 (Caput et al., 1996; Zhang et al., 1997b). It has been shown to be a 
non-signaling decoy receptor, with a short, non-functional cytosolic part (Donaldson et al., 
1998). Its major function is the regulation of IL-13 and IL-4 signaling (Andrews et al., 2006). 
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(iii) Interleukin 7/ Thymic stromal lymphopoietin (TSLP) Cytokine System 
The IL-7 cognate receptor IL-7Rα, in the absence of IL-7 has been shown to pre-exist as 
both inactive homodimer  and as inactive heterodimer in complex with the common gamma 
chain γc (Rose et al., 2009; Rose et al., 2010). In vitro studies show little self-association of IL-
7Rα to form homodimer and high affinity interaction between IL-7Rα EC and γc EC with a KD 
value of 140µM (McElroy et al., 2012). IL-7 signals via the ternary complex of IL-7/IL-7Rα/γc.  
Thymic stromal lymphopoietin (TSLP) (Ray et al., 1996), which shows striking similarity to IL-7 
in its signaling mechanism and functionality, signals via a ternary complex formed of its cognate 
receptor TSLPR and shared co-receptor IL-7Rα. The exact mechanism of association of the 
receptors during complex formation are yet to be revealed. 
 
(iv) Interleukin 9 Cytokine System 
IL-9 signals via its cognate receptor IL-9R (Renauld et al., 1992) and common gamma 
chain γc (Kimura et al., 1995) for signal transduction. IL-9 signaling complex is a ternary 
complex of IL-9/IL-9Rα/γc shared receptor (Bauer, 1998). The details of the interaction of the 
extracellular domains have not been revealed till now. 
 
(v) Interleukin 21 Cytokine system 
The shared coreceptor γc has been shown to be indispensable for IL-21 signaling (Asao et 
al., 2001; Habib et al., 2002). IL-21 interaction with its cognate receptor IL-21R has been 
characterized to be high affinity with KD of 70pM (Zhang et al., 2003). Beside, this independent 
binding of IL-21 to IL-21R (Mehta et al., 2004), IL-21 can directly interact with γc, but with 
relatively low affinity (KD=160µM). The mechanism of IL-21 has been proposed to be via a 
ternary complex of IL-21/IL-21R/γc common receptor.  
 
 
 
B) βc-chain Family 
The common β-chain (βc) is shared between at least 3 cytokines: Granulocyte macrophage 
colony-stimulating factor (GM-CSF), IL-3 and IL-5. Human βc is a 881 residue long, glycoprotein 
receptor with an extracellular part of 427 residues comprising two pairs of FNIII domains and an 
intracellular part of 437 residues. It is the major signal transducing unit harboring the docking 
sites for STAT, MAPK, PI3K etc. 
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Figure 2.16. Model of Signal Transduction for GM-CSF: (A) The low-affinity complex consists of 
GM-CSF bound to GMRα. Interaction with free βc forms the high-affinity hexamer complex. Dodecamer 
(or higher-order) complexes form by lateral aggregation of hexamer complexes to form a fully competent 
signaling complex. JAK2 associated with βc (red spheres) is able to dimerize and transphosphorylate in 
the dodecamer complex but not in the hexamer complex. (Adopted from Hansen et al., 2008); (B) Surface 
representation of the GM-CSF receptor dodecamer complex, showing two interacting hexamer complexes 
and the five sites of interaction. (Adopted from Hercus et al., 2012) 
 
(i) Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) Cytokine System  
GM-CSF is one of the most well studied systems in this group. It is a four helical bundle 
cytokine like most other belonging to type-1 class (Rozwarski et al., 1996; Wong et al., 1985). 
GM-CSF interacts with its cognate receptor GMRα to form the binary complex with interactions 
contributed by Ig and FNIII domains of GMRα (Hercus et al., 1994; Mirza et al., 2010). The 
binding has been shown to be relatively high affinity (KD=100-200 pM) in the presence of the 
shared co-receptor βc compared to GMRα alone (KD=1-10 nM) (Gearing et al., 1989; Hayashida 
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et al., 1990).  GMRα has a N-terminal Ig-domain, two membrane proximal FNIII domains and an 
intracellular part of 54 residues without any role in activation. This GM-CSF/GMRα binary 
complex interacts with the homodimeric βc shared receptor, thus forming the hetero-hexameric 
complex with two GM-CSF/two GMRα/homodimer βc (Hansen et al., 2008). Such two 
heterohexamers interact via sites 4, 5 and 6 (Figure 2.16B) to form a dodecameric signaling 
complex (Figure 2.16A).  
 
(ii) Interleukin 3 Cytokine System 
While only a solution structure of IL-3 is available since 1996 (Feng et al., 1996) , structure 
of IL-3 receptor has not been solved yet.  Based on mutation analysis, domain truncation and 
homology modeling, a putative dodecameric model of activation has been proposed by 
independent investigators (Broughton et al., 2012; Dey et al., 2009). IL3 binds the ligand-
specific IL-3Rα receptor; this binary complex recruits a dimeric shared receptor βc forming a 
2IL3:2IL-3α:2βc hexameric assembly. The extracellular part of IL-3Rα has a N-terminal Ig like 
domain followed by two membrane proximal tandem repeats of fibronectine like type III 
domains. The receptor βc is shared with other members GM-CSF and IL5 of this family. While 
IL-3 interaction with IL-3Rα is relatively low affinity (120nM), interaction of IL-3 with IL-3Rα and 
βc is high affinity (140pM).  Unlike human single βc, mouse β receptor is formed of two subunits 
a shared βc and IL-3 specific βIL-3. The interactions stabilizing this hexamer can be divided into 
three sites: (i) IL-3 interacts with IL-3Rα via the site-1 (ii) dimerization interface between two βc 
dimer formed by domain-4 of one βc  and domain 1 of another βc, referred as site 2 (iii) 
membrane proximal domain 3 of IL-3Rα and domain 4 of βc forms the site 3. Two such hexamer 
units dimerize via 2 (Broughton et al., 2012) or 3 (Dey et al., 2009) interaction sites to form the 
active signaling dodecameric signaling complex. Membrane proximal domains of IL-3Rα and βc 
between hexamer units form the fourth interaction site : site 4. Mutation in this region prevents 
dodecamerization and receptor activation, without affecting the IL-3 mediated hexamerization. 
The interaction of neighboring IL-3  in the interface of two hexamers have been predicted to be 
a leucine zipper interaction and it forms the site 5. This interaction has been hypothesized to be 
the driving force for the hexamer-hexamer dodecamerization. Based on model proposed by Dey 
et al. (2009), a site 6 may exist where N-terminal domains of adjacent IL-3Rα would be 
interacting with each other; while signaling complex model proposed by Broughton et al. (2012) 
contradicts the existence of such site 6. 
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(iii) Interleukin 5 Cytokine System 
IL-5 is a homodimeric cytokine (Milburn et al., 1993) with two units of four helical bundle 
cytokines linked to each other via ionic, hydrophobic and disulfide interaction, in contrast to the 
monomeric IL-3 and GM-CSF (Wells et al., 1994). Although IL-5 is a dimer and it has two 
binding sites each accessible to interact with one cognate receptor, binding of one receptor 
sterically hinders the second binding site. Thus one IL-5 dimer binds to IL-5Rα with 1:1 
stoichiometry (Johanson et al., 1995; Morton et al., 1994; Patino et al., 2011). The crystal 
structures of only binary complex of IL-5/IL-5Rα extracellular part are available (Kusano et al., 
2012; Patino et al., 2011) suggesting a wrench-like architecture. The binary IL-5 signaling 
interactions follow a similar trend as IL-3, recruiting the shared receptor βc to form the active 
signaling complex. Computational modeling based on the ternary complex of GM-CSF/GMRα/βc 
crystal structure (Hansen et al., 2008), shows a octameric complex with two IL-5 dimers: two IL-
5Rα:one βc dimer. Analogous to IL-3 and GMCSF dodecameric signaling complexes, a 
hexadecameric signaling complex of IL-5 has been proposed (Broughton et al., 2012; Patino et 
al., 2011). 
 
C) Glycoprotein 130 (gp130) Family 
There are numerous cytokine receptor systems sharing gp130 framework for signal transduction 
some of which are: IL-6, IL-11, IL-27, IL-30, IL-31, Oncostatin M (OSM), Leukocyte inhibitory 
factor (LIF), ciliary neurotrophic factor (CNTF) and cardiotrophic factor 1 (CTF1). These 
receptors follow mechanistic paradigms which utilize gp130 as the shared co-receptor and 
involve either a hetero-trimeric or a hetero-hexameric signaling complex (Figure 2.17). IL-6 and 
IL-11 signals via dimeric gp130 and a signaling deficient cytokine specific receptor to form a 
hexameric signaling complex. On the other hand, members like OSM, LIF, CNTF and CTF1 
bind gp130 and then recruit their cognate receptors to form the heterotrimeric signaling 
complex. 
(i) Interleukin 6 Cytokine System 
This represent the most well-studied system utilizing gp-130 as its shared co-receptor. IL-6 
is a four helical bundle cytokine (Somers et al., 1997) with both proinflammatory and anti-
inflammatory functionalities. The first step of signaling complex formation nucleates with IL-6 
interacting with its cognate receptor IL-6Rα. IL-6Rα lacks the intracellular JAK-STAT binding 
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regions and thus IL-6/IL-6Rα binary complex is signaling incompetent. The major interactions in 
this binary complex comes from the A and D helices of IL-6, forming the binding site I on IL-6. 
The D3 domain of CRH region of IL-6Rα alone, contributes 70% of binding surface (Boulanger 
et al., 2003). The binding constants for this interaction has been determined to be 9 nM with 1:1 
stoichiometry. This inactive binary complex then recruits the bivalent constitutively dimeric 
gp130 (Tenhumberg et al., 2006) to form a hexameric assembly with two copies of IL-6, IL-6Rα 
and gp130 (Boulanger et al., 2003).  This interaction with gp130 is mediated by two sites: site II 
is a composite site formed by both IL-6 and IL-6α, while site III formed completely of epitopes 
from IL6. 
 
 
 
Figure 2.17. Receptor complexes of IL-6-type cytokines: IL-6-type cytokine receptor complexes 
signal through different combinations of the signaling receptor subunits gp130, LIFR and OSMR, with 
gp130 being used by all the family members. (Adopted from Heinrich et al., 2003) 
 
 
 
(ii) Interleukin 11 Cytokine System  
The atomic structure of IL-11 is not known yet. But it has been proposed to be a long four 
helical bundle cytokine (Yanaka et al., 2011) . Its cognate receptor, IL-11Rα (Yin et al., 1992) 
has at least two isoforms IL-11Rα1 and IL-11Rα2, formed by alternate splicing (Cherel et al., 
1995). IL-11Rα1 has a cytoplasmic part while IL-11Rα2 lacks one. IL-11Rα extracellular part 
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has N-terminal Ig-domain followed by two FNIII domains forming the cytokine receptor 
homology (CRH) domain. The membrane proximal FNIII sub-domain of CRH2 can bind IL-11 
(Schleinkofer et al., 2001). IL-11 interacts with the CRH domain of its cognate receptor via the 
site I (Barton et al., 1999) with a stoichiometry of 1:1 (Barton et al., 2000) and dissociation 
constant KD=10-50nM (Curtis et al., 1997). This binary complex can then interact with gp130 to 
form the signaling complex. The final signaling complex has been suggested to be hexameric by 
independent investigators, formed by two IL-11/two IL-11α1/two gp130 (Barton et al., 2000; 
Neddermann et al., 1996). 
 
 
(iii) Oncostatin M (OSM) 
Signalling by human OSM differs from other type 1 cytokine receptors in a way that it can 
form a heterotrimeric signaling complex using common receptor gp130 and either leukemia 
inhibitory factor receptor (LIFR) or the cognate receptor oncostatin M receptor (OSMR) (Gearing 
and Bruce, 1992; Mosley et al., 1996). The sequential binding proceeds via OSM binding to 
gp130 and then recruiting either LIFR or OSMR in human (Modrell et al., 1994). On the 
contrary, in mouse OSM can only signal via the OSMR receptor and gp130 (Lindberg et al., 
1998). Though these receptors have been shown to mediate the signaling, the exact oligomeric 
nature of the signaling complex is still lacking in literature and require more structural and 
functional studies to obtain mechanistic insights. 
 
(iv) Leukemia inhibitory factor (LIF) 
Leukemia inhibitory factor receptor (LIFR) is the cognate receptor of LIF; however it is 
shared by many other cytokines like OSM, ciliary neurotrophic factor (CNTF), neurotrophin-
1/cardiotrophin-like cytokine and cardiotrophin-1. LIF signals via sequential formation of 
LIF/LIFR binary complex, followed by recruitment of common gp130 (Gearing and Bruce, 1992; 
Hilton and Nicola, 1992; Stewart et al., 1992; Zhang et al., 1998). Among the IL-6 family of 
receptors signaling via a trimeric signaling complex, LIF system has been studied most 
extensively, along with successful crystallographic structure determination (Huyton et al., 2007). 
LIF signaling complex presents an unusual cytokine-receptor interaction revealing an unique 
paradigm for the receptors sharing gp130 and having a hetero-trimeric signaling complex. The 
major binding site is formed by the non-canonical interaction of site III from ligand with Ig-
domain and CRH loops of the receptor, thereby presents a sharp contrast to hexameric 
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signaling complexes of IL-6 family where the “ligand site I/II-receptor CRH” is the major binding 
interactions.        
 
 
D) Interleukin 12 (IL-12) Family 
The very unique feature of this family is the heterodimeric nature of its cytokines. Some of the 
well-studied IL-12 family cytokines include IL-12 itself, IL-23, IL-27 and IL-35 (Figure 2.18). This 
family resembles the IL-6 family by having gp-130 as the shared co-receptor and recruitment of 
this co-receptor by the cytokine-cognate receptor binary complex is inevitable for the activation. 
 
 
 
 
 
Figure 2.18. IL-12 Family of cytokines receptors and predicted binding sites: (A) Four 
different IL-12 family of cytokines presenting the heterodimeric ligands and corresponding modular 
receptors. (B) Predicted binding site 1-3 in IL-12 system (Adopted from Jones and Vignali, 2011). 
 
 
 
(i) Interleukin 12 Cytokine System 
IL-12 (also called IL-12p70) is a disulfide linked heterodimer composed of p35 and p40 
subunits. Its subunit p35 is homologue of other type 1 cytokines like IL-6 and GCSF (Merberg et 
al., 1992). On the other hand, p40 shows similarity with the IL-6Rα and the CNTF (Gearing and 
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Cosman, 1991). Beside IL-12, it also exists as a subunit in IL-23 cytokine. It is composed of a N-
terminal Ig-domain followed by two C-terminal CRH domains. The receptor for IL-12 is a 
heterodimer formed of the cognate receptor IL-12Rβ2 and a shared co-receptor IL-12Rβ1 
(Presky et al., 1996). Both IL-12 and IL-23 utilizes IL-12Rβ1 as the shared co-receptor. Only IL-
12Rβ2 has three cytoplasmic tyrosine residues participating in IL-12 signaling. IL12 can interact 
with IL-12Rβ1 with nanomolar affinity to form a non-signaling complex. But with IL-12Rβ1/ β2 
heterodimer, it interacts with 5-20pM affinity to form the hetero-tetrameric signaling complex.  
 
 
(ii) Interleukin 27 Cytokine System 
IL-27 is a heterodimeric cytokine formed of two subunits: IL-27B (also called Epstein-Barr 
Virus-induced gene 3 or EBI3) and IL-27-p28(also called IL-30) (Pflanz et al., 2002). IL-27B is a 
34 kDa glycoprotein without any membrane anchoring motif (Devergne et al., 1996) and 
considered as the soluble cytokine receptor for IL-30. The structural analysis of IL-27B shows it 
to be composed of a CRH domain comprising two FNIII subdomains, conserved disulfide bridge 
and a C-terminal WSXWS motif (Rousseau et al., 2010). IL-30 is a four helical bundle cytokine 
of 28kDa. The cognate receptor for IL-27 heterodimer has been shown to be a type-1 receptor 
called IL-27Rα (also known as WSX-1 or TCCR) (Pflanz et al., 2004); though this cognate 
receptor can bind IL-27 independently, the IL-27/IL-27Rα is signal-inactive. The shared 
coreceptor for IL-6 family, gp130, has been shown to mediate the signaling. This system has 
been proposed to signal via the quaternary complex of IL-27/IL-27Rα/gp130. (Pflanz et al., 
2002).  
 
 
2.5.2 Non-shared Cytokine Receptors 
These type 1 cytokine receptors do not share their receptors, thus forms homomeric signaling 
complex via their respective cognate receptors only. Well-studied  systems include: growth 
hormone/growth hormone receptor, granulocyte colony-stimulating factor/granulocyte colony-
stimulating factor and erythropoietin/erythropoietin receptor. Although leptin receptor does not 
use any shared receptors, unlike these receptors, the exact oligomeric nature of the signaling 
complex of leptin/LR is not known yet.   
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(i) Growth Hormone 
Growth hormone (GH) drives the dimerization of its cognate receptor GHR by binding to one 
receptor with high affinity followed by recruitment of a second receptor, thus forming a trimeric 
signaling complex (Cunningham et al., 1991; de Vos et al., 1992) (Figure 2.19A). The ligand-
receptor interaction has been quantified to be high affinity with KD value of 2 nM (Uchida et al., 
1999). However, ligand-independent, pre-dimerized inactive GHRs have been observed (Frank, 
2002; Gent et al., 2002). Structural study of the crystallographic structure of GH/GHR complex 
vs. unbound GHR suggests that ligand induced activation is achieved by relative rotation of 
subunits within the constitutive receptor dimer without significant conformational changes 
(Brown et al., 2005). Similar to erythropoietin receptor, in GHR the transmembrane region has 
been shown to playing role in ligand independent oligomerization (Yang et al., 2007).   
 
(ii) Granulocyte colony-stimulating factor 
Granulocyte colony-stimulating factor (G-CSF) can drive the dimerization of its cognate 
receptor G-CSFR to form a stable 2:2 complex (Figure 2.19B) with cross-over receptors 
(Tamada et al., 2006). Formation of quaternary complex involves interaction of ligand site II with 
the CRH domain from one receptor followed by second interaction between site III of G-CSF 
and Ig-like domain of other GCSFR, thus forming a crossover structure. Although the 1:1 and 
1:2 stoichiometry of G-CSF/G-CSFR is well established (Hiraoka et al., 1995a; Hiraoka et al., 
1995b) and the crystal structures of both 1:1 (Aritomi et al., 1999) and 2:2 complex (Tamada et 
al., 2006) have been solved, the oligomeric nature of the signaling complex on cell surface is 
ambiguous with three proposed possibilities: 1:1, 2:2 (Figure 2.19B) and 4:4 complexes 
(Hiraoka et al., 1995a; Hiraoka et al., 1994; Hiraoka et al., 1995b; Horan et al., 1996; Horan et 
al., 1998).   
 
(iii) Erythropoietin 
In contrast to the G-CSFR which is present as monomer on membrane and activated by 
ligand induced dimerization, Erythropoietin receptor (EpoR) is present as inactive constitutive 
dimers on membrane (Livnah, 1999) and activated by Epo-induced conformational change . 
Physical interactions driving this ligand independent dimerization has been attributed and 
localized to both Epo binding site on extracellular part of receptor (Livnah, 1999) as well as the 
transmembrane region (Ebie and Fleming, 2007). The actvation mechanism is quite similar to 
that of growth hormone system, as single Epo interacts with pre-dimerized EpoR to bring 
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conformational changes required for receptor activation and thus signals via a trimeric signaling 
complex (Figure 2.19C).    
 
 
 
Figure 2.19. Three non-shared cytokine receptor systems: These receptor systems function via 
ligand induced formation of homo-oligomeric signaling complex. The systems include growth hormone 
(GH), granulocyte colony stimulating factor (G-CSF) and erythropoietin (Epo) and their respective 
receptors. GH receptor (GHR) exists as constitutive dimer on membrane and activated by the ligand 
induced conformation change in 1 ligand:2 receptor stoichiometry. G-CSF induce dimerization of its 
receptor G-CSFR, thus forming a homodimeric crossover complex of 2:2 stoichiometry. Epo receptor has 
been shown to exist as constitutive dimer and activated by Epo induced conformation rearrangement. 
(Adopted from Brooks and Waters, 2010 for GH/GHR system; from Tamada et al., 2005 for G-CSF/G-
CSFR system; from Patnaik and Tefferi, 2009 for Epo/EpoR system) 
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2.6 MECHANISM OF LEPTIN RECEPTOR ACTIVAION 
2.6.1 Leptin independent receptor oligomerization 
Numerous receptors have been shown to exist as inactive, pre-oligomerized receptor 
complexes before the interaction with the ligand. Dimeric erythropoetin receptor 
(Constantinescu et al., 2001; Livnah, 1999; Remy et al., 1999), dimeric growth hormone 
receptor (Brown et al., 2005; Gent et al., 2002), interferon-γ receptor (Krause et al., 2002), 
interleukin-6 receptor (Schuster et al., 2003) and shared β-receptor of IL-3 family of receptors 
are examples of ligand-independent oligomeric assembly of receptors. Though not much 
structural evidence exist for pre-assembled leptin receptor oligomers on membrane, indirect 
analysis has proven their presence in vivo. 
 
i) Evidences supporting ligand-independent LR oligomerization 
Based on the gel filtration analysis, Devos R. et al. (1997) has concluded that 
extracellular part of LR expresses as preformed homodimer when expressed in baculovirus-
infected insect cells. Coimmunoprecipitation of two different epitope-tagged receptor from COS7 
cells provides evidences in support of leptin independent LR oligomerization on cell surface 
(Nakashima et al., 1997).  
Ligand independent oligomerization has also been shown both in LRlong and LRshort using 
immunoprecipitation and immunoblotting (White and Tartaglia, 1999). The bioluminescence 
resonance energy transfer (BRET)  study of pre-ligand LR on cell surface (Couturier and 
Jockers, 2003) provides a better assessment of the ligand independent oligomerization by 
analyzing at a maximum possible physiological state and minimizing the effects of external 
factors as in (co)immunoprecipitation etc. Direct measurement of BRET signal from receptors 
fused with firefly luciferase (Luc) and yellow fluorescent protein (YFP) from living cells, showed 
a very high basal signal, suggesting the two fluorophores  and so the receptors are at less than 
100 Å apart from each other. Similar observations were obtained in intact cells, isolated plasma 
membrane and light membrane preparation, suggesting LR oligomerization not only exists on 
plasma membrane, but also in other compartments inside cell.   
Based on the western blot analysis of a series of murine LR deletion variants lacking one 
or more than one extracellular domains, LR has been proposed to exist as preformed disulfide 
linked dimer and oligomer on the cell surface (Zabeau et al., 2005).  
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ii) Sites and interactions necessary for ligand independent LR oligomerization 
Use of truncated receptors to study the leptin-independent LR oligomerization shows the 
putative sites of interaction stabilizing these oligomers. The short form LR (LRshort) differs from 
the long form LR (LRlong) in their cytoplasmic side by lacking the box2 and box3 motif, essential 
for STAT signaling. The box1 motif is still present and so JAK2 kinase can still bind LRshort to the 
PNP motif in box1. Basal BRET signal for both form LRlong and LRshort  has been shown to be 
high suggesting both forms exist as oligomers in cells and in extracted membranes (Couturier 
and Jockers, 2003). This nullifies any role of the major part of LRIC that is missing in LRshort to be 
contributing towards ligand independent oligomerization. This leaves the possibility that LRecto, 
transmembrane helix and/or the short LRIC containing box1 motif would be responsible for the 
leptin independent oligomerization.  
 Similar evidences for the existence of LR homo-oligomers of LRlong and LRshort and 
absence of LR hetero-oligomers have been demonstrated using quantitative FRET (Biener et 
al., 2005).  
  Zabeau et al. (2005) has also demonstrated that FNIII domains when expressed in 
isolation, formed disulfide linked dimer and oligomer, suggesting the existence of homotypic 
interactions contributed by FNIII domains to stabilize pre-formed oligomer. As a double mutant 
receptor LR:∆CRH1-∆Ig-C72S/C751S with substituted FNIII cysteines exist as dimers under 
non-reducing condition, Zabeau et al. has concluded that the CRH2 domain may also involve in 
the ligand independent clustering of LRs on membrane. This result has been supported by the 
sequence analysis showing cross-species conservation of cysteines in LR. Similar ligand 
independent dimerization has been seen in erythropoetin receptor (EpoR), where the ligand 
interacting domain plays major role for receptor dimerization in the absence of its ligand 
erythropoietin (Livnah, 1999).  
Recent evidence from the electron microscopy of LRecto has suggested it to be 
monomeric in solution; but the very low concentration of LRecto used in this kind of experiment 
would be a limiting factor especially to rule out existence of any concentration dependent 
oligomerization.  
So based on all these observations, LR seems to exist as a pre-assembled dimer on the 
membrane, the binding epitopes involved being contributed by the transmembrane helix, short 
intracellular part having box1 motif and possibly the LRecto parts.  
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2.6.2 Leptin/Leptin Receptor complex 
Evidence for an oligomeric LR signaling complex first came from the study of GCSFR/LR 
and LR/GCSFR chimera (White et al., 1997). GCSFR/LR chimera has extracellular part of 
GCSFR and trans-membrane and intracellular part of human LR (aa 829-1165). White et al. has 
shown that ligand dependent oligomerization of intracellular part of LR is the pre-requisite for 
signaling by showing that GCSF can drive the dimerization of the extracellular part of 
GCSFR/LR chimera and elicit the LRIC mediated STAT signaling. However this experiment 
could not prove the dimerization capability of leptin. GCSFR, being the closest homologue with 
a sequence identity of 24% with human LR, a 2:2 homology model has been proposed for 
leptin/LR complex (Hiroike et al., 2000). Nonetheless, GCSFR receptor shows dominant 
negative repression, a distinct behavior LR has been found to be resistant to. While co-
transfection of increasing quantity of truncated non-functional GCSFR represses the signaling 
capability of functional GCSFR, due to increasing dimers having at least one partner as 
nonfunctional receptor, LR was found to be relatively resistant to such repression. Such a 
different behavior shown by LR has been attributed to the possibility of an oligomeric signaling 
complex higher than quaternary 2:2 complex (White et al., 1997)  
The second evidence for oligomeric leptin/leptin receptor came from chemical 
crosslinking of 125I-labelled leptin with LR expressed on cell surface followed by SDS PAGE 
(Devos et al., 1997). But the exact oligomeric state of the complex could not be determined 
because of the presence of the higher order oligomers beside major monomer band and a 
second major dimer bands on the SDS PAGE analysis. The formation of a quaternary complex 
(2 Leptin: 2 receptor) between leptin and extracellular part of leptin receptor have been 
demonstrated by same group. According to Devos R. et al., as the receptor exists as a 
preformed dimer on membrane and the final signaling complex upon leptin exposure is a 
homodimeric quaternary complex, leptin signals via conformational change upon leptin binding 
to predimerized LRs; unlike G-CSFR, no leptin induced oligomerization was postulated.  
 
Bioluminescence resonance energy transfer (BRET) study has provided important 
insights into LR signaling complex (Couturier and Jockers, 2003). These experiments suggested 
that leptin induced conformational change of preassembled LR leads to activation of LR. BRET 
signal increased upon leptin exposure to LRshort but not in case of LRlong possibly due to larger 
spatial movements expected for BRET donor and acceptor present at the juxta-membrane  
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Figure 2.20. Proposed models of signaling complex of Leptin/Leptin Receptor complex: 
(A) Homology model for a hexameric leptin/LR complex. LR1 (green) and LR2 (orange) forms core of the 
complex by forming a homo-dimeric crossover via site-2/CRH2 and site-3/Ig interaction. Two additional 
receptors LR3 (blue) and LR4 (pink) are recruited via site 1 of two leptins and bound to the CRH2 
domains of two receptors. (Adopted from Peelman et al., 2006); (B) Electron microscopy based 2 Leptin 
:2 LR model: Two leptin dimerize two Leptin receptor via site-2/CRH2 and site-3/Ig domain interaction, 
forming a homo-dimeric cross-over structure (Adopted from Mancour et al., 2012) 
 
 
regions of LRshort than for LRlong in which the they are relatively far away. BRET donor saturation 
assay suggested a 32±3% that forms significant population of LRshort to be monomeric in 
equilibrium with rest of ~68% dimeric LRshort. Also the proportion of monomeric to dimeric LRshort 
does not change upon ligand binding; so the increase in BRET signal is due to conformational 
change induced by leptin interaction. This may complement earlier observation by David D.W. & 
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Tartaglia L.A. (1999), that leptin treatment does not change the LR homo-oligomer formation. 
Couturier and Jockers have concluded based on this BRET study that leptin induces only 
conformational change upon binding to the predimerized receptor o form the active signaling 
complex.  
Formation of leptin/LR signaling complex and its kinetics has been studied in single cell 
technique involving quantitative fluorescent resonance energy transfer (FRET) (Biener et al., 
2005; Ramanujan et al., 2005). Based on this FRET study, leptin exposure causes both 
conformational reorganization of preformed LRlong homo-oligomers and formation of de-novo 
LRlong homo-oligomers. This conclusion contradicts previous results of Couturier and Jockers 
proposing that leptin binding only induces conformational change and no leptin-induced de novo 
LR oligomerization.  
The weak negative dominant repression by LRshort for LRlong signaling, a phenomenon 
unique to leptin receptor system has been explained based on earlier cellular work (White and 
Tartaglia, 1999). This work involving immunoprecipitation and immunoblotting of two differently 
C-terminally tagged LRlong and LRshort has shown that LR sequence 868-965 containing box1 
motif is essential for LR to repress the constitutively active LR-fa mutant receptor, possibly by 
ligand dependent oligomerization with LR-fa mutant. On the premise that this part of LR is 
essential for JAK binding and that LRshort shows inability to efficiently recruit JAK kinase 
(Bjorbaek et al., 1998; Ghilardi and Skoda, 1997), the weak negative dominant repression 
shown by LRshort can be described as a result of its inefficient JAK binding. The key role of JAK 
binding to stabilize the leptin/LR complex comes from the work of Couturier and Jokers (2003), 
where they have shown decrease in BRET signal upon digitonin mediated solubilization of 
leptin/LR complex happens only in case of LRshort while that of leptin/LRlong complex remains 
unaffected. 
Based on the domain deletion experiments of Fong et al. (1998) and site directed 
mutagenesis by Zabeau et al. (2004), FNIII has been shown to play crucial role in formation of 
the ligand induced signaling complex. As LR with only FNIII domain as extracellular part was 
found to be constitutively active, FNIII-FNIII homotypic interaction between receptor partners 
have been suggested as crucial for ligand dependent LR activation (Zabeau et al., 2005). 
Biochemical and cellular work (Zabeau et al., 2004) has shown that the signaling complex of 
leptin/LR is formed of more than two receptors per signaling complex. In this experimental set 
up, two types of LR were engineered: “LR-F3” and “LR-FFY ∆box1”. Three conserved tyrosines 
(Y985, Y1077, Y1138) in the cytosolic part which are crucial for STAT3 signaling were 
substituted with phenylalanines in “LR-F3”. In case of “LR-FFY ∆box1”, box1 in LRIC part, the 
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site for the JAK2 binding, was truncated. Also Y985 and Y1077 were substituted to 
phenylalanine leaving Y1138 intact which upon phosphorylation provides site for STAT3 
interaction. Hence, “LR-F3” even if can phosphorylate and activate JAK upon ligand binding, 
can not recruit STAT for signaling; while “LR-FFY ∆box1” lacking a JAK binding motif, can not 
phosphorylate the Y1138 and thus incapable for STAT mediated signaling. When either of these 
two types of LR expressing in HEK-293T cells were treated with leptin separately, neither of the 
two LR types could be activated. But co-expression of these two receptor variants resulted in 
successful complementation and LR activation. This complementation can only be explained via 
a mechanism that involves a signaling complex formed of > 2 receptors. Use of chimeric 
receptors with extracellular part corresponding to erythropoietin receptor (EpoR) while 
transmembrane and intracellular parts corresponding to “LR-F3” and “LR-FFY ∆box1”, did not 
produced any leptin induced signal when co-expressed. EpoR is known to signal via the 
conformational change of pre-dimerized receptors. By applying similar constraint to chimeric 
EpoR/LR system and forcing the formation of a leptin induced 2:2 quaternary complex could not 
generate STAT3 signaling. This suggests a signaling complex model involving more than 2 LRs 
per signaling complex. 
Based on the above work (Zabeau et al., 2004), mutagenesis of FNIII cysteines to 
LR:∆CRH1-∆Ig-C672S/C751S (Zabeau et al., 2005) and epitope mapping on leptin (Peelman et 
al., 2004), a hexameric model of LR signaling complex (4 LR/2 leptin), based on the hexameric 
IL6/IL6Rα/gp130 has been proposed (Peelman et al., 2006) (Figure 2.20A). Each leptin, in the 
signaling complex interacts with CRH2 domains from 2 LRs via putative binding sites I and II. 
Two such subunits (2 LR:1 Leptin), interacts with each other via a cross-over involving leptin 
site III/LRIg domain of the other subunit.  
Recently, single particle electron microscopy has been employed to generate 2D images 
and 3D reconstructions of Leptin/LR quaternary complex (Mancour et al., 2012). Leptin has 
been shown to induce dimerization of LRecto, culminating into a quaternary 2:2 complex, which 
have been proposed as the signaling complex for leptin/LR system (Figure 2.20B). The EM 
structure shows high degree of flexibility between the subdomains of CRH2 domain, needed for 
ligand interaction in an induced-fit fashion. An interesting inference is that the ligand interaction 
rigidifies of the membrane proximal CRH2 subdomain thus stabilizing the FNIII domains into a 
“leg like” single conformation, essential for signaling. Based on 3D reconstruction and modeling, 
site III of leptin has been shown to interact the Ig domain of the 2nd receptor chain. CRH1 has 
been shown to not interacting leptin as expected based on Fong T.M. et al (1998) domain 
truncation study. The mode of complex formation has been hypothesized to be cooperative, with 
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formation of 1:1 “leptin-site II”/”LR-CRH2” complex followed by “leptin-site III”/”LR-Ig” domain 
interaction. Essentially, this study shows the low resolution architecture of the leptin induced 
quaternary complex structure of leptin/LRecto. Such a 2:2 quaternary signaling complex 
contradicts previous biochemical (Peelman et al., 2006; Zabeau et al., 2004) and cellular (White 
et al., 1997) studies pointing towards a signaling complex requiring more than two 
receptors/signaling complex.   
 
2.6.3 Hetero-oligomerization of Leptin/leptin receptor complex 
 
Hetero-oligomerization refers to the formation of a signaling complex involving more than 
one leptin receptor isotype. Hetero-oligomerization in leptin receptor system has been in 
discussion, but without much of a consensus, so far. Hetero-dimerization has been shown in 
GCSFR system, by showing how a signaling incompetent G-CSFR inhibits the signaling 
potential of wild type G-CSFR upon heterodimerization; also proving that G-CSFR signals by 
dimerization of its receptors. Absence of such heterodimerization in the LR system has been 
shown by crosslinking on cell surface (Devos R. et al., 1997). Based on this observation, Devos 
R. et al. has explained the marginal dominant negative repression by the LRshort  on LR signaling 
observed earlier by White D.W. et al. (1997).  
White and Tartaglia (1999) on the basis of immunoprecipitation and immunoblotting of 
two differently tagged LRlong and LRshort showed that both receptor subtypes exist as pre-
assembled homo-oligomers only; but leptin interaction leads to receptor hetero-oligomer 
formation; thus contradicting earlier observations of Devos R. et al. (1997).  
Use of chimeric receptors with extracellular part made up of IL-5Rα and IL-5Rβ, 
transmembrane and intracellular parts from LRb
 
and LRa, has enabled specific, targeted hetero-
oligomeric clustering and analysis of STAT-3 signaling capability of such receptors (Bahrenberg 
et al., 2002). Such an experimental set up suggested the signaling incompetence of IL5 induced 
heterodimeric complex with LRa and LRb transmembrane and intracellular parts. This signaling 
incapability has been shown to be due to the incomplete JAK binding motif 1 in LRa.  
Fluorescence resonance energy transfer (FRET) experiments investigating the hetero-
oligomerization of LR in vivo,  suggested the absence of leptin-induced hetero-oligomerization 
on cell surface (Biener et al., 2005). Recent work utilizing BRET and optimized 
coimmunoprecipitation has suggested otherwise the formation of such heterodimeric signaling 
complexes (Biener et al., 2010).  
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2.7 SUMMARY 
Leptin being a pleiotropic cytokine regulates a broad range of physiological processes which 
include appetite, energy metabolism, body weight, both innate and acquired immunity, 
reproduction, bone metabolism, hematopoiesis and angiogenesis. This system has been 
associated with many pathological conditions including obesity, multiple sclerosis, rheumatoid 
arthritis, autoimmune hepatitis and more recently in breast cancer. Due to such important 
physiological and pathophysiological roles played by leptin, understanding of leptin-mediated 
signaling can provide important insights into this system assisting in drug development for 
related disorders. Further understanding of the structural and mechanistic principles driving the 
LR activation via leptin binding will enrich our current knowledge of cytokine/cytokine receptor 
systems. Even though the scientific community has spent more than a decade solving this 
puzzle, little is known about the structure and higher order architecture of this receptor and its 
leptin-bound assembly on cell surface.  
Unraveling the comprehensive structural insights into leptin/LR assemblies has been the central 
objective of this doctoral research project. To achieve this goal, I have employed a hybrid 
approach based on multiple structural biology method such as small angle X-ray scattering and 
electron microscopy.    
Feature comparison of LR system with shared and non-shared cytokine receptors strongly 
suggests it to be a member of the later class. The LR system exhibits many distinct 
organizational features; such as it exists as an ensemble of ligand independent homo-oligomers 
as well as monomers on cell surface, it has multiple isoforms with potential to form 
heterodimers, an extra membrane-distal CRH1 domain not participating in ligand binding or 
receptor activation but having discrete effect on the signaling intensity. Such peculiar features 
suggests that the LR system may employ an unconventional assembly and mechanistic 
principle. Therefore the second objective is to dissect the mechanistic paradigm of leptin 
induced LR activation using antagonist leptins as tools and to converge available information to 
an universal leptin/LR signaling model.        
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Structural and mechanistic paradigm of 
Leptin receptor activation revealed by 
complexes with wild type and 
antagonist leptins* 
 
 
*This chapter has been adapted from the manuscript submitted for publication. 
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3.1 ABSTRACT 
 Leptin, an adipocyte-derived cytokine, signals via its cognate receptor (LR) to serve as a 
metabolic switch, thereby regulating body weight and processes with a high metabolic cost such 
as reproduction and immune responses. The downside of such benevolent pleiotropy has been 
the possible role of leptin-mediated signaling in autoimmune diseases and breast cancer, which 
has raised interest in the targeted antagonism of leptin signaling. We here present comparative 
biochemical and structural studies of the ectodomain of LR (LRecto) in complex with wild type 
and antagonist leptin variants and reveal that the basic assembly principle leading to leptin 
signaling is a 2:2 stoichiometric complex. The cornerstone of the quaternary complex is high-
affinity binding of leptin to the second cytokine receptor homology domain (CRH2) of LRecto, 
which structurally primes additional interactions with the Ig domain of a second leptin-bound 
LRecto. This leads to dimerization of LRecto, which is otherwise devoid of inherent dimerization 
propensity. In contrast, antagonist leptin variants carrying mutations at the epitope interacting 
with LRIg are only able to establish high affinity 1:1 complexes with LRecto. Acetylation of free 
cysteines in LRecto also abrogates quaternary complexes with leptin suggesting a role for intra-
receptor disulfides upon receptor activation. Mechanistic integration of our studies in light of 
diverse prior findings supports an assembly mechanism whereby leptin conformationally 
activates pre-dimerized LR molecules at the cell-surface to seed a higher-order complex with 
4:4 stoichiometry. This mechanistic proposal establishes a new conceptual framework for future 
studies of leptin-mediated signaling. 
Keywords: Leptin | Leptin Receptor | Signaling | Receptor activation  
 
3.2 INTRODUCTION 
Leptin receptor (LR), a type I cytokine receptor, is activated by its cognate ligand leptin secreted 
by the adipose tissue, to regulate a host of essential body functions, such as the homeostasis of 
body weight and energy (Friedman and Halaas, 1998; Halaas et al., 1995; Varela and Horvath, 
2012), the immune system and hematopoiesis (Carbone et al., 2012; Procaccini et al., 2012)  
reproduction and fetal development (Hausman et al., 2012), angiogenesis (Cao et al., 2001; 
Park et al., 2001), and bone formation (Motyl and Rosen, 2012). Leptin-mediated activation of 
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LR signals through the JAK/STAT pathways and also modulates the activity of phosphoinositide 
3-kinase (PI3K), mitogen activated protein kinase (MAPK), extracellular-signal related kinase  
(ERK) and AMP-activated protein kinase (AMPK) (Wauman et al., 2008). The pleiotropic 
signaling via the Leptin-LR axis and its potential in treating a number of pathologies, have been 
a cynosure for more than a decade.  Although leptin monotherapy has been ineffective to curb 
obesity, it has found applications in type-I and type-II diabetes (Wang et al., 2010; Cummings et 
al., 2011), in rare cases of congenital leptin deficiency (Ramachandrappa and Farooqi, 2011), 
as a potential anti-depressant (Lu et al., 2006) and as a biomarker in breast cancer progression 
(Artac and Altundag, 2012). The possible involvement of leptin in autoimmune diseases like 
multiple sclerosis (MS) (De Rosa et al., 2007), rheumatoid arthritis (RA) (Otvos et al., 2011) and 
autoimmune hepatitis (AH) (Sennello et al., 2005) and in cancers (Otvos et al., 2011) has raised 
the interest in leptin and LR antagonists.  
 The LR ectodomain (LRecto) comprises two cytokine receptor homology domains (CRH1 
and CRH2) flanking an Immunoglobulin-like motif (Ig), followed by two membrane-proximal 
fibronectin type III (FNIII) domains (Figure 1A). A single helix transmembrane domain (TM) 
connects LRecto to the intracellular segments, which carry the conserved juxtamembrane motifs 
box1 and box2 for binding of JAKs (Ghilardi and Skoda, 1997). The CRH2 domain is 
responsible for leptin binding (Fong et al., 1998; Iserentant et al., 2005; Peelman et al., 2004) 
while the Ig-like domain is required for receptor activation (Zabeau et al., 2004). Whereas LR 
has been classified as a type 1 cytokine receptor due the presence of conserved WSXWS 
sequence motifs in such receptors, it exhibits a number of distinct organizational features 
suggesting it may employ unique assembly and mechanistic principles. For instance, LR does 
not recruit a co-receptor in the signaling complex; it can undergo ligand-independent 
oligomerization at the cell-surface; it has multiple isoforms that may assemble as hetero-
oligomers (Bacart et al., 2010), the N-terminal CRH1 segment has a hitherto unidentified role in 
receptor activation; LRecto harbors an unprecedented combination of CRH, Ig-like, and FNIII 
domains; These architectural eccentricities are manifested at the mechanistic level as well, 
which is not well understood but was shown to involve pre-oligomeric receptors at the cell-
surface (Biener et al., 2005; Couturier and Jockers, 2003) that upon leptin binding may 
oligomerize further to form a signaling-competent complex of higher order (Zabeau et al., 2004).  
Homology-based structural analysis of leptin, a monomeric cytokine that adopts a four-
helix bundle fold (Zhang et al., 1997), complemented by mutagenesis studies led to proposals 
for three distinct binding sites on leptin (Iserentant et al., 2005; Peelman et al., 2004; Niv-
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Spector et al., 2005; Peelman et al., 2006). The canonical site II interacts with CRH2 domain on 
LR and is essential for high affinity binding, while site III interacts with the Ig domain on LR and 
likely invokes conformational changes necessary for signal transduction. On the other hand the 
role of putative binding site I has been rather controversial due to the lack of robust 
mutagenesis and functional data to fully substantiate its importance. The relevance of site III of 
leptin has inspired the design of leptin variants with potent antagonistic properties (Peelman et 
al., 2004; Gertler et al., 2006), whereby the leptin variants retain their ability to interact with LR 
but are unable to support signaling. Besides their therapeutic potential, such leptin variants 
could serve as excellent tools to probe structural and mechanistic aspects of leptin-LR signaling.  
Despite great progress in our understanding of the structural basis of several 
extracellular signaling assemblies mediated by type I cytokine receptors such as the Interleukin-
6 receptor (IL-6R) (Boulanger et al., 2003; Skiniotis et al., 2005), IL-2R and IL-15R (Wang et al., 
2005; Ring et al., 2012), and the GM-CSF receptor (Hansen et al., 2008), our view of leptin-LR 
complexes and the mechanism of LR activation has not yet come to full circle despite recent 
developments (Carpenter et al., 2012; Mancour et al., 2012). We here employ structural, 
biophysical, biochemical and cellular studies to study the assembly and mechanistic principles 
of mouse LR in complex with wild-type leptin and leptin variants with antagonistic properties. In 
light of a wealth of prior studies, we have arrived to a mechanistic proposal for the assembly of 
leptin-LR signaling complexes, which can now serve as a new working paradigm for future 
mechanistic interrogation of leptin-mediated signaling. 
 
 
3.3 RESULTS 
 
3.3.1. The LR ectodomain adopts a monomeric extended structure  
To enable structural and biophysical studies of the LRecto and its complexes with leptin and 
leptin antagonists we expressed LRecto (CRH1, Ig, CRH2, and tandem FNIII domains) (Figure 
3.1A) in transiently transfected HEK-293T cells in the presence of the mannosidase inhibitor 
kifunensine (Chang et al., 2007) as a recombinant protein construct carrying a C-terminal 
hexahistidine tag. LRecto purified via immobilized metal-ion affinity chromatography and size-
exclusion chromatography (SEC) could be characterized as a monodisperse species using 
multi-angle laser light scattering (MALS) after sample resolution via Field-Force-Fractionation 
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(FFF) consistent with monomeric glycosylated LRecto (Figure 3.1B).  In addition, we investigated 
the possible role of glycosylation in the oligomerization propensity of LRecto by expressing LRecto 
in stably transfected HEK-293S GnTI-/- cells producing LRecto with homogeneous N-linked 
GlcNAc2Man5 glycans and found that it retains its monomeric character. 
We subsequently undertook structural studies of LRecto in solution by small-angle X-ray 
scattering (SAXS). In the first instance, this allowed us to probe the oligomerization tendency of 
LRecto within a broad range of concentrations up to 17µM (3.1 mg/mL) (Table 3.S1, Figure 
3.S1a). To facilitate structural modeling of the SAXS data we first constructed models of LRecto 
based on structure-based sequence alignments, homology modeling, and structure-prediction 
approaches. Indeed, modeling of the SAXS data using ab initio approaches (Franke and 
Svergun, 2009) and restrained rigid-body refinement protocols (Petoukhov and Svergun, 2005) 
coupled to modeling of oligo-mannose glycan trees at 16 N-linked glycosylation sites using 
Glyprot (Bohne-Lang and von der Lieth, 2005; Haniu et al., 1998; Felix et al., 2013) established 
that LRecto adopts a monomeric and extended structure measuring ~80Å x 80Å x 225Å and 
which is hallmarked by an elbow bend centered at the Ig domain (Figure 3.1C and 3.1D, Figure 
3.S1b). The N-terminal CRH1 segment can be described by three structural domains, followed 
by the Ig segment, a CHRH2 segment with two domains, and ends with two FN-III domains. A 
parallel structural study of LRecto via negative-stain electron microscopy (EM), albeit at inherently 
much lower sample concentrations, led to class-averages bearing features closely resembling 
the structural models obtained via SAXS (Figure 3.S1c). 
 
Our finding that LRecto lacks inherent dimerization propensity even at such high concentrations 
came as a surprise because of previous reports that LR exists in a dimeric form at the cell 
surface (Biener et al., 2005; De Vos et al., 1997; White and Tartaglia, 1999) and that such 
predimerized assemblies might be mediated by disulfide bridges between LR molecules 
(Zabeau et al., 2005). In addition, we had also observed that shorter constructs of the 
extracellular segment of LR (LRCRH1-Ig-CRH2 or LRIg-CRH2) showed the tendency to form covalent 
oligomers. To cross-validate the possible role of covalent receptor-receptor interactions we 
selectively captured LR at the cell surface labeled with sulfo-NHS-SS-biotin in the presence of 
iodoacetamide, followed by detection via Western-blotting. Our analysis showed LR as a single 
band corresponding to the monomeric molecular weight (Figure 3.1E), thereby establishing the 
non-covalent character of LR at the cell surface. Thus, in the absence of any inherent 
oligomerization propensity in LRecto, dimerization of LR at the cell surface is likely driven by the 
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transmembrane and intracellular segments of the receptor, and may be enhanced by the 
dimensionality of the membrane (Wu et al., 2011). In this regard, earlier studies investigating 
constitutive LR dimers at the cell-surface demonstrated that the short form of LR lacking the 
intracellular segment was still able to form constitutive dimers (Biener et al., 2005), and that 
constitutive dimers consisting of full length LR are far more stable than LR lacking the 
intracellular segment (Couturier and Jockers, 2003). 
 
 
 
Figure 3.1. Characterization of LRecto in vitro and LR in vivo: (A) Schematic representation of 
LR: LR can be divided into an extracellular part (LRecto), a transmembrane part formed of single-pass 
helix and intracellular part. LRecto has a modular structure with four functional domains: distal 1st cytokine 
receptor homology (CRH1) domain (red), immunoglobulin like (Ig) domain (violet), 2nd cytokine receptor 
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homology (CRH2) domain (orange) followed by two membrane proximal fibronectine type III (FNIII) 
domains (green). (B) Western blot analysis lysis of cell surface LR expressed in HEK293 cells in the 
presence and absence of β-mercaptoethanol (β-ME) showing absence of disulfide linkage in the 
preassembled receptor dimer. (C) Multi-angle laser light scattering (MALLS) analysis of LRecto suggests it 
to be monomeric in solution (D) The calculated scattering from the rigid body model obtained from the X-
ray scattering of LRecto produces a chi square fit of 1.2 against experimental scattering data. (E) SAXS 
based rigid body model of LRecto with following functional domains: CRH1 (red), Ig-domain (violet), CRH2 
(orange) and membrane proximal FNIII (green). 
 
3.3.2 Leptin and LRecto engage in a non-covalent quaternary complex with 2:2 
stoichiometry 
We employed several lines of experimentation to characterize binding of leptin to LRecto and to 
obtain structural insights into the assembly of extracellular leptin:LRecto complexes. Incubation of 
purified recombinant LRecto with a molar excess of leptin, followed by chromatographic analysis 
by SEC typically resulted in two incompletely resolved peaks: a minor high molecular weight 
peak and a major low molecular weight peak. This suggested that the leptin-LRecto complex 
might be a dynamic equilibrium of high and a low molecular-weight complexes with dilution 
favoring the low molecular-weight species. To better characterize these two possible states we 
subjected assembled leptin-LRecto complexes to MALLS-FFF analyses and found that the two 
assemblies are consistent with a binary 1:1 stoichiometry and a quaternary 2:2 complex, 
respectively (Figure 3.2A). Subjecting complexes with 2:2 stoichiometry to a new round of SEC 
resulted in partial dissociation of the 2:2 species to the 1:1 stoichiometric assembly indicating 
the concentration dependence of the assemblies in vitro. Both types of stoichiometric 
complexes could be further stabilized by crosslinking with formaldehyde (Leitner et al., 2010) 
and isolated by SEC, resulting in better preparative resolution of the two candidate molecular 
assemblies. 
 
In light of these findings we sought to characterize the thermodynamic and stoichiometric profile 
of the leptin-LR interaction by isothermal titration calorimetry (ITC). Our approach centered on 
carrying out measurements at concentrations that would be representative of those required to 
maintain the two apparent types of complexes we could identify chromatographically (Figure 
3.2B and 3.2C). Our measurements show that both types of complexes are characterized by 
nearly identical KD values consistent with high affinity binding, while exhibiting very similar 
stoichiometric and thermodynamic profiles.  Upon subjecting the post-ITC protein solutions to 
SEC we obtained elution profiles that cross-validated the exclusive presence of binary 1:1 
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complex in the ITC titration at low concentration (Figure 3.S2a). On the other hand, the post-ITC 
solution at high concentration resolved as mixture of complexes with 2:2 and 1:1 stoichiometries 
(Figure 3.S2b), confirming the lability of the quaternary assembly in a concentration dependent 
manner and the fact that a 2:2 stoichiometry is the maximum attainable for the leptin-LRecto 
complex.  
 
 
 
 
Figure 3.2: Molecular and biophysical characterization of wt-leptin/LRecto complex 
(A) MALS analysis of two incompletely resolved peaks of wt-Leptin/LRecto complex produced molecular 
masses corresponding to 1:1 (blue) and 2:2 (red) complexes (B) ITC of wt-Leptin into LRecto relatively 
lower concentration (C) ITC of wt-Leptin into LRecto at relatively higher concentration that promotes 
formation of 2:2 complex. Both ITC runs were carried out at a temperature of 37º C. 
 
 
3.3.3 Structural studies of leptin in complex with LRecto 
To obtain structural insights into the assembly principles of the  leptin-LRecto complex we 
employed structural studies by small-angle X-ray scattering (SAXS), which in the first instance 
served as an orthogonal method for corroborating the molecular sizes of the two apparent 
stoichiometric complexes of leptin-LRecto with 1:1 and 2:2 stoichiometries (Table 3.S1). Modeling 
of SAXS data measured from purified recombinant leptin-LRecto complex with 2:2 stoichiometry 
after cross-linking using ab initio and rigid-body refinement protocols revealed a frontally 
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symmetric Y-shaped assembly measuring ~225 Å x 300 Å x 160 Å composed of two 1:1 leptin-
LRecto subcomplexes (Figure 3.3A, curve (i) and Figure 3.3B, Figure 3.S3). In a given 1:1 
subcomplex a leptin molecule binds to the CRH2 domain of LRecto consistent to what has been 
termed a site II binding epitope (Peelman et al., 2004), invoking a drastically different 
conformational state of LRecto when compared its unbound state. The apparent consequence of 
such restructuring in LRecto is that the Ig domain becomes primed to associate with a leptin 
molecule in the second 1:1 subcomplex to establish a site-III binding epitope on leptin (Peelman 
et al., 2006). Furthermore, the two N-terminal CRH1 segments and the two membrane-proximal 
FNIII domains extend away from the core of the complex. We note that accounting for 16 N-
linked GlcNAc2Man9 glycans greatly improved model agreements with the scattering data as 
recently shown for other receptors (Felix et al., 2013; Guttman et al., 2013). Upon extrapolating 
our structural studies to characterize the leptin-LRecto complex obeying 1:1 stoichiometry (Figure 
3.3A curve (ii) and Figure 3.3C) we found that this binary complex adopts a conformation that is 
quite different from its structure in the quaternary complex and that of unbound LRecto, as further 
supported by comparisons of the pair-distance distribution functions (Figure 3.3D). 
 
 
3.3.4 Antagonist leptin variants abrogate ligand-induced LR oligomerization 
Given the capacity of leptin to engage LRecto into 2:2 stoichiometric complexes we pursued 
biochemical and structural insights into the possible mode of antagonism by two established 
antagonist leptin variants (Peelman et al., 2004; Niv-Spector et al., 2005).  A parallel reasoning 
was that by studying LR antagonism we might be able to obtain additional mechanistic insights 
into the assembly of cognate ligand-receptor complexes. One of the antagonists employed 
(Leptina1) carries a S120A/T121A double mutation localizing at the beginning of helix D 
(Peelman et al., 2004) and was designed to interrogate the relevance of site III on leptin, while 
the second (Leptina2) bears a substitution 39AAAA42 in the loop linking helices A and B and 
was proposed to impact the leptin-LRIg interaction (Niv-Spector et al., 2005) (27). We note that 
the two sets of mutations cluster close to each other on the leptin scaffold, as the AB loop 
traverses the start of helix D. 
Analyses by SEC-MALLS of Leptina1-LRecto and Leptina2-LRecto complexes revealed that 
in contrast to wild type leptin, the two antagonist leptin variants are only able to engage LRecto in 
a complex obeying 1:1 stoichiometry (Figure 3.4A).  Interestingly, the thermodynamic binding  
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fingerprints for both antagonists (Figure 3.4B) are very similar to that for wild type leptin (Figure 
3.2B), which suggested that the driving force for the assembly of the wild-type leptin complex 
with LRecto is the interaction with LRCRH2 via site II. Structural modeling of the two binary 
complexes via ab initio and rigid-body modeling of SAXS data (Figure 3.4C-E, Figure 3.S4, 
Table 3.S2) led to molecular complexes that strongly resemble the binary complex of wild type 
leptin with LRecto in 1:1 stoichiometry (Figure 3.3C), as further evidenced by comparisons of the 
pairwise distance distribution function (Figure 3.4E). Thus, we can now confirm that Leptina1 
does target site III of leptin, and that Leptina2 also appears to behave as a site III antagonist, 
thereby pointing to the mechanistic importance of this interaction in mediating agonist-induced 
LR dimerization. 
 
 
 
3.3.5 Free cysteines in LRecto may constitute conformational switches for 
activation 
Delineation of the disulfide-bond network in human LRecto has shown that LRecto carries nine free 
cysteines (Haniu et al., 1998). Six of these are conserved in mouse LRecto and at least one of 
them, Cys672 found in the membrane proximal FNIII domain, was shown to be essential for 
receptor activation (Zabeau et al., 2005) (45). In this study we mutated Cys604 in LRCRH2 close 
to the LRCRH2-LRFNIII domain boundary to serine and found that the mutant receptor can only be 
activated at very high leptin concentrations (>500 ng/ml) as measured by rPAP1-luciferase 
reporter activity. Interestingly, the recent crystal structure of LRCRH2 in complex with a Fab 
fragment (Carpenter et al., 2012) provided insights leading to the proposal that a Cys604-
Cys672 intra-receptor disulfide might be important for receptor activation. To extend these 
studies and to obtain insights into the general relevance of unpaired cysteines in the 
conformational competence of LRecto towards complex formation, we alkylated the free 
cysteines in LRecto using iodoacetamide. We discovered that while the acetylated receptor could 
readily form a 1:1 complex with leptin, it lost its ability to undergo leptin-dependent dimerization 
to form a 2:2 quaternary complex (Table 3.S3, Figure 3.S5). Together, these lines of evidence 
show that Cys-604 and Cys-672 are very likely candidates in engaging in an intra-receptor 
disulfide in the context of a leptin-LR
 
quaternary complex and receptor activation. Indeed, recent 
evidence for functionally relevant redox regulation of the common γc receptor was reported in 
the context of IL-2 mediated signaling (Metcalfe et al., 2012). 
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Figure 3.4: Biophysical and structural characterization of Leptina1/LRecto and 
Leptina2/LRecto complexes: (A) MALS of Leptina1/LRecto and Leptina2/LRecto produced molecular 
masses, each corresponding to 1:1 binary complex. (B) ITC carried out at 37º C for each type of 
antagonist Leptin into LRecto shows an enthalpy-driven interaction with nanomolar affinities and 1:1 
stoichiometry. (C) Plot of theoretical scattering intensity from rigid body models of Leptina1/LRecto (orange) 
and Leptina2/LRecto (violet) fitted to the experimental scattering (black) from respective complexes. (D) 
Rigid body models of leptina1/LRecto (from SAXS data at 0.9 mg/ml) and leptina2/LRecto (from SAXS 
measurement at 0.7 mg/ml) binary complex. The color scheme is same as used in fig. 3B. (E) Pair-wise 
distance distribution plot of relative probability vs. distance for LRecto (green), leptina1/LRecto (orange), 
leptina2/LRecto (red) and binary complex of wt-Leptin/LRecto (dotted blue).(F) Five class averages of 
Leptina2/LRecto as revealed by negatively stained single particle electron microscopy (left). Shown to the 
right of each class average is the ab initio model from SAXS in comparable orientation. 
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3.4 DISCUSSION 
The principles underlying the assembly of the leptin-mediated extracellular signaling complex of 
LR had remained unclear despite a large body of literature addressing the physiology and 
biomedical relevance of signaling along the leptin-LR axis (Guo et al., 2012). Receptor 
oligomerization culminating with receptor activation has been observed for many type I cytokine 
receptors but the dependence of receptor oligomerization on ligand binding varies among the 
members. While the growth hormone receptor (Gent et al., 2002) and the erythropoietin 
receptor (Livnah et al., 1999) exist in an inactive dimeric form at the cell surface that becomes 
active upon ligand binding, others like IL-6Rα/gp130 (Boulanger et al., 2003), leukemia 
inhibitory factor receptor (Huyton et al., 2007), and GMCSF-R (Hansen et al., 2008) proceed via 
ligand-induced receptor oligomerization coupled to concomitant conformational changes. LR 
has been reported to exist as a dimer or oligomer at the cell surface (Bacart et al., 2010; Biener 
et al., 2005; DeVos et al., 1997; White and Tartaglia, 1999), yet the conformational impact of 
cognate leptin binding in the assembly of signaling complexes has remained unclear. 
In this study we employed a diverse set of methods and molecular tools, including two 
established leptin antagonists, to provide structural and mechanistic insights into this process, 
an area of research that has recently gained significant momentum (Carpenter et al., 2012; 
Mancour et al., 2012).  By carrying out comparative studies of wild type and antagonist leptins 
we have now shown that high-affinity binding of leptin to the CRH2 domain of LRecto leads to 
structural rearrangements in LRecto to prime assembly of a complex obeying 2:2 stoichiometry.  
This is mediated via a new interaction interface, albeit with a small contribution to the stability of 
the complex and no signs of cooperativity, between leptin participating in a 1:1 complex with 
LRecto with the Ig domain of LRecto in a second 1:1 complex.  Indeed, the likely decrease in the 
number of degrees of freedom due to the dimensionality of the cell membrane may greatly 
impact the thermodynamics and kinetics of the invoked interaction between site III on leptin and 
LRIg (Wu et al., 2011).  
In this regard, we have now provided direct evidence for the importance of this 
interaction by elucidating the structural basis of leptin antagonism by two leptin mutants that 
stall the leptin-LR interaction to
 
1:1 stoichiometric complexes. Indeed, the inability of Leptina2 to 
elicit FRET signal elevation when added to cells expressing LR with intracellular fluorescence 
tags (Niv-Spector et al., 2005) is consistent with the concomitant loss of oligomerization 
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capacity when the functionality of site III is abolished. Furthermore, we have shown that LRecto 
lacks inherent dimerization propensity, a property that now uncouples the role of LRecto from the 
assembly of constitutive, yet inactive, dimeric or oligomeric forms of LR at the cell-surface in the 
absence of ligand (Bacart et al., 2010; Biener et al., 2005; De Vos et al., 1997; White and 
Tartaglia, 1999).  
 
 
 
Figure 3.5. Proposed mechanism for LR activation 
 
 
The main question arising is whether the observed leptin-LRecto complex represents a 
signaling-competent assembly. An analogous complex derived from a negative-stain EM 
analysis also obeys a 2:2 stoichiometry, and has been proposed as a leptin-LR signaling 
complex (Mancour et al., 2012).  The complex is in a drastically different conformational state 
compared to the one we presented here (Figure 3.S6). Despite the structural differences 
between the two assemblies, which as such can be attributed to inherent methodological 
limitations calling for validation via orthogonal methods, it would still be tempting to propose the 
observed quaternary complexes as signaling-competent states. However, we maintain that 
careful consideration of previous work in light of our structural data suggests otherwise. 
Several studies have established that LR exists predominantly as a constitutive dimer at 
the cell-surface (Bacart et al., 2010; Biener et al., 2005; Couturier and Jockers, 2003; De Vos et 
al., 1997; White and Tartaglia, 1999; Bahrenberg et al., 2002). In addition, APB- and FLIM-
based quantitative FRET on single cells (Biener et al., 2005) had suggested ligand-induced 
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conformational changes and de novo oligomerization of LR in situ. Thus, considering 
constitutive LR dimers as basal assemblies for the nucleation of signaling complexes and 
leptin’s ability to dimerize LRecto in vitro, we propose that the model most consistent with a 
higher-order assembly would be a complex obeying 4:4 stoichiometry (Figure 3.5). In this 
model, which contrasts previous proposals (Peelman et al., 2006; Mancour et al., 2012), binding 
of leptin to predimerized but inactive LR at the cell surface induces trans-dimerization of LR-
dimers to establish a signaling-competent complex. Importantly, such new assembly paradigm 
would be consistent with the observed weakly dominant negative repression of LR signaling by 
the short-form of non-signaling LR (De Vos et al., 1997; White et al., 1997) in the context of 
heteromeric LR dimers at the cell surface (Bacart et al., 2010), and supports previous studies 
employing JAK-STAT signaling complementation (Zabeau et al., 2004). Lastly, our proposed 
mechanistic paradigm further highlights the therapeutic importance of leptin antagonist variants 
that can abrogate such assemblies while displaying near wild type affinities to LR. We envisage 
that the herein mechanistic proposal for leptin-mediated activation of LR will set the stage for a 
more targeted mechanistic interrogation of the system as well as renewed efforts in antagonist 
development. 
 
3.5 MATERIALS AND METHODS 
3.5.1 Expression and purification of LRecto: pMET7 vector carrying the DNA encoding the 
extracellular part of murine Leptin Receptor (LRecto) with the amino-terminal native secretion signal and a 
carboxyl-terminal His6-tag was used to transiently transfect 90% confluent HEK-293T cells using 
Polyethyleneimine (1DNA:1.5 Polyethyleneimine molar ratio) and was further cultured in DMEM medium 
containing Penicillin (Sigma) and Streptomycine (Sigma) and in the presence of mannosidase inhibitor 
Kifunensine (Tocris Bioscience) for 4 days at 37 ºC in a 5% CO2 environment . The medium was 
harvested by centrifuging at 10,000g and filtered using 0.2 µm bottle-top filter. The secreted receptor was 
purified by passing it through TALONTM IMAC resin (Clontech), washing with 4mM Imidazole (Sigma 
Aldrich) to remove non-specifically bound protein to matrix, followed by elution with 300mM Imidazole. 
The eluted peak was pooled, concentrated to 1 ml and further purified on a 120 ml Superdex 200 HiLoad 
16/600 column (GE HealthCare) pre-equilibrated with buffer containing 25mM HEPES pH=7.4 and 
100mM Sodium Chloride. The peak fractions were pooled and the purity was assessed using 15% SDS 
PAGE. 
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3.5.2 Expression and purification of wild type and antagonist leptins: Heterologous expression of 
murine Leptin cloned into pET-11a vector in Escherichia coli, followed by solubilization of inclusion body 
in 7 M Urea and refolding produced crude leptin. This preparation was further purified by anion 
chromatography on an ANX FF Column (GE Healthcare Life Sciences) and later by size exclusion 
chromatography using a HiLoad Superdex75 column (GE Healthcare). The homogeneity and purity was 
analyzed by 15% SDS PAGE. 
 
3.5.3 Immuno-precipitation and Western blot of cell surface-biotinylated full length LR: HEK-
293T cells were seeded and after one day were transfected with pMET7 vector encoding murine LR with 
a C-terminal FLAG tag using classical calcium phosphate transfection . After 24 hr of transfection, cells 
were washed with PBS and cultured further with 10% fetal calf serum (Sigma Aldrich). For cell surface 
biotinylation, cells were detached with trypsin and washed three times with ice-cold PBS. Cells were 
resuspended to a final concentration of 25 x 106 cells/ml and treated with 0.1% azide to prevent 
internalization of cell surface receptors. Cells were incubated at room temperature with freshly prepared 
0.8 mM Sulfo-NHS-SS for 30 minutes. To remove unreacted biotin, cells were washed with ice-cold PBS 
containing 0.1% azide. Cells were lysed using modified RIPA buffer containing 50 mM iodoacetamide, to 
prevent non-physiological clustering during processing and lysate was cleared by centrifuging for 10 
minutes at 14000 RPM. In order to enrich the biotinylated receptor using Dymabeads Streptavidin T1 
(Invitrogen), beads were washed 3 times with PBS, cleared lysate was added to the beads, incubated at 
room temperature for 30 min while rotating and washed 3 times with PBS containing 0.1% (v/v) Tween-20 
(Sigma). The biotinylated protein was eluted with laemlli buffer. For detection, samples were heated at 
65° C for 5 minutes, resolved on a 7.5% SDS PAGE with and without reducing agent 2-mercaptoethanol. 
The LR was detected via western blotusing anti-FLAG antibody (Sigma).  
      
3.5.4 Purification of complexes of LRecto with wild type and antagonist leptins: After size 
exclusion chromatography, the purified LRecto and wild type or antagonist leptins, each from size 
exclusion chromatography were concentrated separately to 8 mg/ml and 5mg/ml respectively. A mixture 
of LRecto with 6 times molar excess of ligand was incubated at room temperature for 1 hr followed by 
injection onto a pre-equillibrated Superdex 200 HiLoad 16/600 column. In case of wild type leptin, the 
resulting 1:1 and 2:2 complex peaks were pooled separately for further studies. In case of the 
carboxymethylated LRecto, purified receptor from Superdex 200 was incubated with 5 mM iodoacetamide 
for 1 hr followed by concentration for complex formation. 
 
3.5.5 Formaldehyde mediated chemical cross-linking of LRecto/wt-Leptin complex: 30 µl of 36.5-
38% aqueous solution of formaldehyde (Sigma) was dissolved in 1M HEPES pH=7.4 to a final volume of 
100 µl. 5 µl of this diluted formaldehyde was added to 40 µl of complex of tetrameric LRecto/wt-Leptin at 
0.3-0.8 µM and adjusted to a final volume of 50µl with buffer containing 50 mM HEPES (pH=7.4) and 100 
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mM sodium chloride followed by 3 hr incubation at room temperature. The cross-linking was stopped by 
adding 1 M Tris pH=7.4. This sample was further analyzed on non-reducing SDS PAGE followed by silver 
staining to assess the efficiency of cross-linking.  
 
3.5.6 Isothermal Titration Calorimetry (ITC): The kinetic and thermodynamic parameters of LRecto 
interaction with wt-Leptin and antagonist leptin variants were determined by Isothermal Titration 
Calorimetry. All the protein components were purified in 25 mM HEPES (pH=7.4) containing 100 mM 
sodium chloride and degased immediately before titration. 20 µM of wt-Leptin was titrated against 1.4 ml 
of 1 µM LRecto with 17 discrete injections (3 µl followed by 10 µl each) at 37 ºC and mixing at 307 RPM 
stirring speed. The heat released was recorded using a MicroCal VP-ITC set up (GE Healthcare) and 
analyzed using Origin (OriginLab). The best fitting of the experimental data was obtained using built-in 
“one-set of sites” curve fitting model in Origin and this fit was used to determine the equilibrium constant 
(1/Kd), stoichiometry of interaction (N), enthalpy change (∆H). The change in Gibbs free energy (∆G) was 
calculated using the equation ∆G = -RT ln (1/KD) and the entropy change (∆S) was back calculated using 
∆G = ∆H – T∆S. Similar experiments were performed for Leptina1 and Leptina2 to characterize their 
interaction with LRecto. In order to verify the stoichiometry of the high molecular weight complex, similar 
protocol has been followed using microcal ITC200 by titrating wt-Leptin at 2.4 mg/ml (~148 µM) into 
receptor in cell at 1.2 mg/ml (~8.4 µM). 
 
3.5.7 Binding and Signaling Properties of LRC604S: The cysteine residue on position 604 in the 
mouse LR, cloned in the pMET7 expression vector, was mutated to a serine using standard mutagenesis 
techniques. Resulting receptor was transfected together with the pXP2d2-rPAP1 (rat pancreatitis 
associated protein 1)-luciferase reporter (Eyckerman et al., 2000) with calcium phosphate. Cells were 
stimulated overnight with a serial dilution of leptin, lysed and light emission was measured in a TopCount 
chemiluminescence counter. Leptin binding was determined using the leptin-SEAP (secreted alkaline 
phosphatase) chimera as described earlier (Zabeau et al., 2005) (45). In brief, transfected cells are 
incubated with fusion-protein for 2 hours. After three washing steps, bound enzymatic activity is 
measured with the Phospha-Light assay (Life Technologies) in the TopCount counter. 
 
3.5.8 Multi-angle Laser Light Scattering (MALS): The molecular masses and oligomerization state of 
LRecto and its complexes with wt-Leptin, leptina1, leptina2 in a concentration range of 18-50 µM were 
estimated by multi-angle laser light scattering. The purified protein sample was resolved on an 
asymmetric FFF (Field Flow Fractionation) system (Wyatt Technology) encompassing an ultrafiltration 
membrane (Microdyn-Nadir GmBH) with 10 kDa cut off and spacer of 350 µm height, operated by HPLC 
(Shimadzu) and connected with an online UV detector (Shimadzu), recorded by a 18 angle static light 
scattering detector (DAWN HELEOS) and a refractometer (Optilab T-rEX, Wyatt Technology). In order to 
enhance the resolution between HMW and LMW peaks of wt-Leptin/LRecto complex during FFF elution, 
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the cross flow was optimized. Based on the measured Rayleigh scattering in different angles and the 
established differential refractive index increment of 0.185 mL/g for proteins in solution with respect to the 
change in protein concentration (dn/dc) (61), weight averaged molar masses (Mw) for each species was 
calculated using the ASTRA V software. 
 
3.5.9 Small angle X-ray scattering (SAXS): 
  
Data collection and primary data reduction: SAXS data were measured at beamline SWING at 
SOLEIL Synchrotron (Gif-sur-Yvette, France) with a mounted online HPLC system (David and Perez, 
2009) and beamline ID14-3 of the European Synchrotron Radiation Facility (ESRF, Grenoble) equipped 
with a robotic sample changer. The protein samples of LRecto, its dimeric complex with leptina1 and leptina2 
were measured in bulk mode with at least 3 different concentrations in the range of 0.5-3 mg/ml; while 
sample of wt-Leptin/LRecto complex at 10 mg/ml having both dimeric and tetrameric form in dynamic 
equilibrium, was first resolved through gel filtration column (Shodex KW404-4F) connected online with the 
X-ray scattering set up. Monochromatic X-ray beam of either 1.003 Å (Soleil) or 1.54 Å (ESRF) scattered 
through these monodispersing samples at 293 K were recorded covering the momentum transfer range 
0.01 Å-1< s < 0.6 Å-1, where s=4πsinθ/λ (2θ=scattering angle, λ=wavelength of incident X-ray). In bulk 
mode measurement, absence of X-ray induced radiation damage was confirmed by alignment of 10 two 
dimensional scattering curves obtained from integration of continuous radial scattering data obtained from 
10 independent X-ray scattering measurements with 10 second exposure for each sample. For each 
concentration set, the scattering data was normalized for beam intensity, exposure time and corrected for 
the detector response. Subtraction of buffer scattering from the sample scattering using PRIMUS  
(Konarev et al., 2003) eliminated both buffer background as well as parasitic background arising from 
instrument hardware. For wt-Leptin/LRecto, after resolution on a size exclusion column, 150 frames with 
exposure time 1 second and delay of 0.5 second each were collected for buffer and then for protein peak. 
This 2D data was radially integrated to 1D scattering data and further analyzed with Foxtrot software 
developed at SWING beamline of Soleil synchrotron. Buffer scattering was subtracted from protein 
scattering and radius of gyration (Rg) for each scattering was plotted. The regions with stable Rg found to 
correspond to the peaks corresponding to the 2:2 and 1:1 complex and were used for all further analysis. 
The forward scattering (I0) and radius of gyration (Rg) was determined in PRIMUS from infinite dilution 
extrapolation based on Guinier approximation and compared with corresponding estimates from Gnom 
(Svergun D., 1992) calculated by indirect fourier transformation of the complete one dimensional 
scattering data. The distance distribution function P(r) and maximal dimension Dmax for each scatterer 
was evaluated using Gnom. Molecular masses were calculated based on the forward scattering from a 
calibrated sample viz. bovine serum albumin (ESRF) or water (Soleil). Molecular mass based on porod 
volume was estimated using Autoporod (Petoukhov et al., 2012) and compared with corresponding 
estimates from Guinier approximation. Molecular mass was also determined independent of the 
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calibration standards using SAXSMoW (Fischer et al., 2010) and compared with corresponding forward 
scattering and porod volume based masses.  
 
Ab initio modeling: Ab initio three dimensional shape reconstructions from one dimensional scattering 
data was achieved using DAMMIF (Franke and Svergun, 2009). In order to avoid stochastic error while 
modeling, 20 models were generated by 20 independent runs for each scatterer type. Uniqueness of 
these ab initio shapes were evaluated using DAMAVER (Volkov and Svergun, 2003). When the average 
normalized spatial discrepancy (NSD) value for the 20 models was found to be less than or equal to 1, 
the set was considered as single cluster and the model having lowest NSD average value with respect to 
other 19 models was considered as the representative for the scatterer type. Unlike the receptor and its 
complex with antagonist Leptins, the wt-Leptin/LRecto complex, when modeled using DAMMIF followed by 
DAMAVER analysis, produced average NSD value of ~ 1.6. Visual inspection of these models using the 
molecular viewer PyMol (DeLano Scientific) also showed variability in the models, possibly due to 
flexibility of this system. These models with multimodal distribution were clustered using DAMCLUST and 
the cluster centers were considered as the representative conformers of the wt-Leptin/mLRecto tetrameric 
complex. Evaluation of these models was carried out by analyzing the chi-square values against the 
respective experimental scattering curves. 
 
Rigid-body modeling: SASREF (Petoukhov and Svergun, 2005), a heuristic based simulated annealing 
program in ATSAS package was used to generate low resolution atomic models. The 3D models for 8 
individual receptor structural domains (1 for n-terminal domain (NTD), 2 for CRH1, 1 Ig, 2 CRH2 and 2 
FNIII) were generated as described in Peelman et al., (2006) except for CRH1 and FNIII, which were 
predicted using I-TASSER (Zhang Y., 2008; Roy et al., 2010; Roy et al., 2012). These predicted models 
were used to build ab initio models using SASREF. An inter-domain distance restriction of 3.7 Å was used 
corresponding Cα- Cα distance between consecutive amino acids from the termini of two tandem 
domains. Also the CRH2-leptin distance and CRH2-CRH2 distance from the hexameric signaling complex 
model (Peelman et al., 2004)  were used as the input parameters. A P2 symmetry restraint was used for 
the modeling of 2:2 quaternary complex. In order for the statistical significance 10 parallel runs were 
carried out with identical parameters and the models generated were evaluated using crysol against the 
experimental scattering curve. Rigid body models produced in this manner were found to have relatively 
high chi square values (≥17). In order to improve the fitting, these predicted individual domains were 
glycosylated in silico.  Based on the earlier experimental evidence for the sites of glycosylation on LRecto 
(Haniu et al., 1998) and predicted N-glycosylation sites, these predicted models of individual domains 
were in silico glycosylated using GlyProt server (Bohne-Lang and von der Lieth, 2005). As the receptor 
used for SAXS measurement was expressed in the presence of Kifunensine, the glycosylation moieties 
are expected to be of Glc-NAC2+Mannose6-9 type (Chang et al., 2007) (37). Parallel runs were carried out 
with predicted domains in silico glycosylated with Glc-NAC2+Mannose6, Glc-NAC2+Mannose7 and Glc-
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NAC2+Mannose9 respectively. In order for the statistical significance of these parallel run, in each case 10 
runs were performed and the resultant models were evaluated using crysol. Best results (Chi square 
~5.8) were obtained when “2 Glc-NAC+9 Mannose” trees (GlyProt glycan id: 9146) was used for in silico 
glycosylation. Interestingly, it has been shown using MALDI-TOF experiment that Glc-NAC2+Mannose9 is 
the major glycan when expression is performed in the presence of kifunensine (Chang et al., 2007). The 
initial CRH2-CRH2 distance based on the hexameric signaling complex model (Peelman et al., 2004) was 
further optimized by using the predicted domains in silico glycosylated with Glc-NAC2+Mannose9. The 
stretch V466LQRDGFYECVF477 from the each of the two partnering CRH2 domains were used as 
reference and the distance was found to be 11.2 Å in the modeled hexameric complex. So in order to 
optimize this distance, SASREF runs were carried out in the range of 10.7 Å-11.7 Å with 0.1 Å increment 
(total 11 different values). The statistical significance was assessed by 10 runs for each of the 11 
sampled distances. In subsequent step, the CRH2 (reference Asp509)-leptin (reference Ser132) distance 
was optimized in a similar fashion by sampling 21.5±1.1 Å distance (total 23 distances considering 0.1 Å 
increment). These two distance optimization steps improved the crysol generated chi square value for the 
models to 2.9. The final step involved the chi square based optimization of the models by sampling the 
glycan orientation. This step involved generation of 20 rotamers for the one glycan tree of a domain using 
UCSF Chimera package and 20 (x5 for statistical significance) parallel runs using these 20 rotamers. Best 
rotamer evaluated based on crysol fitting was subsequently segregated while sampling the rotamers of 
the next glycan. Such rotamer sampling method of all the glycans in murine LRecto could be able improve 
the fitting of the models to the experimental scattering with a chi square value of 2.2. Hence, a very large 
conformational space (>1500) has been sampled with a non-random and directed approach in order to 
obtain a best fitting rigid body model from the experimental SAXS data.   
     The best fitting rotamers of glycosylated domains from quaternary complex model optimization were 
subsequently used for the rigid body modeling of LRecto, wt-Leptin/LRecto binary complex, leptina1/LRecto 
complex and leptina2/LRecto complex with P1 symmetry restraint. The quality of these models were 
assessed using Crysol (Svergun et al., 1995) by fitting the models with experimental scattering data.  
 
Normal mode analysis: The conformational transformation of the receptor upon binding with cognate 
ligand or its antagonist forms were modeled using elNémo server (Suhre and Sanejouand, 2004; Suhre 
and Sanejouand, 2004b) which models potential low frequency intermediate conformers. 
 
3.5.10 Single-particle negative-stain Electron Microscopy: Samples  were diluted in base buffer 
(25mM HEPES pH=7.4 containing 100 mM sodium chloride) as required and adsorbed for 1 min to glow 
discharged thin carbon films coating a perforated carbon layer on gold-coated copper grids. These were 
washed with 4 drops of distillated water and negatively stained with 2% (w/v) uranyl acetate (UAc) and 
imaged with a CM10 transmission electron microscope (Philips) operating at 80 kV. Electron micrographs 
where recorded with a 2k charge-coupled device camera (Veleta; Olympus soft imaging solutions GmbH) 
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at a nominal magnification of × 130 000, yielding a final pixel size corresponding to 0.37 nm on the 
specimen scale. Particles were manually selected for single-particle analysis and averaged using the 
EMAN software (Ludtke et al., 1999). 
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3.7 SUPPLEMENTARY FIGURES 
 
 
 
 
 
 
Figure 3.S1. Structural characterization of LRecto (A) Small angle X-ray Scattering of LRecto: 
Scattering intensity was plotted against the momentum transfer measured at three different 
concentrations of the receptor viz. 3.0 (yellow), 1.5 (blue) and 0.9 (green) mg/ml. Inset: Same plot of log I 
vs. momentum transfer at very low scattering angle showing absence of any concentration dependency 
for these measurements. (B) SAXS based ab initio modeling of LRecto: SAXS data from LRecto at 0.9mg/ml 
was used to build 20 ab initio models with P1 symmetry constraint using DAMMIF from ATSAS package. 
DAMAVER was used to average these models and the reference model detected by DAMAVER has 
been presented here in three different orientations in surface view (grey). This dummy bead ab intio 
model has been overlapped with the rigid body model presented as ribbon to show similarity among them 
in spite of difference in the adopted modeling methods. The color scheme for the rigid body model is 
same as in figure 3.1: CRH1 in red, Ig domain in violet, CRH2 domain in orange, FNIII domains in green 
and glycans have been shown as grey sticks. (C) Negative stain electron microscopy of LRecto: Electron 
microscopy based class averages of LRecto. These four class averages  show striking similarity to the 
SAXS based ab initio models. Also the monomeric nature of LRecto derived from MALLS and SAXS 
analysis is supported by this electron microscopy analysis.     
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Figure 3.S2. Size exclusion chromatrography of samples recuperated from ITC runs: Size 
exclusion chromatography of sample recuperated after isothermal titration calorimetry of (A) wt-Leptin at 
20 µM into LRecto at 1 µM and (B) wt-Leptin at 148 µM into LRecto at 8.4 µM. Sample from low 
concentration titration produced a single peak corresponding to the 1:1 binary complex of wt-Leptin/LRecto 
while that at high concentration eluted as two peaks: minor 2:2 quaternary complex and major 1:1 binary 
complex peaks. In each case, excess of wt-Leptin has eluted as minor peak. 
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Figure 3.S3. Structural characterization of wt-Leptin/LRecto quaternary complex by SAXS 
(A) Ab initio modeling of wt-Leptin/LRecto quaternary complex: After integrating the frames with similar 
radius of gyration (Rg) value corresponding to the quaternary complex peak on the size exclusion 
chromatography from online SEC-SAXS measurement, scattering data was used for ab initio modeling 
using DAMMIF from ATSAS package. 20 iterative DAMMIF runs followed by clustering of the resulting 
models using DAMCLUST, produced four clusters. Representative models from these four clusters are 
presented in surface views (grey). All of these cluster centers shows quite similarity in having a bulky core 
and two extended arms. Corresponding fitting of the calculated intensities for each these four cluster 
centers against the experimental SAXS curves are shown along with the chi square value of the fitting. 
(B) DAMMIF bead model of major cluster center  wt-Leptin/LRecto quaternary complex: The bead model 
for the major cluster center from the DAMCLUST generated four clusters from 20 ab initio models of wt-
Leptin/LRecto quaternary complex has been presented in three different orientations in grey surface view. 
The rigid body model generated from same scattering curve using SASREF has been presented as 
cartoon and manually fitted onto the ab initio model. The coloring scheme for different domains of the 
rigid body model is same as in figure 3.3.   
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Figure 3.S4. Structural characterization of LRecto in complex with antagonist Leptins by 
SAXS (A) Ab initio model of leptina1/LRecto binary complex: Small angle X-ray scattering of leptina1/LRecto 
at 0.9 mg/ml was used to generate 20 ab initio models with DAMMIF from ATSAS package. The 
reference model from the averaging of these 20 models using DAMAVER has been shown here in grey 
surface view. The rigid body model generated using SASREF in cartoon view have been fitted onto the 
ab initio models manually. The color scheme for the rigid body model is same as in figure 4. The fitting of 
the calculated scattering from the ab intio model onto the experimental scattering and corresponding chi 
square has been shown. (B) Ab initio model of leptina2/LRecto binary complex: Small angle X-ray scattering 
of leptina2/LRecto at 0.75 mg/ml was used to generate 20 ab initio models with DAMMIF from ATSAS 
package. The reference model from the averaging of these 20 models using DAMAVER has been shown 
here in grey surface view. The rigid body model generated using SASREF in cartoon view have been 
fitted onto the ab initio models manually. The color scheme for the rigid body model is same as in figure 
4. The fitting of the calculated scattering from the ab intio model onto the experimental scattering and 
corresponding chi square has been shown. 
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Figure 3.S5. Concentration independent SAXS scattering: Plot of scattered intensity in log 
scale vs. the momentum transfer, s (in Å-1) recorded at different concentrations for A. LRecto, B. 
leptina1/LRecto binary complex and C. leptina1/LRecto binary complex. Different concentration 
(mg/ml) for each scatterer has been shown as color coded bars. Inset: Plot of log I vs. 
momentum transfer, s (Å-1) at very low scattering angle to assess the concentration effect in 
guinier region. 
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Figure 3.S6. Kratky Plot for A) LRecto, B) Leptina1/LRecto and C) Leptina1/LRecto complex 
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Figure 3.S7. Structural characterization of carboxymethylated LRecto and its complexes 
(A) SAXS scattering of iodoacetamide treated LRecto and its complexes: SAXS scattering intensity have 
been plotted for iodoacetamide treated LRecto (green), its complex with leptina2 (purple) and with wt-Leptin 
(orange) in log scale against the momentum transfer. The standard deviation for each curve has been 
shown in grey. (B) Pairwise distance distribution: The pairwise distance distribution plot for 
carboxymethylated LRecto (green), its complex with leptina2 (purple) and with wt-Leptin (orange). (C) Ab 
initio modeling: The scattering curves from receptor and its complexes have been used to generate ab 
initio models using DAMMIF. Forward intensity, I(0) based molecular weight determination suggested a 
monomeric LRecto and binary complexes for both types of complex. Thus a P1 symmetry restraint have 
been used for ab intio modeling.  
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Figure 3.S8. Comparative analysis of SAXS rigid body model and EM model of wt-
Leptin/LRecto quaternary complex: The rigid body model of wt-Leptin/LRecto quaternary 
complex obtained from SAXS analysis was manually fitted into the EM map of a leptin-LR 
quaternary complex (36).  
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TABLE 3.S1: SAXS analysis of the LRecto and wt-Leptin/LRecto quaternary and binary 
complexes 
 
Data collection  
parameters LRecto 
wt-Leptin/LRecto 
Quaternary complex 
wt-Leptin/LRecto 
Binary  complex 
Beamline ID 14-3, ESRF SWING, Soleil SWING, Soleil 
Detector PILATUS 1M AVIEX PCCD AVIEX PCCD 
Beam Geometry 0.7 x 0.7 mm2 0.45 x 0.04 mm2 0.45 x 0.04 mm2 
Wavelength(Å) 0.931 1.54 1.54 
Q range (Å-1) 0.15–6.110 0.06–6.125 0.06–6.125 
Exposure Time (sec) 100 (10 x 10) 1 1 
Concentration range (mg/ml) 0.9 - 3 10 (injected) 10 (injected) 
Temperature (K) 293 293 293 
Structural Parameters    
I(0) (Å-1) from P(r) 151.6 ± 4.3 0.137 0.067 
Rg (Å) from P(r) 65.4±0.3 87.0 63.9 
I(0) (Å-1) from Guinier 151.3±1.4 0.137 0.067±0.0 
Rg (Å ) (from Guinier) 63.8±1.6 84.9 61.9±0.2 
Dmax (Å) 219.2±0.7 297.1 216.7 
Porod volume estimate, Vρ 
 
244025 1225451 463936 
Excluded volume, Vex(Å3)  346000 1450000 608000 
Molecular Mass (kDa)    
From I(0)* 146.4±4.2 305 149.1 
From SaxsMOW 138.5 --- --- 
From Porod volume (Vp/1.7) 149.6 792.861 289.9 
From excl. volume (Vex/1.7) 203.5 852.9 357.6 
Peptide (Protparam) 93 218  
Modeling Parameters    
Shape reconstruction DAMMIF DAMMIF DAMMIF 
Symmetry P1 P2 P1 
χ2 of reference model 1.1 1.2 - 1.3 1.3 
# of models averaged 20 20 28 
DAMAVER NSD (var) 0.808±0.025 --- --- 
Rigid body modeling SASREF SASREF SASREF 
Initial  χ2 1.2 17.4 4.6 
Final χ2 1.2 2.2 3.5 
Software/Server 
   
Data Reduction BsxCuBE Foxtrot Foxtrot 
Data Processing PRIMUS PrimusQt PrimusQt 
Data Evaluation PRIMUS, Gnom PrimusQt, Gnom PrimusQt, Gnom 
Structure Modeling Dammif, Sasref Dammif, Sasref Dammif, Sasref 
Molecular visualization PyMOL PyMOL PyMOL 
*BSA was used for calibration for data obtained from ESRF, while water was used as molecular weight standard for 
data collected from SWING, Soleil for all the SAXS measurements discussed in this thesis.  
3 
Mechanistic Paradigm of Leptin Receptor Activation 
109 
 
 
TABLE 3.S2 : SAXS analysis of leptina1/LRecto, leptina2/LRecto binary complexes 
 
Data collection  
parameters 
Leptina1/LRecto 
(1:1) 
Leptina2/LRecto 
(1:1) 
Beamline ID 14-3, ESRF ID 14-3, ESRF 
Detector PILATUS 1M PILATUS 1M 
Beam Geometry 0.7 x 0.7 mm2 0.7 x 0.7 mm2 
Wavelength(Å) 0.931 0.931 
Q range (Å-1) 0.15–6.110 0.15–6.110 
Exposure Time (sec) 100 (10 x 10) 100 (10 x 10) 
Concentration range (mg/ml) 0.9 - 2.7 0.7 – 7.5 
Temperature (K) 293 293 
Structural Parameters   
I(0) (Å-1) from P(r) 145.9±6.2 35.7±2.4 
Rg (Å) from P(r) 69.1±0.7 68.6±2.8 
I(0) (Å-1) from Guinier 146.1±6.5 51.0±3.6 
Rg (Å ) (from Guinier) 67.7±0.8 67.0±3.8 
Dmax (Å) 236.4±0.3 234.0±1.5 
Porod volume estimate, Vρ 
 
286541 273948 
Excluded volume, Vex(Å3)  372000 390000 
Molecular Mass (kDa)   
From I(0) 140.9±6.0 155.1±10.5 
From SaxsMOW 164.9 151.7 
From Porod volume (Vp/1.7) 180.4 183.6 
From excl. volume (Vex/1.7) 218.8 229.4 
Peptide (Protparam) 109 109 
Modeling Parameters   
Shape reconstruction DAMMIF DAMMIF 
Symmetry P1 P1 
χ2 of reference model 1.3 0.8 
# of models averaged 20 20 
DAMAVER NSD (var) 1.018±0.067 0.824±0.049 
Rigid body modeling SASREF SASREF 
Initial  χ2 3.3 0.9 
Final χ2 2.5 0.9 
Software/Server 
  
Data Reduction BsxCuBE BsxCuBE 
Data Processing PRIMUS PRIMUS 
Data Evaluation PRIMUS, Gnom PRIMUS, Gnom 
Structure Modeling Dammif, Sasref Dammif, Sasref 
Molecular visualization PyMOL PyMOL 
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TABLE 3.S3 : SAXS analysis of LRecto, leptina1/LRecto, leptina2/LRecto in the presence of the 
sulfhydryl alkylating agent iodoacetamide. 
Data collection 
parameters 
LRecto  
(+iodoacetamide) 
wt-Leptin/LRecto 
(+iodoacetamide) 
Leptina2/LRecto 
(+iodoacetamide) 
Beamline ID 14-3, ESRF ID 14-3, ESRF ID 14-3, ESRF 
Detector PILATUS 1M PILATUS 1M PILATUS 1M 
Beam Geometry 0.7 x 0.7 mm2 0.7 x 0.7 mm2 0.7 x 0.7 mm2 
Wavelength (Å) 0.931 0.931 0.931 
Q range (Å-1) 0.15–6.110 0.15–6.110 0.15–6.110 
Exposure Time (sec) 100 (10 x 10) 100 (10 x 10) 100 (10 x 10) 
Concentration range (mg/ml) 0.9 - 3 0.9 - 2.7 0.7 – 7.5 
Temperature (K) 293 293 293 
Structural Parameters 
   
I(0) (Å-1) from P(r) 20.0±1.0 24.0±0.9 25.6±1.6 
Rg (Å) from P(r) 72.5±4.9 71.6±2.8 68.7±2.6 
I(0) (Å-1) from Guinier 20.0±1.1 24.0±1.1 25.6±1.8 
Rg (Å ) (from Guinier) 70.6±5.2 71.5±5.0 67.2±3.8 
Dmax (Å) 251.2±14.6 245.3±15.8 235.2±13.3 
Porod volume estimate, Vρ 290529 430354 293806 
Excluded volume, Vex(Å3)  421000 513000 390000 
Molecular Mass (kDa) 
   
From I(0) 187.5±9.4 211.0±12.0 221.1±14.4 
From SaxsMOW 199.9 220.8 193.4 
From Porod volume (Vp/1.7) 181.5±21.8 248.7±13.9 183.6±6.5 
From excl. volume (Vex/1.7) 247.6 301.7 229.4 
Peptide (Protparam)    
Modeling Parameters 
   
Shape reconstruction DAMMIF DAMMIF DAMMIF 
Symmetry P1 P1 P1 
χ2 of reference model 0.9 0.8 0.8 
# of models averaged 20 20 20 
DAMAVER NSD (var) 0.779±0.080 1.007±0.070 0.824±0.049 
Rigid body modeling --- --- --- 
Initial  χ2 --- --- --- 
Final χ2 --- --- --- 
Software/Server 
   
Data Reduction BsxCuBE BsxCuBE BsxCuBE 
Data Processing PRIMUS PRIMUS PRIMUS 
Data Evaluation PRIMUS, Gnom PRIMUS, Gnom PRIMUS, Gnom 
Structure Modeling Dammif Dammif Dammif 
Molecular visualization PyMOL PyMOL PyMOL 
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4.1 Abstract 
Despite two decades of studies on the (patho)physiology  of leptin-mediated  Leptin receptor 
(LR activation) our current understanding of the leptin-LR signaling assembly is yet to come to 
full circle with respect to a mechanistic consensus. As we have previously shown, leptin acts via 
dimerization of its cognate receptor thereby displaying pleiotropic functionality ranging from 
energy homeostasis to reproduction, from regulation of immune system to angiogenesis and so 
on. While administration of leptin in diabetes and congenital leptin deficiency established 
promising therapeutic applications, its pathophysiology in obesity, autoimmune disease and 
breast cancer raises unequivocal demand for better understanding of structural and mechanistic 
paradigm of leptin receptor activation. Here we demonstrate that leptin can induce dimerization 
of LR lacking the membrane proximal fibronectin type III (LR∆FNIII) domains, thus suggesting a 
redundant role of these domains in leptin induced LR oligomerization. Earlier studies had shown 
that the FNIII region is essential for the functionality of LR. The affinity of leptin for this construct 
was found to be similar to the full length receptor, with nanomolar affinity and stoichiometry of 
1:1. Based on light scattering and small-angle x-ray scattering data, we demonstrate that 
LR∆FNIII, despite the absence of the membrane proximal domains, can form a quaternary 
complex with wt-Leptin. In contrast, antagonist leptin bearing S120A/T121A mutation could not 
dimerize the LR∆FNIII receptor. These results evidently suggest a functional dichotomy whereby 
while FNIII appears to be redundant in the oligomerization of LR it still may be playing a key role 
in the spatial disposition and orientation of intracellular parts to facilitate a signaling-competent 
conformation.    
Keywords: Leptin | Leptin Receptor | FNIII domain | Receptor oligomerization 
 
4.2 INTRODUCTION 
Leptin, a 16kDa four helical bundle (Zhang et al., 1997a), adipocyte hormone, initially 
discovered as the “obesity causing hormone” has rapidly gained its prominence as a pleiotropic 
cytokine with functions like regulation of body weight and energy homeostasis (Baile et al., 
2000; Bates and Myers, 2003; Halaas et al., 1995; Morton et al., 2005), direct and indirect 
regulation of immune system (Lord et al., 1998; Matarese, 2000), angiogenesis (Park et al., 
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2001), hematopoiesis (Fantuzzi and Faggioni, 2000), bone formation (Cornish et al., 2002), 
reproduction and fetal development (Hoggard et al., 1997). Structurally, Leptin composed of four 
helices, running in up-up-down-down fashion and harbors two cysteines bonded by a disulfide 
bridge. Homology based structure alignment has revealed three distinct putative binding sites 
on Leptin (Peelman et al., 2004): site II has been shown to be directly involved in binding to its 
cognate receptor while site III is inevitable for receptor activation. The experimental work 
described in “Chapter 3” shows that site III is essential for ligand induced receptor 
oligomerization and thereby it explains the mechanism behind the antagonism manifested by 
site III mutants. The role of binding site I is still questionable due to limited and weak 
experimental evidence. Once activated, LR signaling proceeds via JAK2/STAT3 pathway with 
potential crosstalk with other signaling pathways (Wauman and Tavernier, 2011). The 
pleiotropic role of Leptin confers it versatility while simultaneously making it susceptible  towards 
mis-regulations and dys-functionalities. Leptin has been shown to be directly linked in the 
development of autoimmune diseases (La Cava and Matarese, 2004) and cancer (Schaffler et 
al., 2007), thus demanding in-depth understanding of the molecular mechanism of leptin 
induced LR activation.    
    
Leptin acts via binding to LR, a type I cytokine receptor without intrinsic kinase activity and with 
a broad spatial expression ranging from hypothalamic nuclei (Tartaglia et al., 1995), kidney 
(Serradeil-Le Gal et al., 1997), liver (Cohen et al., 2005), mononuclear cells (Sanchez-Margalet 
et al., 2003) etc. The extracellular part of LR (LRecto) is composed of 4 functional regions: distal 
CRH1 domain, followed by Ig-like domain, leptin binding CRH2 domain and two membrane 
proximal FNIII domains (Haniu et al., 1998). CRH1 domain which is composed of 3 subdomains, 
although does not take part in leptin binding or LR oligomerization directly, it has been shown to 
harboring a single nucleotide polymorphism Q223R, resulting in obesity in certain ethnic group 
(Duarte et al., 2006; Quinton et al., 2001) and increased susceptibility towards protozoan 
infection in children (Duggal et al., 2011). CRH2 has been shown to be the major site of leptin 
binding (Fong et al., 1998). Previously we have shown that Ig-domain interaction with site III on 
Leptin is inevitable for leptin mediated LR oligomerization and mutation in site III confers 
antagonism due to loss of oligomerization ability (Chapter 3).  
 
Close homologue gp130 has three membrane proximal FNIII domains, classically known as D4, 
D5 and D6. Deletion of D4 and D6 has been shown to reduce the affinity of  gp130 for IL-6/sIL-
6R complexes, while deletion of D5 completely abolishes the LR activation (Kurth et al., 2000). 
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FNIII domains of GCSFR and gp130 has been shown to orient the intracellular part of 
respective receptors enabling signaling (Hammacher et al., 2000). This has led to the theory 
that the FNIII domains enable the ideal relative orientation of receptor proximal regions with 
respect to each other facilitating the interaction of intracellular domains. FNIII mediated inter-
receptor interactions leading to the formation of constitutively active receptor oligomers have 
been described using chimeric gp130 receptors (Kurth et al., 2000). LR has been shown to be 
constitutively active when the LRecto composed of FNIII domains only suggesting a similar 
behavior of LRFNIII domains. All these evidences point towards a consensus in the functionality 
of FNIII domains in type 1 receptor family where these domains help orienting the intracellular 
part.   
 
However, juxtamembrane FNIII domains have never been shown to have any direct role in 
binding or oligomerization of LR, deletion of this domain makes the LR inactive (Fong et al., 
1998). Mass spectrometric analysis of human leptin (Haniu et al., 1998) and alignment of mouse 
and human leptin receptor suggests, FNIII domains in mouse LR possess two free cysteines: 
Cys672 and Cys751. Substitution mutation C751S has limited effect on LR activity, while C672S 
causes substantial reduction in LR activity. Though these cysteines were initially hypothesized 
to be involved in homotypic interaction in LR dimers (Zabeau et al., 2005), we have shown that 
LR dimers exist as non-covalently linked on plasmamembrane. But based on homology to 
gp130, a putative inter-domain but intra-receptor disulfide bond between CRH2 Cys604 and 
FNIII Cys672 has been modeled from the crystal structure of leptin binding domain solved in 
complex with an antibody (Carpenter et al., 2012). However, employing antagonist Leptin as a 
tool, we have shown oligomerization to be essential for activation.  
 
We have used multidisciplinary approach employing various biophysical and biochemical 
techniques to understand the role of FNIII in the ligand induced LR oligomerization.   
 
 
4.3 RESULTS 
4.3.1. LR∆FNIII is expressed largely as monomer: The purified LR∆FNIII from Talon purification, 
when concentrated and loaded onto size exclusion column SD200, the receptor eluted in two 
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fully-resolved and symmetric peaks: a major low molecular weight (LMW) peak and a minor high 
molecular weight (HMW) peak.  
 
           A.       B. 
 
Figure 4.1. Schematic and biochemistry of LR∆FNIII: (A) Elution profile of LR∆FNIII from size 
exclusion chromatography results in two peaks: minor Peak 1 composed of disulfide-linked dimeric 
receptor and major Peak 2 formed by monomeric receptor as observed on reducing and non-reducing 
SDS PAGE followed by Coomassie Brilliant Blue staining. (B) Schematic representation of LR∆FNIII: 
Amino-terminal 1st cytokine receptor homology domain, CRH1 (red), immunoglobulin domain, Ig (purple), 
carboxy-terminal 2nd cytokine receptor homology domain, CRH2 (orange).  
 
 
 
Further analysis of these peaks on reducing and non-reducing SDS PAGE showed the major 
LMW peak comprises monomeric receptor running between 100kDa and 150kDa marker while 
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the minor HMW peak has disulfide-linked dimeric receptor. The monomeric nature of the LMW 
fraction has also been confirmed by both MALLS and SAXS studies (described elsewhere). We 
observed disulfide mediated clustering of monomeric LR∆FNIII upon storage as analyzed by non-
reducing SDS PAGE. Based on this observation, the disulfide linked dimer was considered non-
physiological artifact. Monomeric LR∆FNIII which represent physiological state of the receptor was 
used for all further studies.   
 
4.3.2 Elimination of FNIII domains has no effect on wt-Leptin induced receptor 
dimerization: The purified monomeric LR∆FNIII upon incubation with four times molar excess of 
wt-Leptin and resolution on a SD200 column, produced  a broad peak possibly formed by fusion 
of more than one peak. This elution profile suggested formation of both high molecular weight 
and low molecular complexes of wt-Leptin/LR∆FNIII, similar to the full length LRecto shown earlier. 
Samples corresponding to left side of this broad peak when analyzed on non-reducing SDS 
PAGE did not showed presence of any disulfide bonds, thus suggesting a non-covalently linked 
higher order complex. The stoichiometry, molecular weight information was further 
characterized. 
 
4.3.3 Antagonist Leptin is unable to dimerize LR∆FNIII : In contrast to the wt-Leptin, 
monomeric LR∆FNIII when incubated with four times molar excess of antagonist leptin bearing 
substitution mutation S120A/T121A in site III and resolved on SD200, produced single peak. 
Further analysis of the fractions corresponding to this peak showed it to be leptina1/LR∆FNIII 
binary complex. Unlike wt-leptin, we did not observed any formation of HMW complex in this 
case suggesting the role of site III-Ig domain interaction essential for leptin mediated 
dimerization. 
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A.       B. 
 
Figure 4.2. Size exclusion chromatography of mLREC-∆FNIII and its complexes: (A) 
Analytical gel filtration of wt-Leptin (pink), LR∆FNIII (green), leptina1/LR∆FNIII complex (red) and wt-
Leptin/LR∆FNIII Complex (blue). The excess Leptin (2nd peak in red  and blue) has eluted corresponding 
the wt-Leptin (pink) peak. For easy interpretation, corresponding schematic representations of LR∆FNIII 
and its binary and quaternary complexes with antagonist leptina1 and wt-Leptin, respectively have been 
shown. (B) The eluted peak fractions have been analyzed on reducing and non-reducing SDS PAGE 
followed by Silver staining.     
 
 
 
4.3.4. Isothermal Titration calorimetry: Isothermal titration calorimetry (ITC) was used for the 
determination of binding constants and stoichiometry of the interaction between LR∆FNIII and 
Leptin variants. LR∆FNIII was found to interact with both leptin types with a 1:1 stoichiometry. 
Based on this result, the broad peak from size exclusion chromatography was assumed to be 
formed of 1:1 and 2:2 complexes, similar to the complete extracellular part of LRecto as shown 
earlier. The dissociation constants for wt-Leptin and Leptina1 was determined to be 3.0 nM and 
4.5 nM, respectively. 
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4.3.5 Small Angle X-ray Scattering: The molecular weight, structural dimension and low 
resolution architecture of receptor alone and in complex with wt-Leptin and Leptina1 was 
determined using small angle X-ray scattering (SAXS). LR∆FNIII and its complex with antagonist 
Leptin, did not show any radiation damage or concentration dependency. However, wt-Leptin/ 
LR∆FNIII showed concentration dependency when measured in bulk mode. The size of the 
receptor and complexes was determined from the Guinier based radius of gyration, while the 
molecular weight was calculated from the zero intensity extrapolation. These molecular weight 
data was found to be compatible with the expected molecular weight determined from size 
exclusion chromatography and chemical crosslinking. SAXS data analysis for LR∆FNIII showed it 
to be monomeric with a molecular weight of 87.8 kDa as extrapolation based molecular weight 
determination suggested a 230.9 kDa complex. Based on the 1:1 stoichiometry of wt-Leptin and 
LR∆FNIII interaction, a 230.9 kDa suggests a quaternary complex with two receptor and two 
ligand. The plot of distance distribution function P(r) showed a similar size for the receptor and 
complexes but different form as expected. The open form of the Kratky plot analysis suggested 
these constructs to be highly flexible. Ab initio shape reconstruction using DAMMIF tool from 
ATSAS package provided further structural information about the receptor and its complexes. 
The receptor ab initio dummy bead model built with a P1 symmetry showed an elongated 
extended multi-domain structure. The ab initio model of 1:1 complex of antagonist Leptin/ 
LR∆FNIII was also reconstructed with a P1 symmetry. This model shows an elongated model 
similar to the receptor alone. As the wt-Leptin/ LR∆FNIII complex is a quaternary complex, it was 
modeled with a P2 symmetry. Interestingly, limited variability was observed among the models 
and clustering using DAMCLUST produced two different clusters. The cluster centers of the 
both clusters shows similar feature having two arms extending from a bulky base. The two 
extended arms in the low resolution structure can easily be interpreted as the CRH1 domain 
while the bulky base is formed by two CRH2 domains interacting two Leptins. The striking 
similarity of these models with the distal part of ab initio model of the quaternary complex of full 
length extracellular receptor and Leptin corroborate each other. This robust SAXS study 
bolsters results obtained by size exclusion chromatography, isothermal titration calorimetry and 
chemical cross-linking study thus clearly suggesting the redundant role of FNIII domains in 
Leptin induced LR dimerization. 
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Figure 4.3. Biophysical characterization of LR∆FNIII interaction with Leptin: (A) Calorimetric 
isotherm and thermodynamic parameters for interaction of LR∆FNIII with wt-Leptin and (B) Calorimetric 
isotherm and thermodynamic parameters for interaction of LR∆FNIII with antagonist leptina1. 
 
4.4 DISCUSSION 
4.4.1. LR∆FNIII is monomeric but has higher tendency to form non-physiological covalent 
clusters:  LR∆FNIII lacks the membrane proximal two FNIII domains harboring two free cysteine 
residues (Haniu et al., 1998). These cysteines have been shown to form clusters resulting in 
covalently linked dimer, trimer and oligomers of FNIII domains when expressed in isolation 
(Zabeau et al., 2005). In spite of the loss of these two cysteines upon FNIII truncation, this 
construct showed higher tendency to form non-physiological disulfide clusters unlike the full 
length LRecto. Considering earlier observation that free cysteines in CRH2 also take part in non-
physiological clustering (Zabeau et al., 2005), such an irony can be explained by our hypothesis 
that a specific role played by FNIII domains where it prevents the random clustering of the free 
cysteines in rest of the part of the receptor in solution by hindering their spatial proximity with 
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steric interference. The majority of monomeric fraction suggests it to be the native form of the 
receptor, compatible with earlier observation that full length LRecto expressed as monomeric 
receptor.       
4.4.2. Thermodynamic parameters of agonist and antagonist Leptin interaction with 
LR∆FNIII: Although FNIII domains have been shown not to take part in ligand binding (Fong et al., 
1998), in order to rule out any indirect effect on the ligand binding by FNIII- mediated modulation 
of overall orientation and relative organization of leptin binding domains, we have performed 
quantitative analysis of their interactions. The 1:1 stoichiometry of LR∆FNIII with wild type and 
antagonist Leptins is compatible with earlier result with full length LRecto. The interactions are 
enthalpy-driven with nanomolar affinities, similar to our previous observation with full length 
LRecto construct. 
4.4.3. Absence of FNIII domains has no effect on Leptin-induced quaternary complex 
formation: In chapter 3 it has been shown that the dimerizing ability of leptin is a prerequisite 
for the LR activation and loss of dimerizing ability of leptin leads to antagonism. Although this 
dimerization involves only CRH2-Ig domains, deletion of FNIII or mutation of FNIII cysteines 
have been shown to affect receptor activation (Zabeau et al., 2005). Our analytical gel filtration 
experiments show that loss of FNIII has no effect on leptin induced dimerization, suggesting this 
loss of activation potential is not related to the oligomerization, thereby establishing the 
dichotomy of receptor function. The CRH2 and Ig is the unit of ligand binding and 
oligomerization, while FNIII unit plays a redundant role in ligand induced oligomerization. 
Nonetheless, this domain may act like a lever, controlling the orientation of  intracellular parts 
upon leptin binding. The antagonist Leptin can only form the 1:1 complex unlike the wt-Leptin, 
corroborating our earlier observation that antagonism is a result of loss of oligomerization by 
leptin site-III-Ig domain interaction.   
4.4.4. Solution structure of the quaternary complex of wt-Leptin/LR∆FNIII shows striking 
similarity to the distal part of wt-Leptin/LRecto complex: The low resolution solution structure  
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Figure 4.4. Small angle X-ray scattering analysis of LR∆FNIII and its complexes: (A) Relative 
plot of log of scattering intensity vs. momentum transfer for LR∆FNIII (green), Leptina1/LR∆FNIII binary 
complex (red) and wt-Leptin/LR∆FNIII quaternary complex (blue); (B) Reference ab initio model among 20 
DAMMIF models generated from scattering data of LR∆FNIII; (C) Cluster centers from two clusters 
produced by DAMCLUST from 20 ab initio models generated using DAMMIF from scattering data of wt-
Leptin/LR∆FNIII complex; (D) Distance distribution plot P(r) for LR∆FNIII (green), Leptina1/LR∆FNIII binary 
complex (red) and wt-Leptin/LR∆FNIII quaternary complex (blue); (E) Guinier region showing linearity at 
lower angle for LR∆FNIII (green), Leptina1/LR∆FNIII binary complex (red) and wt-Leptin/LR∆FNIII quaternary 
complex (blue); (F) Reference ab intio model among 20 DAMMIF models generated from scattering data 
of Leptina1/LR∆FNIII binary complex.       
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of the full length extracellular part of LR in complex with both wild type and antagonist leptins 
have described in chapter 3. Here similar SAXS analysis for the LR∆FNIII and its complexes 
hasbeen carried out. The molecular weight determined from zero intensity extrapolation of 
SAXS curve supports a quaternary complex, thus proving the redundant role of FNIII in 
leptininduced LR oligomerization. SAXS based molecular weight estimation of LR∆FNIII/antagonist 
leptin suggests a binary complex and supports our earlier observation of antagonist Leptin 
forming only binary complex with full length LRecto. The striking similarity of the ab inito models 
of wt-Leptin/LR∆FNIII quaternary complex with the distal part of wt-Leptin/LR∆FNIII complex validates 
the structural paradigm of Leptin induced LR architecture. The existence of two different clusters 
in the ab initio models of wt-Leptin/LR∆FNIII suggests some degree of flexibility exist in the 
solution structure. But both cluster centers have similar features: a compact broad base formed 
by the CRH2-Leptin-Ig domains and two CRH1 arms extending from it. Ab initio models of both 
LR∆FNIII receptor alone and its binary complex with antagonist Leptin are compatible with the 
corresponding models with full length LRecto generated earlier. 
In summary, we showed that FNIII domains, though essential for leptin mediated receptor 
activation, has no role to play in Leptin induced receptor dimerization, thereby establishing a 
distinct and non-overlapping division of roles played by individual LRecto domains. We 
hypothesize that FNIII domain although plays such redundant role in agonist-induced 
dimerization, its inevitability would be arising from its potential role in channelizing the 
conformational change upon leptin binding to the intracellular part of the receptor.  
 
4.5 MATERIALS AND METHODS 
Production of LR∆FNIII: In order for expression of  LR∆FNIII variant containing CRH1-Ig-CRH2 motif of 
extracellular part of murine Leptin receptor (LRecto), the pMET7 vector carrying the corresponding ORF 
from residue 1 to 634 of LRecto  and a C-terminal hexa-His. HEK-293T cells, grown in Roller bottles till 
90% confluency, was transiently transfected with 250µg vector per roller bottle (850cm2) using 
Polyethyleneimine (1DNA:1.5 Polyethyleneimine molar ratio) and was further cultured in DMEM medium 
containing Penicillin and Streptomycin in the presence of Kifunensine at 37° C in a 5% CO2 environment 
for 4 days. The medium was harvested, centrifuged at 10,000g for 30 minutes to pellet down the cell 
debris and the supernatant was loaded onto a TALONTM IMAC resin (Clontech) column at 5ml/min. The 
non-specifically bound proteins to matrix was removed by washing with 4mM Imidazole. Protein of 
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interest was eluted with 300mM imidazole, concentrated and further resolved on a size exclusion column 
of Superdex 200 HiLoad 16/600 column (GE HealthCare) prequillibrated with 25mM HEPES (pH 7.4) 
containing 100mM Sodium Chloride. LR∆FNIII eluted as a single peak; the peak fractions were pooled and 
the purity was assessed by SDS PAGE.  
Production of wild type and antagonist Leptins: Similar method was followed as mentioned in chapter 
3 “Materials and methods” section. 
Isolation of complexes of LR∆FNIII with Leptin variants: Purified LR∆FNIII at 5-7 mg/ml was incubated 
with 4 times molar excess of wild type or antagonist leptin for 30-60 minutes and then resolved on a size 
exclusion column SD200 HiLoad 16/600 (GE HealthCare), pre-equilibrated with 25mM HEPES (pH=7.4) 
containing 100mM Sodium Chloride. The major peak containing monomeric receptor was pooled, 
concentrated and stored at -80ºC after flash freezing in liquid nitrogen.  
Isothermal titration calorimetry: The kinetic and thermodynamic parameters of LR∆FNIII interaction with 
wt-Leptin and Leptina1 were determined by Isothermal Titration Calorimetry. All the protein components 
were purified in 25mM HEPES (pH=7.4) containing 100mM Sodium Chloride and degased immediately 
before titration. 20µM of wt-Leptin was titrated against 1.4ml of 1µM LR∆FNIII with first discrete injection of 
3µl followed by 10µl each at 37 ºC while continuously mixing at 307 RPM stirring speed. The heat 
released was recorded using a MicroCal VP-ITC set up (GE Healthcare) and analyzed using Origin 
(version). The best fitting of the experimental data was obtained using built-in “one-set of sites” curve 
fitting model in Origin and this fit was used to determine the equilibrium constant (1/Kd), stoichiometry of 
interaction (N), enthalpy change (∆H). The change in Gibbs free energy (∆G) was calculated using the 
equation ∆G = -RT ln (1/Kd) and the entropy change (∆S) was back calculated using ∆G = ∆H – T∆S. 
Similar experiments were performed for Leptina1 to characterize their interaction with LR∆FNIII. 
Small angle X-ray scattering: Following steps were followed in order for SAXS analysis.  
a) Data collection and primary data reduction: SAXS data was obtained at the beamline BioSAXS 
station (ID14-3) of ESRF (Grenoble) with a robotic sample changer. The protein samples of LR∆FNIII, 
its binary complex with Leptina1 and quaternary complex with wt-leptin were measured in bulk mode 
with at least 3 different concentrations in the range of 1.0-7.3 mg/ml. Monochromatic X-ray beam of 
1.54 Å was scattered through these monodispersing samples at 293 K were recorded covering the 
momentum transfer range 0.01 Å-1< s < 0.6 Å-1, where s=4πsinθ/λ (2θ=scattering angle, 
λ=wavelength of incident X-ray). In this bulk mode measurement, absence of X-ray induced radiation 
damage was confirmed by alignment of 10 two dimensional scattering curves obtained from 
integration of continuous radial three dimensional scattering data obtained from 10 independent X-ray 
scattering measurements with 10 second exposure for each sample. For each concentration set, the 
scattering data was normalized for beam intensity, exposure time and corrected for the detector 
response. Subtraction of buffer scattering from the sample scattering using PRIMUS (Konarev et al. 
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2003) eliminated both buffer background as well as parasitic background arising from instrument 
hardware. A concentration dependency was reproducibly observed for wt-Leptin/LR∆FNIII complex 
scattering, possibly due to covalent clustering that has been observed for this scatterer at higher 
concentration; thus two concentrations of 0.8 and 1 mg/ml was finally used for further analysis for this 
complex. The forward scattering (I0) and radius of gyration (Rg) was determined in PRIMUS from 
infinite dilution extrapolation based on guinier approximation and compared with corresponding 
estimates from Gnom (Svergun ,1992) calculated by indirect fourier transformation of the complete 
one dimensional scattering data. The distance distribution function P(r) and maximal dimension Dmax 
for each scatterer was evaluated using Gnom. Molecular masses were calculated based on the 
forward scattering from a calibrated sample viz. bovine serum albumin (ESRF) or water (Soleil). 
Molecular mass based on porod volume was estimated using Autoporod (Petoukhov MV et al., 2012) 
and compared with corresponding estimates from Guinier approximation.  
 
b) Ab initio modeling: Ab initio three dimensional shape reconstruction from one dimensional scattering 
data was achieved using DAMMIF (Franke, 2009). In order to avoid stochastic error while modeling, 
20 models were generated by 20 independent runs for each scatterer type. Uniqueness of these ab 
initio shapes were evaluated using DAMAVER (Volkov et al., 2003). When the average normalized 
spatial discrepancy (NSD) value for the 20 models was found to be less than or equal to 1, the set was 
considered as single cluster and the model having lowest NSD average value with respect to other 19 
models was considered as the representative for the scatterer type. Unlike the receptor and its 
complex with antagonist Leptin, the DAMMIF models of wt-Leptin/LR∆FNIII complex, upon visual 
inspection using molecular viewer PyMol (DeLano Scientific) showed variability in the models, possibly 
due to flexibility in this system. So, these models with multimodal distribution were clustered using 
DAMCLUST and the cluster centers were considered as the representative conformers of the wt-
Leptin/LR∆FNIII quaternary complex. Qualitative evaluation of these models were done by analyzing the 
chi square values against the respective experimental scattering curves. 
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4.7 SUPPLEMENTARY FIGURE 
 
 
 
 
 
Figure 4.S1. Small angle X-ray scattering intensity vs. scattering angle: (A) Plot of log of 
intensity of buffer subtracted scattering intensity from LR∆FNIII against momentum transfer (s) at three 
different concentrations. inset: Similar log of intensity vs. momentum transfer (s) at very low angle 
showing scattering intensity is independent of concentration of receptor at both lower and higher angles; 
(B) Similar plot for Leptina1/LR∆FNIII binary complex at four different concentrations. inset: Similar log of 
intensity vs. momentum transfer (s) at very low angle showing absence of concentration dependency. 
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Figure 4.S2. Ab initio model of LR∆FNIII compared to the rigid body model from LRecto: After 
the removal of FNIII domains, the best rigid body model (chi 2.2) obtained from the SAXS analysis of wt-
Leptin/LRecto quaternary complex (surface view, grey) was compared with the ab initio model of wt-
Leptin/LR∆FNIII quaternary complex (sphere view, red).   
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Table 4.S1: SAXS analysis of the LR∆FNIII, Leptina1/LR∆FNIII  binary and wt-Leptin/LR∆FNIII 
quaternary complex 
 
Data collection 
parameters 
LR∆FNIII Leptina1/LR∆FNIII wt-Leptin/LR∆FNIII 
Beamline ID 14-3, ESRF ID 14-3, ESRF ID 14-3, ESRF 
Detector PILATUS 1M PILATUS 1M PILATUS 1M 
Beam Geometry 0.7 x 0.7 mm2 0.7 x 0.7 mm2 0.7 x 0.7 mm2 
Wavelenght (Å) 0.931 0.931 0.931 
Q range (Å-1) 0.15–6.110 0.15–6.110 0.15–6.110 
Exposure Time (sec) 100 (10 x 10) 100 (10 x 10) 100 (10 x 10) 
Concentration range 0.9 - 3 0.9 - 2.7 0.9 - 2.7 
Temperature (K) 293 293 293 
Structural 
Parameters 
   
I(0) (Å-1) from P(r) 103.8 ± 3.1 115.8±9.5 52.2±0.1 
Rg (Å) from P(r) 50.5±2.0 58.0±1.5 83.9±0.2 
I(0) (Å-1) from Guinier 108.9±8.3 120.6±8.9 55.9±0.3 
Rg (Å ) (from Guinier) 51.8±4.5 58.2±1.4 84.2±2.8 
Dmax (Å) 165.3±3.9 189.5±12.9 --- 
Porod volume 185087 300847 1442936 
Excluded volume, 270000 546000 1380000 
Molecular Mass  (kDa) 
From I(0) 87.8 97.9 230.9 
From SaxsMOW 88.2 120.5 191.9 
From Porod volume 125.2 208.8 901.8 
From excl. volume 127.6 321.1 811.7 
Peptide (Protparam) 69.8 85.8 171.6 
Modeling 
Parameters 
   
Shape reconstruction DAMMIF DAMMIF DAMMIF 
Symmetry P1 P1 P2 
χ2 of reference model 0.7 1.5 1.3 
# of models 20 20 20 
DAMAVER NSD (var) 0.5±0.02 0.6±0.09 1.4±0.1 
Rigid body modelling SASREF SASREF SASREF 
Initial  χ2 --- --- --- 
Final χ2 --- --- --- 
Software/Server    
Data Reduction BsxCuBE BsxCuBE Foxtrot 
Data Processing PRIMUS PRIMUS PrimusQt 
Data Evaluation PRIMUS, Gnom PRIMUS, Gnom PrimusQt, Gnom 
Structure Modeling Dammif Dammif Dammif, Damclust 
Molecular PyMOL PyMOL PyMOL 
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Crystallization of murine Leptin 
Receptor and its complexes  
with wild type and  
antagonist Leptin  
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5.1 INTRODUCTION 
Protein X-ray crystallography is one of the paramount methods for the structural 
characterization of proteins at atomic resolution. While electron microscopy and small angle x-
ray scattering are limited by their low resolution, crystallographic structures can provide 
immense information at atomic scale enabling understanding of molecular mechanisms and 
facilitating intelligent designing of novel agonistic and antagonistic drug molecules.   
In Leptin receptor biology, only the crystal structure of the Leptin binding domain has been 
solved in complex with a competitive Fab fragment (Carpenter et al., 2012). As the structure of 
receptor or its subdomains have not been characterized structurally in isolation or with its 
cognate ligand, we decided to set up crystallization trials to obtain diffraction-grade crystals. 
Crystallization trials of full length LRecto and LR∆FNIII and corresponding results have already 
been described in Section 3 and 4, respectively. As these constructs did not yield any crystal 
hits, we have included smaller constructs to increase the probability of getting crystallization hit. 
The strategies which has been followed to increase the yield and quality of proteins have been 
described along with results of crystallization trials. 
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5.2 STABLE CELL LINE PREPARATION 
 
5.2.1 INTRODUCTION 
We have used transient transfection of HEK293T cell line for most of the protein 
production work described earlier. HEK-293 cell line has been a popular protein production 
platform due to easy handling requirement and efficient transfectability. HEK293T, a variant of 
original HEK-293, stably expresses hexameric Simian Vacuolating virus 40 (SV40) large T-
antigen which can bind SV40 enhancers and increase the protein expression levels. In spite of 
such optimized system for heterologous expression, HEK-293T system presents specific 
difficulties for production of glycosylated proteins for the purpose of crystallization. Such 
glycoproteins due to their inherent complexity pertaining to flexible glycans, pose great 
challenge in protein crystallization. Glycosylation is imperative for the correct folding and thus 
Asn residues cannot be substituted without affecting the structural integrity of these proteins. 
Leptin receptor is one of the highly glycosylated receptor with 18 n-linked glycosylation sites as 
shown by mass spectrometry of human LRecto (Haniu et al., 1998). Differential occupancy of 
different glycosylation sites as well as different chain lengths of the glycans results in very high 
degree of inhomogeneity in the protein preparation. In this regard, use of glycosylation inhibitors 
or expression in HEK293S GnTI-/- cell line has been shown to improve the protein homogeneity 
remarkably (Chang et al., 2007). We have used Kifunensine, the alpha-mannosidase I inhibitor, 
that results in N-glycans formed of oligomannose moieties only, Man5–9GlcNAc2 (Fig. 5.1.1). 
Even though complex type glycans were prevented, differential occupancy has produced 
heterogeneity confirmed by closely running multiple bands of the receptor on SDS PAGE 
analysis (Fig. 5.1.2). Random mutagenesis based approach using ethyl methanesulfonate as 
mutagenic agent, a ricin resistant HEK-293 cell line has been created (Reeves et al., 2002). 
This variant called HEK-293S cell line lacks N-acetylglucosaminyltransferase I (so GnTI-/-) 
activity and is unable to glycosylate proteins using complex N-glycans. MALDI-TOF based mass 
spectrometric analysis has shown a very high degree of homogeneity in glycosylation when 
HEK 293S GnTI-/- cell line was used (Chang et al., 2007) (Fig. 5.2.1). So we decided to try this 
system to get protein preparation with highest homogeneity for the purpose of crystallization 
trial.   
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Figure 5.2.1. Manipulation of the Mammalian N-Linked Glycosylation Pathway in HEK293 
Cells: (A) A section of the glycosylation pathway is illustrated.(B–D) MALDI-TOF analysis of the glycans 
of the target glycoprotein (s19A) expressed in (B) HEK293T cells in the presence of the α-mannosidase I 
(MI) inhibitor, kifunensine, at 5 µM, resulting in the addition of oligomannose-type N-glycans, Man5–
9GlcNAc2; (C) ricin-resistant HEK293S cells devoid of GnTI activity, resulting in predominantly 
Man5GIcNAc2N-glycans; and (D) HEK293T cells in the presence of the α-mannosidase II (MII) inhibitor, 
swainsonine, at 20 µM, resulting in the addition of hybrid-type glycans. For MALDI-TOF MS, glycans were 
released directly from SDS-PAGE gel bands by overnight PNGase F digestion. Monosaccharide 
constituents are represented as follows: open diamonds, Gal; closed diamonds, GaINAc; open squares, 
Glc; closed squares, GlcNAc; open circles, Man; stars, sialic acid; dotted diamonds, Fuc. (Adopted from 
Chang V.T. et al., Structure, 2007) 
 
Protein production using transient expression in mammalian cell culture systems involves the 
transfection of cells with vector DNA that remains in the cytoplasm and doesn’t get incorporated 
in genome. Thus the vector does not propagate during cell division and lost within finite period 
of few days due to cell division or other causes. So this method of protein production by 
transient transfection requires repeated transfection utilizing large scale DNA preparation; thus 
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time and cost effective. Although numerous rapid and cost effective transfection expression 
methods have been devised recently (Aricescu et al., 2006; Durocher et al., 2002; Meissner et 
al., 2001), transient transfection requires time consuming large scale DNA preparation and 
continued growth and maintenance of cell lines prior to transfection. Automation of 
maintenance, transient transfection of HEK293T and HEK-293S cell line and protein production 
has been achieved (Zhao et al., 2011), but availability of such platform has been the limiting 
factor. On the contrary, stable expression involves one time transfection followed by 
incorporation of vector into the genomic DNA and propagation to daughter cells during cell 
division. Such stably transfected cells can be stored in liquid nitrogen and propagated 
repeatedly. In order to minimize the time, effort and cost of protein production stable transfection 
was preferred over transient cell line using HEK-293S GnTI-/- cell line. 
 
5.2.2 MATERIALS AND METHODS 
Generation of stable cell lines: HEK-293S GnTI-/- were grown in DMEM medium containing Glutamine, 
Penicillin and Streptomycin until 50-60% confluency in 75 cm2 falcons. Plasmid constructs of pCDNA-4.0 
carrying  LR∆FNIII and LRCRH2-Ig were subjected to single digestion using PvuI restriction enzyme by 
incubating for 4 hr at 37° C and confirmed using Agarose Gel electrophoresis before PCR purification 
(Qiagen PCR purification Kit). Before transfection, old DMEM medium was replaced with new medium 
and transfection was carried out using standard Calcium phosphate transfection protocol. After six hours 
of transfection, medium was replaced with new DMEM medium containing Zeocin, which act as selection 
agent. In order to achieve monoclonal cell lines, once the transfected cells were grown till 60-70% 
confluency, cells were detached using EDTA/Trypsin and grown in four new 175 cm2 falcons in the 
presence of selection agent Zeocine upon following dilutions: 1/5, 1/10, 1/20 and 1/40. After about two 
weeks of growth with repeated renewal of medium in 3-4 days interval, falcons were cut open and each 
individual isolated colonies were blotted onto sterile blotting paper and inoculated into 24-well plates, 
resuspended and grown until 90% confluency. These monoclonal cell lines were transferred to 75 cm2 
falcons and grown till 90% confluency, the expression was induced using tetracyclin and the expression 
levels were quantified by Western blot using anti-His tag antibody. A part of cells were stored in liquid 
nitrogen for future use.    
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Figure 5.2.2. Transient vs. stable expression of LR∆FNIII and LRCRH2-Ig: (A) Western blot of 
pCDNA-4/mLR∆FNIII using anti-His tag antibody: From left to right, transiently expressed receptor in HEK-
293T cells 2nd day, 3rd day, 5th day after transfection, then same construct expressing stably in HEK-293S 
cell line during 5 days after Tetracyclin induction; (B) Western blot of pCDNA-4/ LRCRH2-Ig using anti-His 
tag antibody: From left to right, transiently expressed receptor in HEK-293T cell line, stably expressing 
receptor from five monoclonal strains of HEK-293S cells numbered 803, 804, 805, 809 and 810. All the 
samples are after 3 days of transfection (in case of transient expression) or after 3 days of induction (in 
case of stable expression). 
 
5.2.3 RESULTS 
Comparison of yields from transient vs. stable expression: In case of pCDNA-4/LR∆FNIII 
construct, the yields from transient expression in HEK-293T cell lines did not improve much 
when stably expressed in HEK-293S cell line (Figure 5.2.1). Also the limited glycosylation in 
HEK-293S cell line has limited effect on the amount of sugars, as both 293T and 293S 
expressed receptor run at similar height on SDS-PAGE as detected by Western blotting using 
anti-His tag. In case of pCDNA-4/LRCRH2-Ig construct, the yields from stably transfected HEK-
293S cells were lower compared to the transient expression in HEK-293T cell line. But in this 
case there is conspicuous reduction in molecular weight of the receptor due to limited 
glycosylation in HEK-293S cell line. LR∆FNIII produced in HEK-293S (GnTI-/-) was further being 
used for crystallization trial, but without any successful hit so far. 
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5.3 YIELD OPTIMIZATION OF LRCRH2-Ig and LRCRH2  
 
5.3.1 INTRODUCTION 
LRCRH2-Ig construct was initially cloned in pMET7 and the yield was relatively low for 
crystallization trials. As CRH2 is the leptin binding domain of LR and Ig domain is essential for 
Leptin-site III mediated oligomerization and activation, this construct would be highly crucial for 
both structural and functional study. Theoretically, CRH2-Ig should be the minimal unit required 
for a leptin induced higher order complex. While structural characterization of this quaternary 
complex would be relatively favorable due to absence of more flexible CRH1 and FNIII domains, 
the crystal structure will be sufficiently informative about the binding interface. Based on these 
rational, four CRH2-Ig constructs differing from each other in their N and C-termini were 
designed. 
CRH2 has been shown to be the leptin binding domain. But there was no structural information 
available of the CRH2 alone or in complex with Leptin, until recently the structure was solved for 
the complex of CRH2 expressed in E.coli with a Fab fragment. We decided to include the CRH2 
for optimization of expression by varying the N- and C- termini. Two constructs of CRH2 were 
planned for construction. 
Our earlier plasmids were based on pMET7 vectors utilizing the native secretion signal. We 
decided to PCR amplify CRH2 and CRH2-Ig fragments with different termini from LRecto and 
clone them in pcDNATM4/TO vector (Invitrogen). This vector has a tetracycline-regulated 
expression system without any viral transactivator, thus produces higher yield than other 
regulated mammalian expression system. A highly efficient secretion signal from pHLSec 
(Aricescu et al., 2006) was fused to the n-terminus of the insert and then ligated to 
pcDNATM4/TO. 
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5.3.2 MATERIALS AND METHODS   
Following primers were used for the PCR amplification of CRH2-Ig and CRH2 gene from the pMET7-
LRecto plasmid. 
 
 
 
Name Description Sequence* 
LR_001 
Forward Primer for CRH2-Ig 
GAA  ACC  GGT  ATT  CTG  ACT  AGT  GTT G 
LR_002 GAA  ACC  GGT GTT  GTG  TAT  TTT  CCA C 
LR_003 Forward Primer for CRH2 GAA  ACC  GGT  GTC  AAT  ATC  AAT  ATA  TC 
LR_004 
Reverse Primer for CRH2-Ig and CRH2 
G CTT GGT ACC  CCA  AAA  TTC AGG CCC TC 
LR_005 G CTT  GGT  ACC TAC  ATC  CAT  GAC  AAG  CGT  ATA  G 
*The part of the sequence in yellow will be lost after RE digestion. 
 
Using all possible combinations of forward and reverse primer, total 6 (4 CRH2-Ig and 2 CRH2) fragments 
were PCR amplified. The termini were digested using KpnI and AgeI restriction enzymes and cloned into 
predigested pcDNATM4/TO vector. The cloned vectors were first verified by restriction digestion and then 
by plasmid sequencing. The cloned vectors were named as LR-14, LR-15, LR-24 and so on based on the 
forward and reverse primer used. 
Small scale expression test was carried out by transfecting each vector to HEK-293T cells grown in 6 well 
plates either in the presence or absence of Tetracycline, analyzing the supernatant after 3 days by 
western blot and detecting by anti-His tag antibody.  
 
 
5.3.3 RESULTS 
 
One out of total four pHLsec:CRH2-Ig constructs analyzed, showed drastic increase in the 
expression level compared to that of pMET7 vector. All two pHLsec:CRH2 constructs showed 
higher yield compared to the previous pMET7 variant (Figure 5.3.1). These constructs were 
used for crystallization trials of these receptor variants. 
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Figure 5.3.1. Western blot from mini-expression test of pCDNA constructs: Mini-expression 
test in order to quantify the expression levels of different constructs in HEK-293 cell was done by 
transient transfection followed by western bloting using anti-His6 antibody. 
 
 
 
5.3.4 DISCUSSION 
 
Higher yield of CRH2-Ig and CRH2 will enable the studies of this receptor variants esp. by 
protein crystallization for X-ray crystallography. Though it would be difficult to explain the exact 
mechanism behind this increased expression, most scientific reason would be the role of the  
termini in determining the stability of the receptor both inside cell and outside in the DMEM 
medium. In case of CRH2-Ig construct, the increase in the yield is very drastic and suggests the 
domain border optimization is a crucial way to optimize the yield of multi-domain proteins.  
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5.4 CRYSTALLIZATION TRIAL OF LRCRH2 
 
5.4.1 INTRODUCTION 
The open reading frame for CRH2 domain of murine LR has been cloned in pCDNA-4/TO 
vector with the extrinsic secretion signal from pHLSec (Section 5.2). This domain represent the 
smallest unit with the leptin binding potential. Thus structural characterization of this domain in 
complex with Leptin will provide important insights into the binding epitopes and will help in 
designing of antagonist drugs. However, in theory the absence of Ig-domain will disable the 
formation of a higher order quaternary complex. Recently, the crystal structure of human CRH2 
domain, expressed in Escherichia coli has been solved in complex with a competitive Fab 
fragment (Carpenter et al., 2012). However, the structure of CRH2 domain alone or in complex 
with cognate ligand is not available yet. So we decided to purify, analyze and set up 
crystallization trials for the isolated murine CRH2 domain and its complex with wild type as well 
as antagonist leptins. 
 
5.4.2 MATERIALS AND METHODS 
Production of Leptin binding domain CRH2: HEK-293T cells, grown in 175cm2 Falcons or 850 cm2 
Roller bottles till 90% confluency in DMEM medium containing Penicillin and Streptomycin, were 
transiently transfected with appropriate transfection agent in fresh DMEM medium containing Penicillin 
and Streptomycin in the presence of α-mannosidase inhibitor Kifunensine. The transfection agent was 
prepared by incubating pCDNA-4/TO-LRCRH2 plasmid with Polyethyleneimine (PEI) in a 1:1.5 molar ratio 
for at least 8 minutes at 37° C and a final quantity of 50µg of Plasmid DNA was used for cells grown on 
175cm2 surface area. After 4 days of transfection, the medium was harvested, centrifuged at 10,000g for 
30 minutes to remove cell debris and 2 lt of this medium was loaded onto a 20 ml TALON Superflow 
column (Clontech) overnight. Non-specifically bound proteins to the talon resin was washed by 4mM 
Imidazole followed by elution of LRCRH2 using 300mM Imidazole. Further purification was done by 
resolving on a size exclusion SD200 column (GE Healthcare) equilibrated with 25mM HEPES (pH=7.4) 
containing 100mM Sodium Chloride. The eluted fractions were analyzed on SDS PAGE and fractions 
containing LRCRH2 were pooled and stored at -80°C after flash freezing in liquid Nitrogen. 
Deglycosylation of LRCRH2: In order to increase the homogeneity, receptor was concentrated to 1mg/ml 
and incubated with endoglycosidase H (New England Biolabs) enzyme overnight. After deglycosylation, 
endoglycosidase H was removed by gel filtration chromatography.  
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Acetylation of Free Cysteines: In order to prevent the non-physiological clustering of free cysteines in 
LRCRH2, the fractions from size exclusion chromatography containing monomeric receptor were pooled 
and treated with 5mM Iodoacetamide for 1 hr at room temperature in ambient light. After the 
carboxymethylation was complete, excess of Iodoacetamide was removed by concentrating the mixture 
to 1 ml and resolving on a size exclusion column, pre-equillibrated with 25mM HEPES (pH=7.4) 
containing 100mM Sodium Chloride. 
 
 
Figure 5.4.1. Production of LRCRH2/Leptin Complex for crystallization: (A) Size exclusion 
chromatography of LRCRH2 after Talon IMAC purification produced two distinct peaks (orange) I and II; 
Complex of wt-Leptin and carboxymethylated LRCRH2 resolved on the size exclusion column (purple) 
producing peak III ;  (B) Non-reducing SDS PAGE analysis of fractions from size exclusion 
chromatography of LRCRH2 shows peak 1 to be composed of disulfide linked dimers and peak 2 composed 
of monomeric CRH2; (C) Non-reducing SDS PAGE analysis of 1. carboxymethylated LRCRH2 before 
complex formation and gel filtration, 2. Pellet obtained during carboxymethylation with Iodoacetamide, 
Marker (M) and peak III eluted from size exclusion chromatography of binary complex obtained by 
incubating LRCRH2 incubated with wt-Leptin. Binary complexes of leptina1 and leptina2 have been prepared 
in similar procedure for crystallization (data not shown). 
Isolation of complex of LRCRH2 with Leptin variants: Iodoacetamide-treated and deglycosylated 
receptor and each Leptin variant was concentrated to 5mg/ml and 10mg/ml separately. The receptor was 
then incubated with 6 times molar excess of Leptin variant for 30 minutes, followed by size exclusion 
chromatography. Fractions containing CRH2 and Leptin were pooled and used for crystallization trial 
without storing any further. Similar protocol was also followed with unperturbed receptor, only 
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Iodoacetamide treated receptor and Iodoacetamide untreated deglycosylated receptor in order to get 
corresponding complexes.  
Crystallization Trial: LRCRH2 alone and its complexes with Leptin variants viz. wt-leptin, leptina1 and 
leptina2 were concentrated to ~ 5 mg/ml and 8 mg/ml and nearly 600 drops were set up with different 
crystallization conditions from various commercially available viz. Proplex (96) from Molecular 
Dimensions, Crystal Screen Lite (48), PEG ION 1 & 2 (96), Index Screen (96) and Crystal Screen 1 & 2 
(96) from Hampton. 
5.4.4 RESULTS  
Purification of LRCRH2 and isolation of complexes: Size exclusion chromatography of LRCRH2 
obtained from the elution from  Talon IMAC purification, produced two peaks. Reducing and 
non-reducing SDS PAGE analysis of fractions obtained from size exclusion chromatography 
showed the composition of those two peaks: (i) The high molecular weight peak contains 
covalently clustered dimeric LRCRH2; while (ii) The low molecular weight peak comprises 
monomeric LRCRH2 (Figure 5.4.1). The monomeric mLREC:CRH2, being the physiological form 
was used for all further analysis.Successful formation of binary complex of LRCRH2/Leptin in 1:1 
stoichiometric ratio was achieved when the iodoacetamide treated LRCRH2 was incubated with 
six molar excess of Leptin and resolved on size exclusion column. SDS PAGE analysis further 
confirmed the composition of the complex. Formaldehyde cross-linking suggested the complex 
to be a 1:1 complex. 
Crystallization Trial: In spite of a very wide approach (~600 conditions) for the crystallization of 
LRCRH2 alone or in complex with different murine Leptin variants has failed. Majority of drops 
produced amorphous precipitate and brownish precipitate. 
5.4.5 DISCUSSION 
Crystallization trial of CRH2 domain has not been successful either in isolation or in complex 
with cognate ligand. The flexible sugar tree on the protein surface may increase the flexibility of 
this system and reduce homogeneity; but previous works have shown CRH2 domain alone 
expressed in bacterial host and thus not having any glycans attached not producing any crystal 
(Carpenter et al., 2012). Thus non-crystallizability of isolated CRH2 could be its inherent 
property. Similar reasons may exist for the non-crystallizability of its complexes with leptin 
variants. 
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5.5 CRYSTALLIZATION TRIAL OF LRCRH2-Ig 
 
5.5.1 INTRODUCTION 
 
The crystal structure of human CRH2 domain in complex with a competitive antibody (PDB ID: 
3V6O) is the only available structure of LR (Carpenter et al., 2012) till now. Our attempt to 
crystallize the leptin binding unit from murine leptin receptor was failed as described in 6.4 
section. So we decided to attempt the crystallization trial of LRCRH2-Ig construct. The expression 
and yield of this construct has been optimized by subcloning into pCDNA plasmid with the 
optimized secretion signal from pHLSec plasmid (Section 6.2). The CRH2-Ig can contribute both 
CRH2-Leptin site II and Ig-Leptin site III interactions, thus has the potential to form the 
quaternary complex. Crystal structure of such quaternary complex will provide immense 
information about the binding and activation epitopes on Leptin and its cognate receptor 
enabling designing of novel antagonist and agonistic molecules with potential therapeutic use in 
various leptin related pathophysiology. 
 
5.5.2 MATERIALS AND METHODS 
Similar methods were followed as for LRCRH2 described earlier in 5.3. 
 
5.5.3 RESULTS 
 
Purification of LRCRH2-Ig and its complexes: IMAC using Talon resin followed by the gel 
filtration chromatography of eluted peak using Superdex 200 HiLoad 16/600, produced single 
symmetric peak (Fig. 5.5.1). Upon complex formation with excess of wt-Leptin with subsequent 
resolution on same gel filtration column showed the existence of Leptin induced higher order 
oligomerization of LRCRH2-Ig. However, similar analysis for corresponding complex with leptina1 
produced only a single peak formed by binary complex suggesting absence of any quaternary  
leptina1/LRCRH2-Ig. This behavior supports our initial hypothesis that CRH2-Ig, indeed is the 
minimal subunit required for the leptin induced receptor oligomerization. 
 
Crystallization Trial: For crystallization trial, LRCRH2-Ig after purification from gel filtration 
chromatography, has been carboxymethylated and complexed with leptina1. This  
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Figure 5.5.1. Purification and crystallization of mLREC:CRH2-Ig and its complexes: (A) 
Relative elution profile of mLREC:CRH2-Ig (green) and wt-Leptin/mLREC:CRH2-Ig complex (brown) (B) 
SDS-PAGE analysis of peak fractions I, II and III.  
 
 
binary complex upon a large-scale crystallization trial involving ~600 conditions, has not 
produced any hits so far.  
 
5.5.4 DISCUSSION 
 
We were able to successfully express, purify the receptor construct LRCRH2-Ig and isolated its 
complex with wt- and leptina1. Interestingly, we showed that this receptor construct can form the 
quaternary complex with wt-Leptin, suggesting redundant role of CRH1 and FNIII domains in 
ligand induced oligomerization. Although this construct itself or in complex with leptina1 has not 
produced any crystallization hit in large scale crystallization trials yet, use of antibodies may 
improve the crystallizability of the receptor as has been observed in the case of Leptin binding 
domain (Carpenter et al., 2012). 
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5.6 CRYSTALLIZATION TRIAL OF LRecto 
 
5.6.1 INTRODUCTION 
 
The biochemical, biophysical and low resolution structural characterization of LRecto has already 
been described in chapter 3. This protein construct has also been subjected for extensive 
crystallization both alone, in complex with cognate ligand. 
 
5.6.2 MATERIALS & METHODS 
 
Similar procedures have been followed as described in Chapter 3 for the production of proteins 
and isolation of complexes for crystallization trial. 
 
 
5.6.3 RESULTS AND DISCUSSION 
 
Purification and isolation of LRecto and its complexes: LRecto purified from transiently 
expressing HEK293T cell line in the presence of Kifunensine upon incubation with 6 times molar 
excess of wild type murine Leptin (wt-Lep) expressed and purified from E. coli, for 30 min at 
room temperature followed by resolution on a Size exclusion column produced two incompletely 
resolved peaks: a minor high molecular weight (HMW) peak and a major low molecular weight 
(LMW) peak (Figure 5.6.1A). As the HMW complex is susceptible to dilution-dependent 
dissociation, this tetrameric complex has been stabilized by Formaldehyde mediated chemical 
crosslinking (Figure 5.6.2). The purity of LRecto and leptin has been assessed by SDS-PAGE 
after purification (Figure 5.6.1B).  
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Figure 5.6.1. Isolation of LRecto and its complexes: (A) Size exclusion chromatography of LRecto 
(green), leptina1/LRecto binary complex (orange), leptina2/LRecto binary complex (violet) and  wt-
Leptin/LRecto complex. The wt-Leptin/LRecto elutes as a two incompletely resolved peaks corresponding to 
the high molecular quaternary complex and low molecular weight binary complex peaks. (B) The purity of 
the complex of wt-Leptin/LRecto corresponding to the high molecular weight peak has been assessed by 
SDS PAGE followed by silver staining. M:molecular weight marker; 1: with reducing agent 2-
mercaptoethanol; 2: without reducing agent 2-Mercaptoethanol. 
 
 
Figure 5.6.2. Chemical crosslinking of quaternary complex of wt-Leptin/LRecto: The high 
molecular peak fractions from gel filtration chromatography has been subjected to formaldehyde 
mediated crosslinking and cross-linked complex was resolved on size exclusion column, producing a high 
molecular weight and low molecular weight peaks. Inset: SDS PAGE analysis of the peak fractions in the 
presence of reducing agent suggests, successful crosslinking of the 1:1 binary and 2:2 quaternary 
complexes. 
Crystallization Trial: Crystallization trial of unliganded LRecto with and without endoH mediated 
deglycosylation and their complexes with wt- and antagonist leptins have been largely 
unsuccessful. Most of the drops produced brown precipitate. LRecto treated with iodoacetamide 
to prevent non-physiological clustering has also been subjected with and without ligands; but no 
crystallization hit has been obtained yet.  
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Conclusion and 
Prospects 
 
Ironically, the structural and mechanistic aspects of leptin mediated leptin receptor activation is 
still an enigma despite of the scientific endeavor during last two decade.  Though such 
endeavor has expanded our knowledge beyond the role of this system in obesity by linking the 
leptin to multitude of pathophysiologies including autoimmune disease and breast cancer 
development, our quest surrounding the very first event initiated upon leptin binding to the 
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receptor and culminated with an active signaling complex is still a black box. The intrinsic 
complexity of leptin/leptin receptor system reflects from its structural similarity with a family of 
shared cytokine receptors called gp130 family  and yet following an activation paradigm 
completely different from the members of this family. While gp130 family of receptors share the 
gp130 coreceptor, Leptin receptor signals on its own by homo-oligomerization. Although G-
CSF/G-CSFR system shows the highest degree of sequence homology to this receptor, the 
existence of multiple non-signaling leptin receptor isoforms and their weak dominant negative 
repression on leptin receptor signaling indicating a complete novel receptor activation paradigm 
may underlie this system. Moreover, the lack of structural information on the LR-LR and LR-
leptin interactions have obstructed our understanding of this complex system. 
This doctoral research work begun in 2009 with an aim to characterize the leptin receptor 
extracellular domains using various structural biology and biophysical tools. Albeit, unavailability 
of any structural information about the extracellular part of the receptor and its complex with 
leptin at that time, provided the logical freedom for an unprejudiced approach, utilizing all the 
available structural biology tools like X-ray crystallography, small angle X-ray scattering and 
electron microscopy for simultaneous characterization of the receptor and its complexes. 
Availability of the antagonist leptin variants complimented this study by dichotomizing the high 
affinity binding from agonist-induced oligomerization and conformational changes inevitable for 
receptor activation. A plethora of biochemical, biophysical and structural biology  tools 
deciphered many facets of this system, unexplored earlier.  
Various biochemical experiments in conjunction with small angle X-ray scattering could able to 
show the underlying mechanism of leptin induced LR activation proceeds via the receptor 
oligomerization. On the contrary, the lack of such dimerizing ability was observed for the two 
antagonist leptins included for the study, confirming the role of leptinsite-III/LRIg interaction to be 
the principal driving force for the leptin induced oligomerization. Our observation of the absence 
of any receptor-receptor homotypic covalent interaction in the leptin induced higher-order 
complexes disproved a previous proposal of disulfide-linked signaling complex and disproved 
the proposed role of FNIII domain in such inter-receptor disulfide interaction. The intriguing 
observation of the monomeric nature of the receptor’s  complete extracellular part inspired to 
revisit the assessment of the proposed existence of disulfide clustered receptor dimers on 
membrane. Inclusion of iodoacetamide in the analysis of membrane receptors confirmed the 
absence of any disulfide bridge, conclusively suggesting the LR exists on membrane as non-
covalent dimer. Truncation of FNIII domains which have been shown to be inevitable for 
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signaling, did not affect the ligand induced receptor oligomerization, suggesting their redundant 
role in oligomerization. The solution structure analysis both at high concentrations using small 
angle X-ray scattering and at low concentrations using negative stain electron microscopy, has 
provided immense information on the low resolution architecture of the primordial complexes 
formed at the cell surface upon ligand binding. This 2:2 quaternary complex generated using 
SAXS although lacks the basic necessity of the >2 receptor for the signaling complex formation, 
primed to propose an activation model which consolidates available biochemical and cellular 
paradigms of the signaling complex in literature. Outcome of above experiments together with 
the available information suggests towards a signaling competent four leptin receptor/four leptin 
model formed by leptin induced dimerization of the preformed inactive leptin receptor dimers. 
Leptin receptor being a connecting link between the unshared cytokine receptors and the gp130 
family of shared cytokine receptors, its unique mechanistic behavior may be the reflection of a 
novel mechanistic paradigm. Although current high resolution structure determination using X-
ray crystallography has failed, use of non-competitive antibodies could be a boon for the 
structure determination of the leptin/leptin receptor complex, providing break-through 
understanding of the structure and mechanism of this system. Also further research work along 
the molecular understanding of the receptor activation will widen our horizon in leptin physiology 
as a pleiotropic hormone and its pathophysiology in autoimmune diseases and breast cancer. 
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 Scientific Publications 
1. Structural and mechanistic paradigm of Leptin Receptor activation revealed by study of its complexes with 
wild type and antagonist leptins     [Communicated] 
(Authors: Moharana, K., Zabeau, L., Peelman, F., Ringler, P., Stahlberg, H., Tavernier, J., Savvides, S. N.) 
 
Abstract: The adipocyte-derived cytokine leptin signals via its cognate receptor (LR) to serve as a metabolic switch, thereby 
regulating body weight and processes with a high metabolic cost such as reproduction and immune responses. The downside of 
such benevolent pleiotropy has been the possible role of leptin-mediated signaling in autoimmune diseases and breast cancer, 
which has raised interest in the targeted antagonism of leptin signaling. We here present comparative biochemical and 
structural studies of the ectodomain of LR (LRecto) in complex with wild type and antagonist leptin variants to reveal that the 
basic structural assembly leading to leptin signaling is a 2:2 stoichiometric complex. The quaternary complex is mediated by 
high-affinity binding of leptin to the CRH2 junction of LRecto, which is devoid of dimerization propensity, to elicit conformational 
changes that enable additional interactions with the Ig domain of a second leptin-bound LRecto. In contrast, antagonist leptin 
variants carrying mutations at the epitope interacting with LRIg are only able to establish high affinity 1:1 complexes with LR. 
Acetylation of free cysteines in LRecto also abrogates quaternary complexes with leptin suggesting a role for the formation of 
intra-receptor disulfides upon receptor activation. Together, our studies point to an assembly mechanism at the cell-surface 
whereby leptin recruits pre-dimerized LR molecules to form a higher-order complex obeying a 4:4 stoichiometry. This 
mechanistic proposal consolidates a large body of prior studies and establishes a new conceptual framework for future studies 
of leptin-mediated signaling. 
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2. Redundant role of FNIII domains in Leptin induced Leptin Receptor oligomerization     [In Preparation] 
(Authors: Moharana, K., Zabeau, L., Peelman, F., Tavernier, J., Savvides, S. N.) 
 
Abstract: Despite two decades of studies on the (patho)physiology  of leptin-mediated  Leptin receptor (LR activation) our 
current understanding of the leptin-LR signaling assembly is yet to come to full circle with respect to a mechanistic consensus. 
As we have previously shown, leptin acts via dimerization of its cognate receptor thereby displaying pleiotropic functionality 
ranging from energy homeostasis to reproduction, from regulation of immune system to angiogenesis and so on. While 
administration of leptin in diabetes and congenital leptin deficiency established promising therapeutic applications, its 
pathophysiology in obesity, autoimmune disease and breast cancer raises unequivocal demand for better understanding of 
structural and mechanistic paradigm of leptin receptor activation. Here we demonstrate that leptin can induce dimerization of 
LR lacking membrane proximal fibronectin type III (LRΔFNIII) domains, thus suggesting a redundant role of these domains in leptin 
induced LR oligomerization. Earlier studies had shown that the FNIII region is essential for the functionality of LR. The affinity of 
leptin for this construct was found to be similar to the full length receptor, with nanomolar affinity and stoichiometry of 1:1. 
Based on light scattering and small-angle x-ray scattering data, we demonstrate that LRΔFNIII, despite the absence of the 
membrane proximal domains, can form a quaternary complex with wt-Leptin. In contrast, antagonist leptin bearing 
S120A/T121A mutation could not dimerize the LRΔFNIII receptor. These results evidently suggest a functional dichotomy whereby 
while FNIII appears to be redundant in the oligomerization of LR it still may be playing a key role in the spatial disposition and 
orientation of intracellular parts to facilitate a signaling-competent conformation. 
Following milestones represent my accomplishments during my Doctoral research work: 
• Eukaryotic expression (Transient and Stable) and purification of extracellular LR variants 
• Isolation of receptor-ligand complexes for co-crystallization trial 
• Establishment of stable cell lines 
• Protein production optimization by redesigning constructs 
• Biophysical characterization of interactions using Isothermal Titration Calorimetry (ITC) 
• Molecular characterization of complexes using Multi-Angle Light Scattering (MALS) 
• Low resolution structural characterization using Small angle X-ray scattering (SAXS) 
• Low resolution (~5Å) protein crystallography 
• Electron microscopic (EM) grid preparation and processing of EM images 
• Programming and automation of large-scale SAXS data analysis pipeline using PERL and PYTHON programming 
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